VOLUME 12 1980

PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR

Editor-in-Chief

MATTHEW J. WAYNER

Published by

ANKHO International Inc

Fayetteville, New York

PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR

Editor-in-Chief

MATTHEW J. WAYNER

Brain Research Laboratory, Syracuse University, 601 University Avenue, Syracuse, N. Y. 13210 U.S.A.

Regional Editors

R. L. BALSTER, Department of Pharmacology, Medical College of Virginia, Virginia Commonwealth University, Richmond, Virginia 23298

A. BARBEAU, Department of Neurobiology, Clinical Research Institute of Montreal, 110 West Pine Avenue, Montreal (130), Quebec, Canada

J. R. BOISSIER, Faculté de Médecine de Paris, Unité de Neuropsychopharmacologie, 2 rue d'Alésia, 75014 Paris, France

G. R. BREESE, Department of Psychiatry, University of North Carolina School of Medicine, Chapel Hill, North Carolina 27514

E. A. CARLINI, Department of Psychobiology, Escola Paulista de Medicina, Rua Botucatu, 862, 04023 – São Paulo, Brasil

J. COCHIN, Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, 80 East Concord Street, Boston, Massachusetts 02118

D. V. COSCINA, Section of Neurochemistry, Clarke Institute of Psychiatry, 250 College Street, Toronto, Ontario M5T 1R8, Canada

B. COX, Pharmaceuticals Division, Imperial Chemical Industries, Ltd., Mereside, Alderly Park, Macclesfield, Cheshire, United Kingdom SK10 4TG

G. ELLMAN, Brain Behavior Research Center, Sonoma State Hospital, Eldridge, CA 95431

K. ERIKSSON, Research Laboratories of State Alcohol Monopoly, Box 350, 00101 Helsinki 10, Finland

J. L. FALK, Department of Psychology, Rutgers University, New Brunswick, New Jersey 08903

E. GELLER, Neurobiochemistry Laboratory, T-85 Veterans Administration, Brentwood Hospital, Los Angeles, California 90073

S. P. GROSSMAN, Department of Psychology, University of Chicago, Chicago, Illinois 60637

Y. GUTMAN, Department of Pharmacology, The Hebrew University, Hadassah Medical School, P.O. Box 1172, Jerusalem, Israel

J. HANO, Polish Academy of Sciences, Institute of Pharmacology, 52, Ojcowska Street, 31 344 Krakow, Poland

J. A. HARVEY, Department of Psychology, University of Iowa, Iowa City, Iowa 52242

P. JANSSEN, Research Laboratoria, Janssen Pharmaceutica, 2340-Beerse, Belgium

D. A. KHARKEVICH, Department of Pharmacology, First Medical Institute, 2/6, Bolshaja Pirogovhkaja Street, Moscow, G-435, USSR

J. KNOLL, Director, Department of Pharmacology, Semmelweis University of Medicine,1445 Budapest, VIII, Nagyvárad tér 4

I. P. LAPIN, Laboratory of Psychopharmacology, Bekhterev Institute, Bekhtereva ul., 3, 193019 Leningrad, USSR

A. E. LEBLANC, Biological Studies Research Division, Alcoholism and Drug Addiction Research Foundation, 33 Russell Street, Toronto, Ontario M5S 2S1, Canada

V. G. LONGO, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 Roma, Italy

H. MATTHIES, Institut für Pharmakologie und Toxikologie, Medizinische Akademie Magdeburg, 301 Magdeburg, Leipziger Strasse 44, German Democratic Republic

N. K. MELLO, Alcohol and Drug Abuse Research Center, Harvard Medical School, McLean Hospital, Belmont, Massachusetts 02178

R. D. MYERS, Departments of Psychiatry and Pharmacology, University of North Carolina School of Medicine, Chapel Hill, NC 27514

R. H. RECH, Department of Pharmacology, Michigan State University, B440 Life Sciences, East Lansing, Michigan 48824

C. R. SCHUSTER, Department of Psychiatry, University of Chicago, 950 East 59th Street, Chicago, Illinois 60637

D. S. SEGAL, Department of Psychiatry, School of Medicine, University of California, San Diego, La Jolla, California 92037

L. S. SEIDEN, Department of Pharmacology, University of Chicago, Chicago, Illinois 60637

E. B. SIGG, Department of Neuropharmacology, Research Division, Hoffman-La Roche Inc., Nutley, New Jersey 07110

G. SINGER, Department of Psychology, La Trobe University, Bundoora, Victoria 3083, Australia

T. L. SOURKES, Allan Memorial Institute of Psychiatry, 1025 Pine Avenue West, Montreal 112, P.Q., Canada

W. C. STERN, Medical Division, Burroughs Wellcome Co., 3030 Cornwallis Road, Research Triangle Park, NC 27709

S. TADOKORO, Behavior Research Institute, School of Medicine, Gunma University, 3-39-22, Showamachi Maebashi 371, Japan

T. THOMPSON, Department of Psychiatry, University of Minnesota, Research Unit, Medical School, Box 392, Mayo Memorial Building, Minneapolis, Minnesota 55455

U. UNGERSTEDT, Department of Pharmacology, Karolinska Institutet, S-104 01 Stockholm 60, Sweden

W. L. VEALE, Division of Medical Physiology, Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada

J. E. VILLARREAL, Department of Behavioral Pharmacology, Instituto Miles de Terepeutica Experimental, Division de Laboratorios Miles de Mexico, S.A. de C.V., Apartado Postal 22026, Mexico 22, D.F.

Z. VOTAVA, Department of Pharmacology, Research Institute of Pharmacy and Biochemistry, Praha 3, Kouřimská 17, Czechoslovakia

W. WUTTKE, Institut für Pharmakologie, Farbenfabriken Bayer AG, 56 Wuppertal-Elberfeld, Friederich-Ebert-Straße 217, Germany

T. YANAGITA, Central Institute for Experimental Animals, 1433 Nogawa, Kawasaki 211, Japan

Editorial Advisory Board

B. AGRANOFF (*Ann Arbor*)
B. BEER (*Pearl River*)
M. H. APRISON (*Indianapolis*)
E. F. DOMINO (*Ann Arbor*)
D. X. FREEDMAN (*Chicago*)
E. GLASSMAN (*Chapel Hill*)
H. KALANT (*Toronto*)
A. J. MANDELL (*San Diego*)
J. MENDELSON (*Boston*)
J. ROSECRANS (*Richmond*)
P. A. SHORE (*Dallas*)
S. H. SNYDER (*Baltimore*)
E. USDIN (*Rockville*)
R. J. WURTMAN (*Cambridge*)

PHARMACOLOGY BIOCHEMISTRY & BEHAVIOR
ISSN 0091-3057

Subscription, postpaid $250 per year for Libraries, Research Establishments and all other multiple user Institutions. Private individuals whose departmental libraries subscribe may obtain this Journal for their personal use at a reduced rate of $30 per year.

Publishing and Advertising Offices:
ANKHO Iinternational Inc.
7374 Highbridge Terrace, P.O. Box 426, Fayetteville, New York 13066 U.S.A.

Back issues are available. Write for Back Issue Price List.
Published monthly.

Copyright © 1980 ANKHO International Inc.

Second class postage paid at Fayetteville, NY 13066

Postmaster: If undeliverable send POD Form 3579 to P.O. Box 426, Fayetteville NY 13066

Printed at SALINA PRESS, Syracuse, New York, U.S.A.

PHARMACOLOGY BIOCHEMISTRY & BEHAVIOR

VOLUME 12 NUMBER 1 JANUARY 1980

CONTENTS

Effect of neuroleptics and tricyclic antidepressants upon d-amphetamine discrimination. SCHECHTER, M. D. 1

Transfer of information with brain extracts from donors to recipients in passive-avoidance behavior. TOZZI, W., P. SALE and L. ANGELUCCI 7

Effects of chlordiazepoxide, food familiarization, and prior shock experience on food choice in rats. COOPER, S. J. and A. MCCLELLAND 23

Apomorphine-induced stereotypic cage climbing in mice as a model for studying changes in dopamine receptor sensitivity. WILCOX, R. E., R. V. SMITH, J. A. ANDERSON and W. H. RIFFEE 29

Single and repeated air blast stress and brain histamine. MAZURKIEWICZ-KWILECKI, I. M. . 35

Dorsal periaqueductal gray punishment, septal lesions and the mode of action of minor tranquilizers. GRAEFF, F. G. and J. N. P. RAWLINS 41

Effects of acute and chronic administration of phenobarbital and d-amphetamine on schedule-controlled behavior. HARRIS, R. A. and D. SNELL 47

Differential behavioral responses of spontaneously hypertensive (SHR) and normotensive (WKY) rats to d-amphetamine. McCARTY, R., C. C. CHIUEH and I. J. KOPIN 53

Locomotor effects of catecholaminergic drugs on herpes-infected mice. SEEGAL, R. F., E. SIKORA and J. HOTCHIN 61

Comparison of phencyclidine and three analogues on fixed-interval performance in rhesus monkeys. BRADY, K. T., R. L. BALSTER, L. T. MELTZER and D. SCHWERTZ 67

Development of narcotic tolerance and physical dependence: Effects of Pro-Leu-Gly-NH_2 and cyclo (Leu-Gly). BHARGAVA, H. N., R. WALTER and R. F. RITZMANN 73

Studies of memory: A reevaluation in mice of the effects of inhibitors on the rate of synthesis of cerebral proteins as related to amnesia. RAINBOW, T. C., P. L. HOFFMAN and L. B. FLEXNER 79

Schedule-dependent tolerance to behavioral effects of Δ^9-tetrahydrocannabinol when reinforcement frequencies are matched. GALBICKA, G., D. M. LEE and M. N. BRANCH 85

The effects of peptides on the stimulus properties of ethanol. CHIPKIN, R. E., J. M. STEWART and K. CHANNABASAVAIAH 93

EEG effects of hallucinogens and cannabinoids using sleep-waking behavior as baseline. FAIRCHILD, M. D., D. J. JENDEN, M. R. MICKEY and C. YALE 99

Nicotine and amphetamine: Differential tolerance and no cross-tolerance for ingestive effects. BAETTIG, K., J. R. MARTIN and W. CLASSEN 107

Interaction between phencyclidine (PCP) and gaba-ergic drugs: Clinical implications. MENON, M. K., W. G. CLARK and C. VIVONIA 113

Effects of 6-methoxy-1,2,3,4-tetrahydro-β-carboline (6-MeO-THβC) on audiogenic seizures in DBA/2J mice. SPARKS, D. L. and N. S. BUCKHOLTZ 119

Effects of GABA receptor blockade on stimulation-induced feeding and self-stimulation. PORRINO, L. J. and E. E. COONS 125

Effect of chronic treatment with estrogen on the dipsogenic response of rats to angiotensin. FREGLY, M. J. 131

Development of tolerance to the rewarding effects of self-administered S(+)-amphetamine. McCOWN, T. J. and R. J. BARRETT 137

Perinatal or adult exposure to cannabinoids alters male reproductive functions in mice. DALTERIO, S. L. 143

Drug dependence potential of viloxazine hydrochloride tested in rhesus monkeys. YANAGITA, T., Y. WAKASA and H. KIYOHARA 155

BRIEF COMMUNICATION

Effects of heroin and naltrexone on plasma prolactin levels in man. ELLINGBOE, J., J. H. MENDELSON and J. C. KUEHNLE 163

ANNOUNCEMENTS 167

PHARMACOLOGY BIOCHEMISTRY & BEHAVIOR

VOLUME 12 NUMBER 2 FEBRUARY 1980

CONTENTS

Effects of dietary supplements and a tryptophan-free diet on aggressive behavior in rats. KANTAK, K. M., L. R. HEGSTRAND, J. WHITMAN and B. EICHELMAN 173

The effects of p-chlorophenylalanine, fenfluramine and α-methyltyrosine on marking responses in the male Mongolian gerbil (*Meriones unguiculatus*). BATTY, J. and B. J. MEYERSON 181

Circling behavior in rats with partial, unilateral nigro-striatal lesions: Effect of amphetamine, apomorphine, and DOPA. HEFTI, F., E. MELAMED, B. J. SAHAKIAN and R. J. WURTMAN 185

Studies on the involvement of GABA in the aggression directed by groups of intact or gonadectomized male and female mice towards lactating intruders. HAUG, M., S. SIMLER, L. KIM and P. MANDEL 189

Feeding elicited by benzodiazepine-like chemicals in puppies and cats: Structure-activity relationships. DELLA-FERA, M. A., C. A. BAILE and C. L. McLAUGHLIN 195

Effects of dexamethasone, corticosterone, and ACTH on lordosis in ovariectomized and adrenalectomized-ovariectomized rats. DE CATANZARO, D. and B. B. GORZALKA .. 201

Corticosterone effects on rat brain template active region chromatin. BROWN, H. and L. UPHOUSE 207

Prenatal exposure to prednisone permanently alters fighting behavior of female mice. REINISCH, J. M., N. G. SIMON and R. GANDELMAN 213

^{3}H-Δ^9-Tetrahydrocannabinol, ^{3}H-cannabinol and ^{3}H-cannabidiol: Penetration and regional distribution in rat brain. ALOZIE, S. O., B. R. MARTIN, L. S. HARRIS and W. L. DEWEY 217

Ethanol intakes and preferences in the desalivate rat. ROEHRS, T. A. and H. H. SAMSON .. 223

Monoamine roles in retention and reversal of delayed response in cats. ROBERGE, A. G., C. BOISVERT and J. EVERETT 229

A role for environmental factors in the production of digitalis toxicity. NATELSON, B. H., S. L. HOFFMAN and N. A. CAGIN 235

Suppression by lithium of voluntary alcohol intake in the rat: Mechanism of action. BOLAND, F. J. and M. H. STERN 239

Scopolamine and KCl injections into the caudate nucleus. Overtraining-induced protection against deficits of learning. PRADO-ALCALA, R. A., P. KAUFMANN and R. MOSCONA 249

The effects of chlorimipramine and protriptyline on tube running activity in mice. PERSSON, S.-Å. . 255

Tube running activity in mice: A method to evaluate the behavioural effects of drugs. PERSSON, S.-Å. and G. WAHLSTRÖM 259

Effects of d-amphetamine and fenfluramine on feeding patterns and activity of obese and lean Zucker rats. GRINKER, J. A., A. DREWNOWSKI, M. ENNS and H. KISSILEFF 265

Strain specific alterations in hippocampal cholinergic function following acute footshock. SCHMIDT, D. E., D. O. COOPER and R. J. BARRETT 277

Effects of neonatal and adult 6-hydroxydopamine treatment on random-interval behavior. LEVINE, T. E., L. ERINOFF, D. P. DREGITS and L. S. SEIDEN 281

DRL performance in 6-hydroxydopamine-treated rats. LEVINE, T. E., P. S. McGUIRE, T. G. HEFFNER and L. S. SEIDEN 287

Renin, water drinking, salt preference and blood pressure in alcohol preferring and alcohol avoiding rats. LINKOLA, J., I. TIKKANEN, F. FYHRQUIST and M. RUSI 293

Effect of acute ethanol ingestion on integrated plasma prolactin levels in normal men. ELLINGBOE, J., J. H. MENDELSON, J. C. KUEHNLE, A. S. T. SKUPNY and K. D. MILLER .. 297

BRIEF COMMUNICATIONS

Amphetamine discrimination: Onset of the stimulus. SILVERMAN, P. B. and B. T. HO 303

Chronic Δ^9-tetrahydrocannabinol administration and schedule-induced aggression. CHEREK, D. R., T. THOMPSON and T. KELLY 305

Rat strain differences in brain monoamine metabolism following para-chlorophenylalanine treatment. EMERY, D., J. ENGEL and K. LARSSON 311

Effect of lethal doses of morphine on brain amines in isolated and aggregated mice. MOHRLAND, J. S. and A. L. CRAIGMILL 313

Apomorphine and glycoprotein synthesis in rat hippocampus. JORK, R., G. GRECKSCH, M. JIRKA, B. LÖSSNER and H. MATTHIES 317

Effect of serotonin on Y-maze retention and hippocampal protein synthesis in rats. WETZEL, W., V. M. GETSOVA, R. JORK and H. MATTHIES 319

ABSTRACTS

Alcoholism: A Family Illness. Fourth Annual Conference on Alcoholism. February 22-23, 1980. ... 323

PHARMACOLOGY BIOCHEMISTRY & BEHAVIOR

VOLUME 12 NUMBER 3 MARCH 1980

CONTENTS

Membrane Na^+K^+ATPase activity: Changes using an experimental model of alcohol dependence and withdrawal. COWAN, C. M., J. O. CARDEAL and E. A. CAVALHEIRO 333

Paradoxical aversive conditioning with ethanol. CUNNINGHAM, C. L. and J. G. LINAKIS 337

Lysine vasopressin attenuation of diethyldithiocarbamate-induced amnesia. ASIN, K. E. 343

Tonic immobility in domestic fowl: Anticataleptic effects of quipazine. WALLNAU, L. B. 347

Enhancement of tyrosine hydroxylase activity by Oxotremorine does not affect REM sleep in the rat. RAMM, P. and H. TAUB 353

Effect of cyproterone acetate on steroid-induced sexual behavior in adult ewes. FABRE-NYS, C. and J. P. SIGNORET 359

Facilitation of copulatory performance in male rats by naloxone: Effects of hypophysectomy, 17α-estradiol, and luteinizing hormone releasing hormone. MYERS, B. M. and M. J. BAUM . 365

The failure of alpha-methyl-para-tyrosine to produce supersensitivity in 6-OHDA lesioned rats. WILLIS, G. L. and G. SINGER 371

Paradoxical sleep and memory: Long-term disruptive effects of anisomycin. GUTWEIN, B. M., P. J. SHIROMANI and W. FISHBEIN 377

Inverse relationship between whole brain monoamine levels and audiogenic seizure susceptibility in mice: Failure to replicate. LINTS, C. E., J. F. WILLOTT, P. Y. SZE and L. H. NENJA .. 385

Tail pinch facilitation of self-stimulation in the rat—dependence upon dopamine and independence upon dopamine and independence of opiates. KATZ, R. J., K. A. ROTH and K. SCHMALTZ 389

Behavioral effects of prenatal ethanol exposure and differential early experience in rats. OSBORNE, G. L., W. F. CAUL and K. FERNANDEZ 393

Meperidine's effects under shock titration and shock discrimination procedures. DYKSTRA, L. A. 403

The effects of scopolamine on three different types of suppressed behavior of rats. McKIM, W. A. . 409

Behavioral effects of morphine on free-operant avoidance under hyperbaric pressure. CURLEY, M. D., J. M. WALSH and L. S. BURCH 413

β-Adrenergic manipulation in amygdala central n. alters rabbit heart rate conditioning. GALLAGHER, M., B. S. KAPP, R. C. FRYSINGER and P. R. RAPP 419

Morphine selectively influences macronutrient intake in the rat. MARKS-KAUFMAN, R. and R. B. KANAREK 427

Naloxone reduces fluid intake: Effects of water and food deprivation. OSTROWSKI, N. L., T. L. FOLEY, M. D. LIND and L. D. REID 431

The neurochemical control of crying. PANKSEPP, J., R. MEEKER and N. J. BEAN 437

The use of conditioned defensive burying to test the effects of pimozide on associative learning. BENINGER, R. J., A. J. MacLENNAN and J. P. J. PINEL 445

BRIEF COMMUNICATIONS

Intraindividual consistency in catecholamine and cortisol excretion patterns over experimental conditions. LUNDBERG, U. and L. FORSMAN 449

Unilateral mesolimbicocortical dopamine denervation decreases locomotion in the open field and after amphetamine. JESTE, D. V. and G. P. SMITH 453

Circadian rhythm of apomorphine-induced stereotypy in rats. NAKANO, S., C. HARA and N. OGAWA 459

A simple double channel swivel for infusions of fluids into unrestrained animals. BLAIR, R., B. FISHMAN, Z. AMIT and J. R. WEEKS 463

A quantitative analysis of ethanol and acetaldehyde expired by inbred mouse strains. FIORIGLIO, C., J. WOOD, R. A. HARTLINE and C. W. SCHNEIDER 467

PHARMACOLOGY BIOCHEMISTRY & BEHAVIOR

VOLUME 12 NUMBER 4 APRIL 1980

CONTENTS

Effect of various forms of training and stimulation on the incorporation of ^{32}P into nuclear phosphoproteins of the rat brain. SOUZA, D. O., E. ELISABETSKY and I. IZQUIERDO 481

Shock-induced defensive fighting in the rat: Evidence for cholinergic mediation in the lateral hypothalamus. BELL, R. and K. BROWN 487

Iron deficiency during early development in the rat: Behavioral and physiological consequences. WEINBURG, J., P. R. DALLMAN and S. LEVINE 493

Ethanol dependence produced in rats by nutritionally complete diets. GOLDMAN, M. E., S. S. MILLER, R. L. SHOREY and C. K. ERICKSON 503

Brain neurotransmitter receptor systems in mice genetically selected for differences in sensitivity to ethanol. DIBNER, M. D., N. R. ZAHNISER, B. B. WOLFE, R. A. RABIN and P. B. MOLINOFF 509

Postsynaptic efficacy of dopamine: Possible suppression by estrogen. GORDON, J. H., R. A. GORSKI, R. L. BORISON and B. I. DIAMOND 515

Biphasic effects of serotonin on tonic immobility in domestic fowl. HENNIG, C. W. 519

Dietary amino acid precursors: Effects on central monoamines, aggression, and locomotor activity in the mouse. THURMOND, J. B., N. R. KRAMARCY, S. M. LASLEY and J. W. BROWN 525

Amnestic potency of proline analogs correlates with anti-spreading depression potency. VAN HAREVELD, A., A. CHERKIN and J. L. DAVIS 533

Enhanced self-stimulation responding from the substantia nigra after chronic amphetamine treatment: A role for conditioning factors. KOKKINIDIS, L. and R. M. ZACHARUKO 543

Brain histamine: Plasma corticosterone, spontaneous locomotor activity and temperature. MAZURKIEWICZ-KWILECKI, I. M. and G. D. PRELL 549

The maternal pheromone and bile acids in the lactating rat. KILPATRICK, S. J., M. BOLT and H. MOLTZ 555

d-Amphetamine, operant history, and variable-interval performance. POLING, A., K. KRAFFT and L. CHAPMAN 559

Regional brain morphine injections selectively attenuate aspects of septal hyperreactivity: A multivariate assessment. VALDES, J. J., W. R. CAMERON, S. EVANS and F. H. GAGE III ... 563

Effectiveness of lofexidine in blocking morphine-withdrawal signs in the rat. SHEARMAN, G. T., H. LAL and R. C. URSILLO 573

Effect of chronic morphine on the response to and disposition of other drugs. HOWD, R. A. and G. T. PRYOR 577

Stimulus effects of morphine in the monkey: Quantitative analysis of antagonism. TEAL, J. J. and S. G. HOLTZMAN 587

Effects of scopolamine, pentobarbital, and amphetamine on radial arm maze performance in the rat. ECKERMAN, D. A., W. A. GORDON, J. D. EDWARDS, R. C. MACPHAIL and M. I. GAGE 595

Effects of lesions of the ventral medial tegmentum on locomotor activity, biogenic amines and response to amphetamine in rats. SESSIONS, G. R., J. L. MEYERHOFF, G. J. KANT and G. F. KOOB 603

Calcitonin reduces feeding in man, monkey and rat. PERLOW, M. J., W. J. FREED, J. S. CARMAN and R. J. WYATT 609

The effects of various barbiturates on LiCl induced taste aversion. JOLICOEUR, F. B., M. J. WAYNER, A. D. MERKEL, D. B. RONDEAU and R. B. MINTZ 613

Suppressive effects of intraperitoneal and intraventricular injections of nicotine on muricide and shock-induced attack on conspecifics. WALDBILLIG, R. J. 619

BRIEF COMMUNICATIONS

Physical dependence and tolerance development after chronic exposure to low levels of morphine in the rat. KOSERSKY, D. S., M. D. KOWOLENKO and J. F. HOWES 625

A chronic subcutaneous gastric cannula in adult rats. ALTAR, A. 629

ANNOUNCEMENTS 633

PHARMACOLOGY BIOCHEMISTRY & BEHAVIOR

VOLUME 12 NUMBER 5 MAY 1980

CONTENTS

Comparative effects of synthetic enkephalinamides and morphine on abstinence responses in morphine-dependent mice. BHARGAVA, H. N. 645

Calcium enhancement of alcohol and drug-induced sleeping time in mice and rats. ERICKSON, C. K., T. D. TYLER, L. K. BECK and K. L. DUENSING 651

Interactions between stimulants and depressants on schedule-controlled behavior. FORD, R. D., R. H. RECH and D. TOBIN 657

Two sensitive periods for the amnesic effect of anisomycin. GRECKSCH, G. and H. MATTHIES 663

Behavioral and neurochemical effects of dietary tyrosine in young and aged mice following cold-swim stress. BRADY, K., J. W. BROWN and J. B. THURMOND 667

Dietary tryptophan modulation and aggressive behavior in mice. KANTAK, K. M., L. R. HEGSTRAND and B. EICHELMAN 675

Suppression of mouse killing by lateral hypothalamic infusion of atropine sulfate in the rat: A general behavioral suppression. ALBERT, D. J. 681

Pharmacologic and behavioral effects of EMD 28422: A novel purine which enhances (^{3}H) diazepam binding to brain benzodiazepine receptors. SKOLNICK, P., K.-L. LOCK, B. PAUGH, P. MARANGOS, R. WINDSOR and S. PAUL 685

The effect of halothane on mice selectively bred for differential sensitivity to alcohol. BAKER, R., C. MELCHIOR and R. DEITRICH 691

Effects of Δ^9-THC on human platelet phospholipids. KALOFOUTIS, A., J. LEKAKIS and A. KOUTSELINIS 697

Anorexigenic effects of two amines obtained from *Catha edulis* Forsk. (Khat) in rats. ZELGER, J. L. and E. A. CARLINI 701

A bioassay of ethanol-dependence in rats. LE MAGNEN, J., P. MARFAING-JALLAT and D. MICELI 707

Intraventricular ACTH reduces social interaction in male rats. FILE, S. E. and A. CLARKE . 711

Characterisation of adjustments to the structure of feeding behaviour following pharmacological treatment: Effects of amphetamine and fenfluramine and the antagonism produced by pimozide and methergoline. BLUNDELL, J. E. and C. J. LATHAM 717

Deprivation-dependent effects of amphetamine on concurrent measures of feeding and activity. COLE, S. O. 723

Pain modulating and reward systems: A single brain mechanism? LE MAGNEN, J., P. MARFAING-JALLAT, D. MICELI and M. DEVOS 729

The α-naphthoxyacetic acid-elicited retching involves dopaminergic inhibition in mice. FURUKAWA, T. and K. YAMADA 735

Decreased startle reactivity in the end-to-side portacaval shunted rat. WARBRITTON, J. D., III, M. A. GEYER, B. JEPPSSON and J. E. FISCHER 739

Phenytoin reversal and prevention of morphine-induced catalepsy in the rat. COOKSON, S. L. and J. D. MANN 743

PGD_2 effects on rodent behavior and EEG patterns in cats. LAYCHOCK, S. G., D. N. JOHNSON and L. S. HARRIS 747

Copulation-induced abbreviation of estrus in the female guinea pig: Block by clonidine. IRVING, S. M., R. W. GOY and G. A. DAVIS 755

Modification of the behavioral effects of phencyclidine by repeated drug exposure and body weight changes. WOOLVERTON, W. L., B. R. MARTIN and R. L. BALSTER 761

Effects of diazepam-infrasounds combination on locomotor activity and avoidance behaviour of rats. SPYRAKI, C., Z. PAPADOPOULOU, B. ZIS and D. VARONOS 767

α-MSH effects on novelty-induced defecation, plasma 11-OHCS and whole brain catecholamines in hypophysectomized rats. DATTA, P. C. and M. G. KING 773

Extinction and recovery of cocaine self-administration following 6-hydroxydopamine lesions of the nucleus accumbens. ROBERTS, D. C. S., G. F. KOOB, P. KLONOFF and H. C. FIBIGER 781

Increased drinking stimulated by exposure to lithium-conditioned taste cues: Effects of conditioning trials and drug dose. DOMJAN, M., G. A. GEMBERLING and D. J. GILLAN 789

Comparison of morphine, meperidine, anileridine, and alphaprodine on schedule-controlled responding and analgesia. LEANDER, J. D. 797

The effects of several barbiturates on lithium chloride induced taste aversion. WAYNER, E. A., G. SINGER, M. J. WAYNER and F. C. BARONE 803

The taste aversion induction properties of two long duration barbiturates. WAYNER, E. A., G. SINGER, M. J. WAYNER and F. C. BARONE 807

BRIEF COMMUNICATIONS

An inexpensive portable device for measuring puffing behavior by cigarette smokers. HENNINGFIELD, J. E., J. YINGLING, R. R. GRIFFITHS and R. PICKENS ... 811

A new injection technique for intracerebral drug administration in behaving animals. STEIN, E. A. and D. RODD 815

Effects of isoproterenol and chlordiazepoxide on drinking and conflict behaviors in rats. PATEL, J. B. and J. B. MALICK 819

Blockade of audiogenic seizures by bromocryptine GONZÁLEZ PÉREZ, J. N. and A. GONZÁLEZ-QUEVEDO 823

PHARMACOLOGY BIOCHEMISTRY & BEHAVIOR

VOLUME 12 NUMBER 6 JUNE 1980

CONTENTS

Hypothalamic knife cut obesity in hyper or hypothyroid rats. LOWELL, B. B., R. M. GOLD and C. A. ADAMCHUK 837

Circadian rhythm in the effect of theophylline on the behavioral thermoregulation of the white sucker, *Catostomus commersoni*. KAVALIERS, M. 843

Time-dependent changes in the effects of cholinesterase inhibitors on shuttle-box avoidance. GONZALEZ, L. P. and H. L. ALTSHULER 847

PCA: Effects on ejaculation, thermoregulation, salivation, and irritability in rats. HUMPHRIES, C. R., M. O'BRIEN and G. PAXINOS 851

Chemical lesions of both dorsal and median raphe nuclei and changes in social and aggressive behaviour in rats. FILE, S. E. and J. F. W. DEAKIN 855

The effect of amphetamine on delayed response performance in the monkey. WEIGHT, M. L., R. M. RIDLEY and H. F. BAKER 861

Effects of phencyclidine and ketamine in pigeons on behavior suppressed by brief electrical shocks. WENGER, G. R. 865

Selective permeation of the blood-brain barrier as a cause of the anomalous properties of 'atypical' neuroleptics. HERBERG, L. J. and T. B. WISHART 871

Effects of 5-hydroxytryptamine on defecation in open-field behavior in rats. KAMEYAMA, T., M. SUZUKI and T. NABESHIMA 875

Effects of cinanserin and p-chlorophenylalanine and their interaction with d-amphetamine on DRL performance in rats. MELE, P. C. and M. A. CAPLAN 883

Prolonged electrophysiological and behavioral alterations following a single injection of methadone in the cat. SNYDER, E. W., D. E. SHEARER, C. SCHLEHUBER, R. E. DUSTMAN and E. C. BECK 893

A comparison of the effects of d-amphetamine, cocaine, imipramine and pentobarbital on local and overall rates of responding maintained under a four-component multiple fixed-interval schedule. ZUCCARELLI, R. R. and J. E. BARRETT 899

Effects of alcohol on visually evoked responses in rats during addiction and withdrawal. BIERLEY, R. A., D. S. CANNON, C. K. WEHL and R. E. DUSTMAN 909

Pimozide-induced suppression of responding: Evidence against a block of food reward. MASON, S. T., R. J. BENINGER, H. C. FIBIGER and A. G. PHILLIPS 917

TRH-induced behavioral arousal in developing rats pretreated with 6-hydroxydopa. NOMURA, Y. and K. OKI 925

Effects of pimozide on lever pressing behavior maintained on an intermittent reinforcement schedule. GRAY, T. and R. A. WISE 931

Increased self-administration of d-amphetamine after destruction of 5-hydroxytryptaminergic neurons. LYNESS, W. H., N. M. FRIEDLE and K. E. MOORE 937

Effect of antidepressant agents on β-adrenergic receptor and neurotransmitter regulatory systems. MEYERSON, L. R., H. H. ONG, L. L. MARTIN and D. B. ELLIS 943

The effects of amphetamine or caffeine on the response to glucoprivation in rats with rostral zona incerta lesions. McDERMOTT, L. J. and S. P. GROSSMAN 949

In vivo determination of endogenous biogenic amines in rat brain using HPLC and push-pull cannula. LOULLIS, C. C., J. N. HINGTGEN, P. A. SHEA and M. H. APRISON 959

Reinforcing effects of morphine microinjection into the ventral tegmental area. PHILLIPS, A. G. and F. G. LEPIANE 965

REVIEW

Inappropriate use of albino animals as models in research. CREEL, D. 969

BRIEF COMMUNICATIONS

Effects of some β-carbolines on phenylethylamine and apomorphine stereotypies in rats. KARI, I., S. RAPAKKO and M. M. AIRAKSINEN 979

The effect of schedule removal on the maintenance of heroin self-injection. MADDEN, C., T. P. S. OEI and G. SINGER 983

Naloxone depresses osmoregulatory drinking in rats. CZECH, D. A. and E. A. STEIN 987

AIMS AND SCOPE

Pharmacology Biochemistry & Behavior will publish original reports of systematic studies in the areas of pharmacology, biochemistry, toxicology and behavior in which the primary emphasis and theoretical context are behavioral; and brief communications which describe a new method, technique or apparatus and results of experiments which can be reported briefly with limited figures and tables. Behavioral studies as such will not be published unless they are obviously pertinent and make a significant contribution to pharmacology, biochemistry or toxicology. A limited number of relevant reviews and theoretical articles, results of symposia, and more comprehensive studies as monograph supplements will also be published. Articles will be published in English.

The accepted abbreviation for *Pharmacology Biochemistry & Behavior* for bibliographic citation is *Pharmac. Biochem. Behav.*

INSTRUCTIONS TO AUTHORS

Manuscripts should be sent directly to the Editor-in-Chief or to the most proximal Regional Editor for review and will be published within three months or less after formal acceptance.

STYLE OF MANUSCRIPT

General Form. (1) Manuscripts should be submitted in duplicate and should be typewritten, double spaced with wide margins on good quality paper. (2) The title page should contain: title of paper; author(s); laboratory or institution of origin with city, state, zip code, and country; complete address for mailing proofs; a running head not to exceed 50 characters including spaces between words. (3) References, footnotes, and legends for illustrations should be typed on separate sheets, double spaced. (4) Illustrations (unmounted photographs) should be identified on the reverse with figure number and author(s) name; when necessary the top should be clearly marked. (5) Each table should be typed on a separate sheet and double spaced. (6) All dimensions and measurements must be specified in the metric system. Standard nomenclature, abbreviations and symbols, as specified by Royal Society Conference of Editors. Metrication in Scientific Journals, *Am. Scient.* **56**: 159–164, 1968, should be used throughout. (7) Italics should not be used for the purpose of emphasis.

Title. The title should not be longer than 85 characters, including spaces between words.

Papers in a series such as: "Studies on . . . I." will not be accepted.

Length of Paper. The Editors insist upon clear, concise statement of facts and conclusions. Fragmentation of material into numerous short reports is discouraged.

Abstract. Each paper submitted must be accompanied by an abstract, which does not exceed 170 words and must be suitable for use by abstracting journals. Abstracts should be prepared as follows:

> EVANS, B. K., S. ARMSTRONG, G. SINGER, R. D. COOK AND G. BURNSTOCK. *Intracranial injection of drugs: comparison of diffusion of* . . . PHARMAC. BIOCHEM. BEHAV. Marked differences in extent of diffusion have been . . .

A list of from 3–12 (or more) words or short phrases suitable for indexing terms should be typed at the bottom of the abstract page accompanying the manuscript. These terms will be printed with the paper at the end of the abstract.

Drugs. Proprietary (trademarked) names should be capitalized. The chemical name should precede the trade, popular name, or abbreviation of a drug the first time it occurs.

Footnotes. Title page footnotes should be numbered consecutively. Text footnotes should not be used, the material should be incorporated into the text. Table footnotes: see *Tables* (b).

References. Literature cited should be numbered in brackets in text (only one reference to a number) and listed in alphabetical order on a separate sheet at the end of the manuscript. *Do not recite names of authors within the text.* Journal citations in the reference list should contain the following: (a) surnames and initials of all authors (surname of first author precedes initials; initials precede surnames of all co-authors); (b) title of article; (c) journal title abbreviated as listed in the 4th edition of the *World List of Scientific Periodicals;* (d) volume, inclusive pages, and year. Example:

1. Abrams, R. and H. T. Hammel. Hypothalamic temperature in unanesthetized albino rats during feeding and sleeping. *Am. J. Physiol.* **206**: 641–646, 1964.

Book references should be in the following order: author, title, city of publication, publisher, year, and pages. Example:

1. Thompson, T. and C. R. Schuster. *Behavioral Pharmacology.* Englewood, New Jersey: Prentice-Hall, Inc., 1968, p. 297.

Citations such as "Unpublished observations," "Personal communication," "Manuscript in preparation," "To be published," should not be entered in the list of References, but may be noted in the text without serial numbers, in parentheses.

Illustrations. (a) Prepare for use in a single column width whenever possible. (b) All drawings for reduction to a given size should be drawn and lettered to the same scale. (c) All illustrations should be referred to as figures and numbered in Arabic numerals. (d) Lettering should be done in India ink or other suitable material and must be proportionate to the size of the illustrations if it is to be legible after reduction. Lettering should be sized so that its smallest elements (subscripts or superscripts) will be readable when reduced. (e) When possible all lettering should be within the framework of the illustration; likewise the key to symbols should be on the face of the chart. The following standard symbols should be used as they are easily available to the printer. ○ ● △ ▲ □ ■ + (f) Actual magnification of all photomicrographs should be given. Dimension scale should be indicated. (g) Sharply contrasting unmounted photographs of figures on glossy paper are required.

Tables. (a) Each table should have a brief heading; explanatory matter should be in footnotes, not as part of the title. (b) Table footnotes should be indicated in the body of the table in order of their appearance with the following symbols: * † ‡ § ¶ # **, etc. (c) Tables must not duplicate material in text or illustrations. (d) Vertical rules should be omitted. (e) Short or abbreviated column heads should be used. (f) Statistical measures of variation, SD, SE, etc., should be identified. (g) Analysis of Variance Tables should not be submitted but significant F's should be incorporated where appropriate within the text. The appropriate form for reporting F values is: $F(11,20) = 3.05$, $p < 0.01$.

Formulas and Equations. Structural chemical formulas, process flow-diagrams, and complicated mathematical expressions should be kept to a minimum. Usually chemical formulas and flow-diagrams should be drawn in India ink for reproduction as line cuts.

All subscripts, superscripts, Greek letters, and unusual characters must be clearly identified.

Anesthesia. In describing surgical procedures on animals, the type and dosage of the anesthetic agent should be specified. Curarizing agents are not anesthetics; if these were used, evidence must be provided that anesthesia of suitable grade and duration was employed.

Proofs. Corrections to the proofs must be restricted to printer's errors only. Other than these, any other alterations will be charged to the author.

Reprints. Each author will receive with his galley proofs a reprint order form which must be completed and returned with the proofs. Late orders cannot be filled since reprints are run at the time the Journal is printed. Senior author receives 25 reprints free.

Pharmacology Biochemistry and Behavior, Vol. 12. Copyright © 1980 by ANKHO International Inc.
All rights of reproduction in any form reserved. Printed in the U.S.A.

PHARMACOLOGY BIOCHEMISTRY & BEHAVIOR

VOLUME 12 1980

SUBJECT INDEX

A10
  activity, 603
  amphetamine, 603
  dopamine, 603
  lesions, 603
  norepinephrine, 603
  serotonin, 603
  ventral medial tegmentum, 603
Abstinence syndrome
  dependence, 645
  D-Ala^2-Met^5-enkephalinamide, 645
  D-Met^2-Pro^5-enkephalinamide, 645
  hypothermia, 645
  morphine, 645
  naloxone, 645
Acetaldehyde
  analysis, 467
  ethanol, 467
  expiration, 467
  mice strains, 467
Acetylcholine
  chlordiazepoxide, 437
  distress vocalizations, 437
  norepinephrine, 437
  opiates, 437
  serotonin, 437
γ-Acetylenic GABA
  aminooxyacetic acid, 113
  d-amphetamine, 113
  baclofen, 113
  locomotor stimulation, 113
  muscimol, 113
  phencyclidine, 113
  surgical anesthesia, 113
ACTH
  adrenal, 201
  adrenalectomy, 201
  anxiety, 711
  bombesin, 93
  corticosterone, 201
  delta sleep-inducing peptide, 93
  dexamethasone, 201
  enkephalin, 93
  ethanol, 93
  female sexual behavior, 201
  His-Pro diketopiperazine, 93
  lordosis, 201
  naloxone, 93
  ovariectomy, 201
  peptide, 93
  social interaction, 711
  stimulus properties of drugs, 93
  substance P, 93
  thyrotropin releasing hormone, 93
Activity
  A10, 603
  amphetamine, 603
  d-amphetamine, 265
  catalepsy, 347
  chickens, 347
  dopamine, 603
  dopaminergic system, 347
  fenfluramine, 265
  haloperidol, 347
  lesions, 603
  meal patterns, 265
  norepinephrine, 603
  quipazine, 347
  raphe model, 347
  serotonergic system, 347
  serotonin, 603
  stereotypy, 347
  tonic immobility, 347
  ventral medial tegmentum, 603
  Zucker rat, 265
Addiction
  ethanol, 909
  latencies, 909
  neural hyperexcitability, 909
  peak-to-peak amplitudes, 909
  photic afterdischarge, 909
  rebound, 909
  recovery time, 909
  visual evoked response, 909
  withdrawal, 909
Adenylate cyclase
  β-adrenergic receptor, 509
  dopaminergic receptor, 509
  ethanol, 509
  genetics, 509
  muscarinic cholinergic receptor, 509
Adipose tissue
  d-amphetamine, 543
  chronic administration, 543
  conditioning factors, 543
  response sensitization, 543
  self-stimulation, 543
  substantia nigra, 543
Adrenal
  ACTH, 201
  adrenalectomy, 201
  corticosterone, 201
  dexamethasone, 201
  female sexual behavior, 201
  lordosis, 201
  ovariectomy, 201
Adrenalectomy
  ACTH, 201
  adrenal, 201
  corticosterone, 201
  dexamethasone, 201
  female sexual behavior, 201
  lordosis, 201
  ovariectomy, 201

Adrenaline
catecholamines, 449
correlation, 449
cortisol, 449
heart rate, 449
humans, 449
noradrenaline, 449
response consistency, 449
sex differences, 449
Adrenergic system
clonidine, 755
copulation, 755
estrus, 755
β-Adrenergic receptor
adenylate cyclase, 509
amygdala central nucleus, 419
antidepressants, 943
dihydroalprenolol binding, 943
dopaminergic receptor, 509
ethanol, 509
genetics, 509
heart rate conditioning, 419
isoproterenol, 419
monoamine oxidase, 943
monoamine uptake inhibition, 943
muscarinic cholinergic receptor, 509
propranolol, 419
receptor sensitivity, 943
Aggregation
catecholamines, 313
isolation, 313
lethal dose, 313
morphine, 313
serotonin, 313
Aggression
amino acids, 525
amygdala, 189
anterior colliculus, 189
atropine sulfate, 681
cholinergic, 681
diet, 525
5,7-dihydroxytryptamine, 855
dipropylacetate, 189
frontal cortex, 189
GABA, 189
gonadectomy, 189
hippocampus, 855
hypothalamus, 189
lactation, 189
lateral hypothalamus, 681
lidocaine, 681
locomotion, 525
locomotor activity, 855
monoamines, 525
mouse killing, 681
olfactory bulb, 189
posterior colliculus, 189
raphe nuclei, 855
serotonin, 855
social interaction, 855
striatum, 855
tolerance, 525
Aggressive behavior
aging, 667
chronic administration, 305
diet supplement, 667
dopamine, 667
motor activity, 667
norepinephrine, 667
precursor amino acids, 667
schedule-induced behavior, 305
serotonin, 667
stress, 667
Δ^9-tetrahydrocannabinol, 305
tyrosine, 667
Aging
aggressive behavior, 667
diet supplement, 667
dopamine, 667
motor activity, 667
norepinephrine, 667
precursor amino acids, 667
serotonin, 667
stress, 667
tyrosine, 667
Albinism
catecholamines, 969
melanin, 969
tyrosinase, 969
tyrosine, 969
Alcohol
alcohol dependence, 333
alcohol withdrawal, 333
audiogenically induced seizures, 333
ethanol, 297
hippocampus, 333
man, 297
membrane ATPase, 333
prolactin, 297
Alcohol dependence
alcohol, 333
alcohol withdrawal, 333
audiogenically induced seizures, 333
hippocampus, 333
membrane ATPase, 333
Alcohol preference
blood pressure, 293
drinking, 293
ethanol, 293
fluid volume control, 293
hypertension, 293
renin, 293
strain differences, 293
Alcohol withdrawal
alcohol, 333
alcohol dependence, 333
audiogenically induced seizures, 333
hippocampus, 333
membrane ATPase, 333
Alcoholism
biogenic amines, 239
conditioned taste aversion, 239
lithium chloride, 239
voluntary alcohol intake, 239
Alphaprodine
anileridine, 797
meperidine, 797
morphine, 797
naloxone, 797
schedule-controlled responding, 797
Ambient temperature
p-chloroamphetamine, 851
ejaculation, 851
irritability, 851
salivation, 851
thermoregulation, 851

Ambulatory activity
d-amphetamine, 723
anorexia, 723
feeding, 723
food deprivation, 723
interrelationship of drug effects, 723
rearing, 723

Amino acids
aggression, 525
diet, 525
locomotion, 525
monoamines, 525
tolerance, 525
Aminooxyacetic acid
γ-acetylenic GABA, 113
d-amphetamine, 113
baclofen, 113
locomotor stimulation, 113
muscimol, 113
phencyclidine, 113
surgical anesthesia, 113
Amnesia
anisomycin, 79, 377, 663
brightness discrimination, 663
cycloheximide, 79
ECS, 377
inhibitory avoidance, 377
long-term memory, 377
memory, 79
memory lability, 377
paradoxical sleep, 377
protein synthesis, 377, 663
protein synthesis inhibition, 79
sensitive periods, 663
short-term memory, 377
slow-wave sleep, 377
Amobarbital
barbital, 613, 803
drinking, 613
hexobarbital, 613
lithium chloride, 613, 803
pentobarbital, 613, 803
phenobarbital, 803
secobarbital, 803
taste aversion, 613, 803
Amphetamine
A10, 603
activity, 603
anorexia, 107
antagonism, 717
antidepressants, 1
apomorphine, 61, 185, 949
body weight, 107, 701
caffeine, 949
catecholamines, 287
cathine, 701
cathinone, 701
p-chlorophenylalanine, 883
chlorpromazine, 1
cinanserin, 883
circling behavior, 185
clozapine, 1
cross-tolerance, 107, 701
delayed response, 861
2-deoxy-D-glucose, 949
desipramine, 1
discrimination learning, 595
DOPA, 185
dopamine, 185, 603, 717
DRL, 287, 883
drug-induced discrimination, 1
drug interactions, 883
eating, 717
feeding, 949
fenfluramine, 717
fluphenazine, 1
food intake, 701
frontal lobe, 861
haloperidol, 1
herpes simplex virus, 61
6-hydroxydopamine, 185, 287
hypertonic saline, 949
hypodipsia, 107
imipramine, 1
ingestive effects, 107
insulin, 949
khat, 701
lateral hypothalamic syndrome, 949
lesions, 603
locomotor activity, 61
memory, 595
methergoline, 717
methylscopolamine, 595
monkey, 861
neuroleptics, 1
nicotine, 107
nigro-striatal neurons, 185
norepinephrine, 603
nortryptiline, 1
operant behavior, 287
pentobarbital, 595
pimozide, 717
radial arm maze, 595
recovery of function, 949
response rate, 883
scopolamine, 595
serotonin, 603, 717, 883
short-term memory, 595
spatial discrimination, 595
spatial memory, 595
substantia nigra, 185
thioridazine, 1
tolerance, 107, 701
trifluoperazine, 1
ventral medial tegmentum, 603
visual discrimination, 861
zona incerta, 949
(+)-Amphetamine
drug discrimination, 303
d-Amphetamine
γ-acetylenic GABA, 113
activity, 265
adipose tissue, 543
ambulatory activity, 723
aminooxyacetic acid, 113
anorexia, 723
apomorphine, 53
arousal, 453
baclofen, 113
catecholamines, 53
chronic administration, 543
cocaine, 657, 899
conditioning factors, 543
diazepam, 657
5,7-dihydroxytryptamine, 937
dopamine, 453
experimental hypertension, 53
exploratory behavior, 453
feeding, 723
fenfluramine, 265
fixed-ratio schedule, 559, 865
food deprivation, 723
6-hydroxydopamine, 453
5-hydroxytryptamine, 937
imipramine, 899
interrelationship of drug effects, 723
interresponse-time-greater-than-t schedule, 559
ketamine, 865
lever-press, 559
locomotion, 453
locomotor stimulation, 113

d-Amphetamine (continued)
meal patterns, 265
mesolimbic dopamine system, 453
methaqualone, 657
morphine, 865
muscimol, 113
nucleus accumbens, 937
open field, 453
operant behavior, 899
operant history, 559
pentobarbital, 865, 899
phencyclidine, 113, 865
phenobarbital, 47
punishment, 865
rate-dependent effects, 559, 899
rearing, 723
response sensitization, 543
schedule-controlled behavior, 47, 657
schedules of reinforcement, 899
self-administration, 937
self-stimulation, 543
serotonin, 53
SHR rat, 53
stereotypy, 53
substantia nigra, 543
surgical anesthesia, 113
tolerance, 47
variable-interval schedule, 559
WKY rat, 53
Zucker rat, 265
S(+)-Amphetamine
brain disappearance, 137
reward, 137
self-administration, 137
tolerance, 137
Amygdala
aggression, 189
anterior colliculus, 189
dipropylacetate, 189
frontal cortex, 189
GABA, 189
gonadectomy, 189
hypothalamus, 189
lactation, 189
olfactory bulb, 189
posterior colliculus, 189
Amygdala central nucleus
β-adrenergic receptors, 419
heart rate conditioning, 419
isoproterenol, 419
propranolol, 419
Analgesic tolerance
cyclo(Leu-Gly), 73
hypothermia, 73
jump threshold, 73
MIF, 73
morphine, 73
naloxone, 73
physical dependence, 73
Pro-Leu-Gly-NH_2, 73
Analgesics
heroin, 983
schedule, 983
self-injection, 983
Analysis
acetaldehyde, 467
ethanol, 467
expiration, 467
mice strains, 467
Angiotensin I
angiotensin II, 131
estradiol benzoate, 131
urinary sodium, 131
urine output, 131
water intake, 131
Angiotensin II
angiotensin I, 131
estradiol benzoate, 131
urinary sodium, 131
urine output, 131
water intake, 131
Anhedonia
neuroleptics, 931
operant behavior, 931
pimozide, 931
reward, 931

Anileridine
alphaprodine, 797
meperidine, 797
morphine, 797
naloxone, 797
schedule-controlled responding, 797
Animal hypnosis
biphasic effects, 519
raphe nuclei, 519
serotonin, 519
tonic immobility, 519
Anisomycin
amnesia, 79, 377, 663
brightness discrimination, 663
cycloheximide, 79
ECS, 377
inhibitory avoidance, 377
long-term memory, 377
memory, 79
memory lability, 377
paradoxical sleep, 377
protein synthesis, 377, 663
protein synthesis inhibition, 79
sensitive periods, 663
short-term memory, 377
slow-wave sleep, 377

Anorexia
ambulatory activity, 723
amphetamine, 107
d-amphetamine, 723
body weight, 107
cross-tolerance, 107
feeding, 723
food deprivation, 723
hypodipsia, 107
ingestive effects, 107
interrelationship of drug effects, 723
nicotine, 107
rearing, 723
tolerance, 107
Antagonism
amphetamine, 717
dopamine, 717
eating, 717
fenfluramine, 717
methergoline, 717
pimozide, 717
serotonin, 717
Anterior colliculus
aggression, 189
amygdala, 189
dipropylacetate, 189
frontal cortex, 189
GABA, 189
gonadectomy, 189
hypothalamus, 189

lactation, 189
olfactory bulb, 189
posterior colliculus, 189
Anticonvulsant
EEG, 747
neuromuscular coordination, 747
prostaglandin D_2, 747
sedation, 747
sleeping time, 747
spontaneous locomotor activity, 747
Antidepressants
β-adrenergic receptor, 943
amphetamine, 1
chlorpromazine, 1
clozapine, 1
desipramine, 1
dihydroalprenolol binding, 943
drug-induced discrimination, 1
fluphenazine, 1
haloperidol, 1
imipramine, 1
monoamine oxidase, 943
monoamine uptake inhibition, 943
neuroleptics, 1
nortryptiline, 1
receptor sensitivity, 943
thioridazine, 1
trifluoperazine, 1
Anxiety
ACTH, 711
chlordiazepoxide, 41
dorsal periaqueductal gray, 41
electrical stimulation, 41
footshock, 41
punishment, 41
septal lesions, 41
social interaction, 711

Apomorphine
amphetamine, 61, 185, 949
d-amphetamine, 53
caffeine, 949
β-carbolines, 979
catecholamines, 53, 281
chronopharmacology, 459
circadian rhythm, 459
circling behavior, 185
2-deoxy-D-glucose, 949
development, 281
DOPA, 185
L-DOPA, 281
dopamine, 185, 515
dopamine receptor sensitivity, 29
dopaminergic neurons, 735
estrogen, 515
experimental hypertension, 53
feeding, 949
fucose, 317
glycoprotein synthesis, 317
herpes simplex, 61
hippocampus, 317
6-hydroxydopamine, 185, 281
hypertonic saline, 949
insulin, 949
lateral hypothalamic syndrome, 949
locomotor activity, 61
α-napthoxyacetic acid, 735
neuroleptics, 29
nigro-striatal neurons, 185
operant behavior, 281
ovariectomy, 515
paranoid psychosis, 979
phenylethylamine, 979
protoveratrine-A, 735
recovery of function, 949
retching, 735
schizophrenia, 979
serotonin, 53
SHR rat, 53
spiroperidol, 29
stereotypic activity, 29
stereotypy, 53, 459, 515, 979
substantia nigra, 185
tryptolines, 979
vomiting, 735
WKY rat, 53
zona incerta, 949

Apparatus
chronic subcutaneous gastric cannula in adult rats, 629
inexpensive portable device for measuring puffing behavior by cigarette smokers, 811
new injection technique for intracerebral drug administration in rats, 815
simple double channel swivel for infusions of fluids into unrestrained animals, 463
Arousal
d-amphetamine, 453
dopamine, 453
exploratory behavior, 453
6-hydroxydopamine, 453
locomotion, 453
mesolimbic dopamine system, 453
open field, 453
Arrythmias
digitalis, 235
ouabain, 235
stress, 235
toxicity, 235
Arylcyclohexylamines
fixed-interval performance, 67
ketamine, 67
monkey, 67
phencyclidine, 67
schedule-controlled behavior, 67
Associative learning
defensive burying, 445
dopamine, 445
neuroleptics, 445
pimozide, 445
Atropine sulfate
aggression, 681
cholinergic, 681
lateral hypothalamus, 681
lidocaine, 681
mouse killing, 681
Attenuation
diethyldithiocarbamate-induced amnesia, 343
lysine vasopressin, 343
passive avoidance, 343

Audiogenic seizures
brain levels, 385
bromocryptine, 823
chlorimipramine, 119
dopaminergic pathways, 823
5-hydroxytryptamine, 385
5-hydroxytryptophan, 119
6-methoxy-1,2,3,4-tetrahydro-β-carboline, 119
norepinephrine, 385
pargyline, 119
serotonin, 119
spiroperidol, 823
1,2,3,4-tetrahydro-β-carboline, 119

Audiogenically induced seizures
alcohol, 333
alcohol dependence, 333
alcohol withdrawal, 333
hippocampus, 333
membrane ATPase, 333
Aversion therapy
blocking, 337
ethanol, 337
lithium chloride, 337
second-order conditioning, 337
taste aversion conditioning, 337
Avoidance behavior
hyperbaric pressure, 413
morphine, 413
Avoidance conditioning
brain, 481
caudate nucleus, 481
cholinergic, 277
classical conditioning, 481
footshock, 277
high affinity choline uptake, 277
hippocampus, 277, 481
liver, 481
nuclear phosphoproteins, 481
sensory stimulation, 481
septo-hippocampal pathway, 277
strain differences, 277
striatum, 277
Avoidance learning
brain catecholamine levels, 767
diazepam, 767
infrasound environment, 767
locomotor activity, 767

Baclofen
γ-acetylenic GABA, 113
aminooxyacetic acid, 113
d-amphetamine, 113
locomotor stimulation, 113
muscimol, 113
phencyclidine, 113
surgical anesthesia, 113
Bar test
catalepsy, 743
morphine, 743
naloxone, 743
phenytoin, 743
phenytoin-morphine antagonism, 743
Barbital
amobarbital, 613, 803
chronic morphine, 577
conditioned avoidance response, 577
diazepam, 577
drinking, 613
drug interaction, 577
ethanol, 577
hexobarbital, 613
lithium chloride, 613, 803, 807
naloxone, 577
pentobarbital, 577, 613, 803
phenobarbital, 577, 803, 807
secobarbital, 803
taste aversion, 613, 803, 807
thiopental, 577
Behaving animals
drug self-administration, 815
fluid pump, 815
intracerebral drug administration, 815
Behavior
cat, 893
EEG, 893
methadone, 893
prolonged effects, 893
visual evoked potential, 893
Behavioral arousal
central catecholamine neurons, 925
development, 925
α-flupenthixol, 925
6-hydroxydopamine, 925
phenoxybenzamine, 925
TRH, 925
Behavioral effects
body weight, 761
pharmacokinetics, 761
phencyclidine, 761
tissue localization, 761
tolerance, 761
Behavioral responsivity
discriminant function analysis, 563
endogenous opiate system, 563
lesions, 563
limbic system, 563
morphine, 563
naloxone, 563
septal hyperreactivity, 563
Behavioral teratology
ethanol, 393
fetal alcohol, 393
open field, 393
Y-maze avoidance, 393
Behavioral thermoregulation
circadian rhythm, 843
theophylline, 843
Benzodiazepines
cat, 195
chemically stimulated feeding, 195
diazepam, 195
dog, 195
elfazepam, 195
food intake, 195
Benzodiazepine receptors
diazepam, 685
EMD 28422, 685
purines, 685
Bile
cholic acid, 555
lactation, 555
maternal pheromone, 555
Biogenic amines
alcoholism, 239
conditioned taste aversion, 239
lithium chloride, 239
voluntary alcohol intake, 239
Biphasic effects
animal hypnosis, 519
raphe nuclei, 519
serotonin, 519
tonic immobility, 519
Blocking
aversion therapy, 337
ethanol, 337
lithium chloride, 337
second-order conditioning, 337
taste aversion conditioning, 337
Blood-brain barrier
hypothalamus, 871
intraventricular injection, 871
metoclopramide, 871
neuroleptics, 871
schizophrenia, 871
self-stimulation, 871
spiroperidol, 871

Blood levels
desalivation, 223
ethanol, 223
ethanol intake, 223
ethanol preference, 223
Blood pressure
alcohol preference, 293
drinking, 293
ethanol, 293
fluid volume control, 293
hypertension, 293
renin, 293
strain differences, 293
Body shakes
clonidine, 573
diarrhea, 573
lofexidine, 573
morphine, 573
naloxone, 573
withdrawal, 573
Body weight
amphetamine, 107, 701
anorexia, 107
behavioral effects, 761
cathine, 701
cathinone, 701
cross-tolerance, 107, 701
food intake, 701
hypodipsia, 107
ingestive effects, 107
khat, 701
nicotine, 107
pharmacokinetics, 761
phencyclidine, 761
tissue localization, 761
tolerance, 107, 701, 761
Body weight regulation
cannabinol, 143
exteroceptive stimulus from conspecifics, 143
follicle-stimulating hormone, 143
luteinizing hormone, 143
perinatal exposure, 143
pheromones, 143
pituitary-gonadal axis, 143
sexual behavior, 143
sexual differentiation, 143
testis function, 143
testosterone, 143
Δ^9-tetrahydrocannabinol, 143
transfer of cannabinoids via milk, 143
Bombesin
ACTH, 93
delta sleep-inducing peptide, 93
enkephalin, 93
ethanol, 93
His-Pro diketopiperazine, 93
naloxone, 93
peptide, 93
stimulus properties of drugs, 93
substance P, 93
thyrotropin releasing hormone, 93
Brain
A10, 603
amygdala, 189, 419
anterior colliculus, 189
avoidance conditioning, 481
caudate nucleus, 249, 371, 481
cerebellum, 217
classical conditioning, 481
cortex, 35, 217
dorsal periaqueductal gray, 41
frontal cortex, 189
frontal lobe, 861
hippocampus, 217, 277, 317, 319, 333, 481, 855
hypothalamus, 35, 125, 189, 217, 549, 837, 871
lateral hypothalamus, 371, 487, 681
limbic system, 563
liver, 481
mesolimbic system, 453
midbrain, 35
nuclear phosphoproteins, 481
nucleus accumbens, 781, 937
olfactory bulb, 189
paraventricular nucleus, 837
pituitary, 365
posterior colliculus, 189
raphe nuclei, 519, 855
rostral pons, 353
sensory stimulation, 481
septum, 41
striatum, 277, 855
substantia nigra, 185, 543
ventral medial tegmentum, 603
ventral tegmental area, 965
zona incerta, 949

Brain catecholamine levels
avoidance learning, 767
diazepam, 767
infrasound environment, 767
locomotor activity, 767
Brain chromatin
corticosterone, 207
development, 207
template active region, 207
Brain cytochrome c
brain non-heme iron, 493
hole-board, 493
iron deficiency, 493
open field, 493
passive avoidance, 493
pituitary-adrenal system, 493
Brain disappearance
S(+)-amphetamine, 137
reward, 137
self-administration, 137
tolerance, 137
Brain distribution
brain penetrability, 217
^{3}H-cannabidiol, 217
^{3}H-cannabinol, 217
cerebellum, 217
cortex, 217
hippocampus, 217
hypothalamus, 217
medulla, 217
midbrain, 217
pharmacokinetics, 217
striatum, 217
^{3}H-Δ^9-tetrahydrocannabinol, 217
Brain extracts
information transfer, 7
learning, 7
memory consolidation, 7
passive avoidance, 7
Brain levels
audiogenic seizures, 385
5-hydroxytryptamine, 385
norepinephrine, 385
Brain monoamines
dopamine, 311
5-hydroxytryptamine, 311
parachlorophenylalanine, 311
strain differences, 311

Brain non-heme iron
brain cytochrome c, 493
hole-board, 493
iron deficiency, 493
open field, 493
passive avoidance, 493
pituitary-adrenal system, 493
Brain penetrability
brain distribution, 217
^{3}H-cannabidiol, 217
^{3}H-cannabinol, 217
cerebellum, 217
cortex, 217
hippocampus, 217
hypothalamus, 217
medulla, 217
midbrain, 217
pharmacokinetics, 217
striatum, 217
^{3}H-Δ^9-tetrahydrocannabinol, 217
Brain rewarding system
naloxone, 729
opiate systems, 729
pain modulating system, 729
taste aversion, 729
taste preference, 729
Brightness discrimination
amnesia, 663
anisomycin, 663
hippocampus, 319
memory consolidation, 319
protein synthesis, 319, 663
sensitive periods, 663
serotonin, 319
Bromocryptine
audiogenic seizures, 823
dopaminergic pathways, 823
spiroperidol, 823
t-Butanol
calcium, 651
chloral hydrate, 651
EDTA, 651
EGTA, 651
ethanol, 651
ionophores, 651
pentobarbital, 651
sleeping time, 651

Caffeine
amphetamine, 949
apomorphine, 949
2-deoxy-D-glucose, 949
feeding, 949
hypertonic saline, 949
insulin, 949
lateral hypothalamine syndrome, 949
recovery of function, 949
zona incerta, 949
Calcitonin
drinking, 609
feeding, 609
satiety, 609
urination, 609
weight loss, 609
Calcium
t-butanol, 651
chloral hydrate, 651
EDTA, 651
EGTA, 651
ethanol, 651
ionophores, 651
pentobarbital, 651
sleeping time, 651
^{3}H-Cannabidiol
brain distribution, 217
brain penetrability, 217
pharmacokinetics, 217
Cannabinoids
EEG in sleep-walking behavior, 99
hallucinogens, 99
long-term EEG frequency analysis, 99
LSD, 99
mescaline, 99
psilocybin, 99
synhexyl, 99
Δ^9-tetrahydrocannabinol, 99
Cannabinol
body weight regulation, 143
exteroceptive stimulus from conspecifics, 143
follicle-stimulating hormone, 143
luteinizing hormone, 143
perinatal exposure, 143
pheromones, 143
pituitary-gonadal axis, 143
sexual behavior, 143
sexual differentiation, 143
testis function, 143
testosterone, 143
Δ^9-tetrahydrocannabinol, 143
transfer of cannabinoids via milk, 143
^{3}H-Cannabinol
brain distribution, 217
brain penetrability, 217
pharmacokinetics, 217
Carbachol
cholinergic mechanism, 487
jump threshold, 487
lateral hypothalamus, 487
physostigmine, 487
scopolamine, 487
shock-induced defensive fighting, 487
Carbohydrate
dietary self-selection, 427
fat, 427
feeding behavior, 427
morphine, 427
protein, 427
β-Carbolines
apomorphine, 979
paranoid psychosis, 979
phenylethylamine, 979
schizophrenia, 979
stereotypy, 979
tryptolines, 979
Cat
behavior, 893
benzodiazepines, 195
chemically stimulated feeding, 195
diazepam, 195
dog, 195
EEG, 893
elfazepam, 195
food intake, 195
methadone, 893
prolonged effects, 893
visual evoked potential, 893
Catalepsy
activity, 347
bar test, 743
chickens, 347
dopaminergic system, 347
haloperidol, 347
morphine, 743
naloxone, 743

phenytoin, 743
phenytoin-morphine antagonism, 743
quipazine, 347
raphe model, 347
serotonergic system, 347
stereotypy, 347
tonic immobility, 346
Catecholamines
adrenaline, 449
aggregation, 313
albinism, 969
amphetamine, 287
d-amphetamine, 53
apomorphine, 53, 281
correlation, 449
cortisol, 449
development, 281
L-DOPA, 281
DRL, 287
experimental hypertensions, 53
heart rate, 449
high performance liquid chromatography, 959
humans, 449
6-hydroxydopamine, 281, 287
indoles, 959
isolation, 313
lethal dose, 313
melanin, 969
morphine, 313
noradrenaline, 449
operant behavior, 281, 287
oxotremorine, 353
push-pull perfusion, 959
response consistency, 449
rostral pons, 353
schedule dependent behavior, 959
serotonin, 53, 313
sex differences, 449
SHR rat, 53
sleep, 353
stereotypy, 53
tyrosinase, 969
tyrosine, 969
tyrosine hydroxylase, 353
WKY rat, 53
Cathine
amphetamine, 701
body weight, 701
cathinone, 701
cross tolerance, 701
food intake, 701
khat, 701
tolerance, 701
Cathinone
amphetamine, 701
body weight, 701
cathine, 701
cross tolerance, 701
food intake, 701
khat, 701
tolerance, 701
Caudate nucleus
avoidance conditioning, 481
brain, 481
cholinergic blockade, 249
classical conditioning, 481
eating and drinking deficits, 371
hippocampus, 481
6-hydroxydopamine, 371
lateral hypothalamus, 371
learning, 249
liver, 481
α-methylparatyrosine, 371
monoamine accumulation, 371
nigrostriatal dopamine, 371
nuclear phosphoproteins, 481
overtraining, 249
post-synaptic supersensitivity, 371
potassium chloride, 249
scopolamine, 249
sensory stimulation, 481
Central catecholamine neurons
behavioral arousal, 925
development, 925
α-flupenthixol, 925
6-hydroxydopamine, 925
phenoxybenzamine, 925
TRH, 925
Cerebellum
brain distribution, 217
brain penetrability, 217
^{3}H-cannabidiol, 217
^{3}H-cannabinol, 217
^{3}H-Δ^9-tetrahydrocannabinol, 217
Chemically stimulated feeding
benzodiazepines, 195
cat, 195
diazepam, 195
dog, 195
elfazepam, 195
food intake, 195
Chickens
activity, 347
catalepsy, 347
dopaminergic system, 347
haloperidol, 347
quipazine, 347
raphe model, 347
serotonergic system, 347
stereotypy, 347
tonic immobility, 346
Chloral hydrate
t-butanol, 651
calcium, 651
EDTA, 651
EGTA, 651
ethanol, 651
ionophores, 651
pentobarbital, 651
sleeping time, 651
Chlordiazepoxide
acetylcholine, 437
anxiety, 41
conflict behavior, 819
distress vocalizations, 437
dorsal periaqueductal gray, 41
drinking, 819
electrical stimulation, 41
fear, 23
food familiarization, 23
food novelty, 23
food preference, 23
footshock, 23, 41
isoproterenol, 819
neophobia, 23
norepinephrine, 437
opiates, 437
punishment, 41
septal lesions, 41
serotonin, 437
Chlorimipramine
audiogenic seizures, 119
5-hydroxytryptamine, 255
5-hydroxytryptophan, 119

Chlorimiprimine (continued)
6-methoxy-1,2,3,4-tetrahydro-β-carboline, 119
noradrenaline, 255
pargyline, 119
protriptyline, 255
serotonin, 119
1,2,3,4-tetrahydro-β-carboline, 119
tube running activity, 255
p-Chloroamphetamine
ambient temperature, 851
ejaculation, 851
irritability, 851
salivation, 851
thermoregulation, 851
p-Chlorophenylalanine
amphetamine, 883
cinanserin, 883
defecation, 875
5,6-dihydroxytryptamine, 875
DRL, 883
drug interactions, 883
emotionality, 875
fenfluramine, 181
5-hydroxytryptamine, 875
5-hydroxytryptophan, 875
marking behavior, 181
α-methyltyrosine, 181
open field, 875
reserpine, 875
response rate, 883
serotonin, 883
shuttle box, 875
testosterone, 181
Chlorpromazine
amphetamine, 1
antidepressants, 1
clozapine, 1
desipramine, 1
drug-induced discrimination, 1
fluphenazine, 1
haloperidol, 1
imipramine, 1
neuroleptics, 1
nortryptiline, 1
thioridazine, 1
trifluoperazine, 1
Cholic acid
bile, 555
lactation, 555
maternal pheromone, 555
Cholinergic
aggression, 681
atropine sulfate, 681
avoidance conditioning, 277
footshock, 277
high affinity choline uptake, 277
hippocampus, 277
lateral hypothalamus, 681
lidocaine, 681
mouse killing, 681
septo-hippocampal pathway, 277
strain differences, 277
striatum, 277
Cholinergic blockade
caudate nucleus, 249
learning, 249
overtraining, 249
potassium chloride, 249
scopolamine, 249
Cholinergic mechanism
carbachol, 487
jump threshold, 487
lateral hypothalamus, 487
physostigmine, 487
scopolamine, 487
shock-induced defensive fighting, 487
Cholinesterase inhibition
neostigmine, 847
physostigmine, 847
shuttle-box avoidance, 847
Chronic administration
adipose tissue, 543
aggressive behavior, 305
d-amphetamine, 543
conditioning factors, 543
response sensitization, 543
schedule-induced behavior, 305
self-stimulation, 543
substantia nigra, 543
Δ^9-tetrahydrocannabinol, 305
Chronic morphine
barbital, 577
conditioned avoidance response, 577
diazepam, 577
drug interaction, 577
ethanol, 577
naloxone, 577
pentobarbital, 577
phenobarbital, 577
thiopental, 577
Chronic preparation
subcutaneous gastric
cannula, 629
Chronopharmacology
apomorphine, 459
circadian rhythm, 459
stereotypy, 459
Cigarette smoking
human research, 811
interbout interval, 811
puff monitor, 811
puff rate, 811
puffing behavior, 811
Cinanserin
amphetamine, 883
p-chlorophenylalanine, 883
DRL, 883
drug interaction, 883
response rate, 883
serotonin, 883
Circadian rhythm
apomorphine, 459
behavioral thermoregulation, 843
chronopharmacology, 459
corticosterone, 549
histamine, 549
hypothalamus, 549
spontaneous locomotor activity, 459
stereotypy, 459
temperature, 549
theophylline, 843
Circling behavior
amphetamine, 185
apomorphine, 185
DOPA, 185
dopamine, 185
6-hydroxydopamine, 185
nigro-striatal neurons, 185
substantia nigra, 185
Classical conditioning
avoidance conditioning, 481
brain, 481
caudate nucleus, 481
hippocampus, 481

liver, 481
nuclear phosphoproteins, 481
sensory stimulation, 481
Clonidine
adrenergic system, 755
body shakes, 573
copulation, 755
diarrhea, 573
estrus, 755
lofexidine, 573
morphine, 573
naloxone, 573
withdrawal, 573
Clozapine
amphetamine, 1
antidepressants, 1
chlorpromazine, 1
desipramine, 1
drug-induced discrimination, 1
fluphenazine, 1
haloperidol, 1
imipramine, 1
neuroleptics, 1
nortryptiline, 1
thioridazine, 1
trifluoperazine, 1

Cocaine
d-amphetamine, 657, 889
diazepam, 657
dopamine, 781
6-hydroxydopamine, 781
imipromine, 899
methaqualone, 657
nucleus accumbens, 781
operant behavior, 899
pentobarbital, 899
rate-dependent effects, 899
schedule-controlled behavior, 657
schedules of reinforcement, 899
self-administration, 781
Conditioned avoidance response
barbital, 577
chronic morphine, 577
diazepam, 577
drug interaction, 577
ethanol, 577
naloxone, 577
pentobarbital, 577
phenobarbital, 577
thiopental, 577
Conditioned emotional response
extinction, 409
operant behavior, 409
punishment, 409
scopolamine, 409
suppressed responding, 409
variable interval schedule, 409

Conditioned responses
drinking, 789
drug conditioning, 789
lithium chloride, 789
taste aversion conditioning, 789
Conditioned taste aversion
alcoholism, 239
biogenic amines, 239
dependence, 707
ethanol, 707
lithium chloride, 239
voluntary alcohol intake, 239
withdrawal syndrome, 707

Conditioning
glutamate, 533
memory trace, 533
l-proline, 533
l-proline analogs, 533
retrograde amnesia, 533
spreading depression, 533
Conditioning factors
adipose tissue, 543
d-amphetamine, 543
chronic administration, 543
response sensitization, 543
self-stimulation, 543
substantia nigra, 543

Conflict behavior
chlordiazepoxide, 819
drinking, 819
isoproterenol, 819
Copulation
adrenergic system, 755
chonidine, 755
estrus, 755
Correlation
adrenaline, 449
catecholamines, 449
cortisol, 449
heart rate, 449
humans, 449
noradrenaline, 449
response consistency, 449
sex differences, 449
Cortex
brain distribution, 217
brain penetrability, 217
^{3}H-cannabidiol, 217
^{3}H-cannabinol, 217
corticosterone, 35
histamine, 35
hypothalamus, 35
midbrain, 35
stress, 35
^{3}H-Δ^{9}-tetrahydrocannabinol, 217

Corticosterone
ACTH, 201
adrenal, 201
adrenalectomy, 201
brain chromatin, 207
circadian rhythm, 549
cortex, 35
development, 207
dexamethasone, 201
female sexual behavior, 201
histamine, 35, 549
hypothalamus, 35, 549
lordosis, 201
midbrain, 35
ovariectomy, 201
spontaneous locomotor activity, 549
stress, 35
temperature, 549
template active region, 207
Cortisol
adrenaline, 449
catecholamines, 449
correlation, 449
heart rate, 449
humans, 449
noradrenaline, 449
response consistency, 449
sex differences, 449

Cross-tolerance
amphetamine, 107, 701
anorexia, 107
body weight, 107, 701
cathine, 701
cathinone, 701
food intake, 701
hypodipsia, 107
ingestive effects, 107
khat, 701
nicotine, 107
tolerance, 107, 701
Cyclo(Leu-Gly)
analgesic tolerance, 73
hypothermia, 73
jumpthreshold, 73
MIF, 73
morphine, 73
naloxone, 73
physical dependence, 73
Pro-Leu-Gly-NH_2, 73
Cycloheximide
amnesia, 79
anisomycin, 79
memory, 79
protein synthesis inhibition, 79
Cyproterone acetate
estradiol, 359
ewe, 359
receptivity, 359
sexual behavior, 359
testosterone, 359

Defecation
p-chlorophenylalanine, 875
5,6-dihydroxytryptamine, 875
emotionality, 875
11-hydroxycorticosterone, 773
5-hydroxytryptamine, 875
5-hydroxytryptophan, 875
hypophysectomy, 773
α-MSH, 773
novelty, 773
open field, 875
reserpine, 875
shuttle box, 875
whole brain dopamine, 773
whole brain norepinephrine, 773
Defensive burying
associative learning, 445
dopamine, 445
neuroleptics, 445
pimozide, 445
Delayed response
amphetamine, 861
L-DOPA, 229
dopamine, 229
frontal lobe, 861
5-hydroxytryptophan, 229
monkey, 861
R04-4602, 229
serotonin, 229
visual discrimination, 861
Delta sleep-inducing peptide
ACTH, 93
bombesin, 93
enkephalin, 93
ethanol, 93
His-Pro diketopiperazine, 93
naloxone, 93
peptide, 93
stimulus properties of drugs, 93
substance P, 93
thyrotropin releasing hormone, 93
2-Deoxy-D-glucose
amphetamine, 949
apomorphine, 949
caffeine, 949
feeding, 949
hypertonic saline, 949
insulin, 949
lateral hypothalamic syndrome, 949
recovery of function, 949
zona incerta, 949
Dependence
abstinence syndrome, 645
conditioned taste aversion, 707
D-Ala^2-Met^5-enkephalinamide, 645
D-Met^2-Pro^5-enkephalinamide, 645
ethanol, 707
hypothermia, 645
morphine, 645
naloxone, 645
withdrawal syndrome, 707
Dependence potential
physical dependence, 155
rhesus monkey, 155
self-administration, 155
viloxazine, 155
Deprivation
drinking, 431
ingestion, 431
morphine, 431
naloxone, 431
opioids, 431
Desalivation
blood levels, 223
ethanol, 223
ethanol intake, 223
ethanol preference, 223
Desipramine
amphetamine, 1
antidepressants, 1
chlorpromazine, 1
clozapine, 1
drug-induced discrimination, 1
fluphenazine, 1
haloperidol, 1
imipramine, 1
neuroleptics, 1
nortryptiline, 1
thioridazine, 1
trifluoperazine, 1
Development
apomorphine, 281
behavioral arousal, 925
brain chromatin, 207
catecholamines, 281
central catecholamine neurons, 925
corticosterone, 207
L-DOPA, 281
α-flupenthixol, 925
6-hydroxydopamine, 281, 925
operant behavior, 281
phenoxybenzamine, 925
template active region, 207
TRH, 925

Dexamethasone
ACTH, 201
adrenal, 201
adrenalectomy, 201
corticosterone, 201
female sexual behavior, 201

lordosis, 201
ovariectomy, 201
Diarrhea
body shakes, 573
clonidine, 573
lofexidine, 573
morphine, 573
naloxone, 573
withdrawal, 573
Diazepam
d-amphetamine, 657
avoidance learning, 767
barbital, 577
benzodiazepine receptors, 685
benzodiazepines, 195
brain catecholamine levels, 767
cat, 195
chemically stimulated feeding, 195
chronic morphine, 577
cocaine, 657
conditioned avoidance response, 577
dog, 195
drug interaction, 577
elfazepam, 195
EMD 28422, 685
ethanol, 577
food intake, 195
infrasound environment, 767
locomotor activity, 767
methaqualone, 657
naloxone, 577
pentobarbital, 577
phenobarbital, 577
purines, 685
schedule-controlled behavior, 657
thiopental, 577
Diet
aggression, 525
amino acids, 525
locomotion, 525
monoamines, 525
tolerance, 505
Dietary self-selection
carbohydrate, 427
fat, 427
feeding behavior, 427
morphine, 427
protein, 427
Diet supplement
aggressive behavior, 667
aging, 667
dopamine, 667
motor activity, 667
norepinephrine, 667
precursor amino acids, 667
serotonin, 667
stress, 667
tyrosine, 667
Diethyldithiocarbamate-induced amnesia
attenuation, 343
lysine vasopressin, 343
passive avoidance, 343
Digitalis
arrythmias, 235
ouabain, 235
stress, 235
toxicity, 235

Dihydroalprenolol binding
β-adrenergic receptor, 943
antidepressants, 943
monoamine oxidase, 943
monoamine uptake inhibition, 943
receptor sensitivity, 943
5,6-Dihydroxytryptamine
p-chlorophenylalanine, 875
defecation, 875
emotionality, 875
5-hydroxytryptamine, 875
5-hydroxytryptophan, 875
open field, 875
reserpine, 875
shuttle box, 875
5,7-Dihydroxytryptamine
aggression, 855
d-amphetamine, 937
hippocampus, 855
5-hydroxytryptamine, 937
locomotor activity, 855
nucleus accumbens, 937
raphe nuclei, 855
self-administration, 937
serotonin, 855
social interaction, 855
striatum, 855
Dipropylacetate
aggression, 189
amygdala, 189
anterior colliculus, 189
frontal cortex, 189
GABA, 189
gonadectomy, 189
hypothalamus, 189
lactation, 189
olfactory bulb, 189
posterior colliculus, 189

Discriminant function analysis
behavioral responsivity, 563
endogenous opiate system, 563
lesions, 563
limbic system, 563
morphine, 563
naloxone, 563
septal hyperreactivity, 563
Discrimination
electric shock, 403
meperidine, 403
morphine, 403
SKF-525A, 403
squirrel monkey, 403
titration, 403
Discrimination learning
amphetamine, 595
memory, 595
methylscopolamine, 595
pentobarbital, 595
radial arm maze, 595
scopolamine, 595
short-term memory, 595
spatial discrimination, 595
spatial memory, 595
Discriminative stimulus
drug discrimination, 587
morphine, 587
naloxone, 587
naltrexone, 587
pA_2, 587
Distress vocalizations
acetylcholine, 437
chlordiazepoxide, 437
norepinephrine, 437
opiates, 437
serotonin, 437

Dog
benzodiazepines, 195
cat, 195
chemically stimulated feeding, 195
diazepam, 195
elfazepam, 195
food intake, 195
DOPA
amphetamine, 185
apomorphine, 185
circling behavior, 185
dopamine, 185
6-hydroxydopamine, 185
nigro-striatal neurons, 185
substantia nigra, 185
L-DOPA
apomorphine, 281
catecholamines, 281
delayed responses, 229
development, 281
dopamine, 229
6-hydroxydopamine, 281
5-hydroxytryptophan, 229
operant behavior, 281
R04-4602, 229
serotonin, 229
Dopamine
A 10, 603
activity, 603
aggressive behavior, 667
aging, 667
amphetamine, 185, 603, 717
d-amphetamine, 453
antagonism, 717
apomorphine, 185, 515
arousal, 453
associative learning, 445
brain monoamines, 311
circling behavior, 185
cocaine, 781
defensive burying, 445
delayed responses, 229
diet supplement, 667
DOPA, 185
L-DOPA, 229
eating, 717
endorphin, 389
estrogen, 515
exploratory behavior, 453
fenfluramine, 717
fluspirilene, 389
6-hydroxydopamine, 185, 453, 781
5-hydroxytryptamine, 311
5-hydroxytryptophan, 229
lesions, 603
locomotion, 453
mesolimbic dopamine system, 453
methergoline, 717
motor activity, 667
naltrexone, 389
neuroleptics, 445
nigro-striatal neurons, 185
norepinephrine, 603, 667
nucleus accumbens, 781
open field, 453
ovariectomy, 515
parachlorophenylalanine, 311
pimozide, 445, 717
precursor amino acids, 667
R04-4602, 229
self-administration, 781
self-stimulation, 389
serotonin, 229, 603, 667, 717
stereotypy, 515
strain differences, 311
stress, 389, 667
substantia nigra, 185
tail pinch, 389
tyrosine, 667
ventral medial tegmentum, 603
Dopamine receptor sensitivity
apomorphine, 29
neuroleptics, 29
spiroperidol, 29
stereotypic activity, 29
Dopaminergic neurons
apomorphine, 735
α-naphthoxyacetic acid, 735
protoveratrine-A, 735
retching, 735
vomiting, 735
Dopaminergic pathways
audiogenic seizures, 823
bromocryptine, 823
spiroperidol, 823
Dopaminergic receptor
adenylate cyclase, 509
β-adrenergic receptor, 509
ethanol, 509
genetics, 509
muscarinic cholinergic receptor, 509
Dopaminergic system
activity, 347
catalepsy, 347
chickens, 347
haloperidol, 347
quipazine, 347
raphe model, 347
serotonergic system, 347
stereotypy, 347
tonic immobility, 347
Dorsal periaqueductal gray
anxiety, 41
chlordiazepoxide, 41
electrical stimulation, 41
footshock, 41
punishment, 41
septal lesions, 41
Double channel
flow-thru, 463
infusions, 463
swivel, 463
unrestrained animals, 463
Drinking
alcohol preference, 293
amobarbital, 613
barbital, 613
blood pressure, 293
calcitonin, 609
chlordiazepoxide, 819
conditioned responses, 789
conflict behavior, 819
deprivation, 431
drug conditioning, 789
ethanol, 293
feeding, 609
fluid volume control, 293
hexobarbital, 613
hypertension, 293
hypertonic saline, 987
ingestion, 431
isoproterenol, 819
lithium chloride, 613, 789
morphine, 431

naloxone, 431, 987
opioids, 431
pentobarbital, 613
renin, 293
satiety, 609
strain differences, 293
taste aversion, 613
taste aversion conditioning, 789
urination, 609
weight loss, 609
DRL
amphetamine, 287, 883
catecholamines, 287
p-chlorophenylalanine, 883
cinanserin, 883
drug interactions, 883
6-hydroxydopamine, 287
response rate, 883
operant behavior, 287
serotonin, 883
Drug
γ-acetylenic GABA, 113
alcohol, 333
alphaprodine, 797
aminooxyacetic acid, 113
amobarbital, 613, 803
amphetamine, 1, 61, 107, 185, 287, 595, 603, 701, 717, 861, 883, 949
d-amphetamine, 47, 53, 113, 265, 453, 543, 559, 657, 723, 865, 899, 937
(+)-amphetamine, 303
s(+)-amphetamine, 137
anileridine, 797
anisomycin, 79, 377, 663
apomorphine, 29, 53, 61, 185, 281, 317, 459, 515, 735, 949, 979
atropine sulfate, 681
baclofen, 113
barbital, 577, 613, 803, 807
bromocryptine, 823
t-butanol, 651
caffeine, 949
^{3}H-cannabidiol, 217
cannabinol, 143
^{3}H-cannabinol, 217
carbachol, 487
β-carbolines, 979
cathine, 701
cathinone, 701
chloral hydrate, 651
chlordiazepoxide, 23, 41, 437, 819
chlorimipramine, 119, 255
p-chloroamphetamine, 851
p-chlorophenylalanine, 181, 875, 883
chlorpromazine, 1
cinanserin, 883
clonidine, 573, 755
clozapine, 1
cocaine, 657, 781, 899
cycloheximide, 79
cyproterone acetate, 359
2-deoxy-D-glucose, 949
desipramine, 1
dexamethasone, 201
diazepam, 195, 577, 657, 685, 767
diethyldithiocarbamate, 343
digitalis, 235
5,6-dihydroxytryptamine, 875
5,7-dihydroxytryptamine, 855, 937
dipropylacetate, 189
DOPA, 185, 229, 281
elfazepam, 195
EMD 28422, 685
D-Ala^2-Met^5-endephalinamide, 645
D-Met^2-Pro^5-enkephalinamide, 645
ethanol, 93, 223, 293, 297, 337, 393, 467, 503, 509, 577, 651, 691, 707, 909
fenfluramine, 181, 265, 717
α-flupenthixol, 925
fluphenazine, 1
fluspirilene, 389
haloperidol, 1, 347
halothane, 691
heroin, 163, 983
hexamethonium, 619
hexobarbital, 613
6-hydroxydopamine, 185, 281, 287, 371, 453, 781, 925
5-hydroxytryptophan, 119, 229, 875
imipramine, 1, 899
isoproterenol, 419, 819
ketamine, 67, 865
khat, 701
lidocaine, 681
lithium chloride, 239, 337, 613, 789, 803, 807
lofexidine, 573
LSD, 99
mecamylamine, 619
meperidine, 403, 797
mescaline, 99
methadone, 893
methaqualone, 657
methergoline, 717
6-methoxy-1,2,3,4-tetrahydro-β-carboline, 119
α-methylparatyrosine, 371
methylscopolamine, 595
α-methyltyrosine, 181
metoclopramide, 871
morphine, 73, 313, 403, 413, 427, 431, 563, 573, 577, 587, 625, 645, 743, 797, 865, 965
muscimol, 113
naloxone, 73, 93, 365, 431, 563, 573, 577, 587, 625, 645, 729, 743, 797, 965, 987
naltrexone, 163, 389, 587
α-naphthoxyacetic acid, 735
neostigmine, 847
nialamide, 259
nicotine, 107, 619
nortryptiline, 1
ouabain, 235
oxotremorine, 353
parachlorophenylalanine, 311
pargyline, 119
pentobarbital, 577, 595, 613, 651, 803, 865, 899
phencyclidine, 67, 113, 761, 865
phenobarbital, 47, 577, 803, 807
phenoxybenzamine, 925
phenylethylamine, 979
phenytoin, 743
physostigmine, 487, 847
picrotoxin, 125
pimozide, 445, 717, 917, 931
potassium chloride, 249
prednisone, 213
propranolol, 419
protoveratrine-A, 735
protriptyline, 255
psilocybin, 99
quipazine, 347
reserpine, 875
R04-4602, 229
scopolamine, 249, 409, 487, 595
secobarbital, 803
SKF-525A, 403
spiroperidol, 29, 823, 871
synhexyl, 99

Drug (continued)
1,2,3,4-tetrahydro-β-carboline, 119
Δ^9-tetrahydrocannabinol, 85, 99. 143, 305, 697
^{3}H-Δ^9-tetrahydrocannabinol, 217
theophylline, 843
thiopental, 577
thioridazine, 1
trifluoperazine, 1
tryptolines, 979
viloxazine, 155
Drug conditioning
conditioned responses, 789
drinking, 789
lithium chloride, 789
taste aversion conditioning, 789
Drug discrimination
(+)-amphetamine, 303
discriminative stimulus, 587
morphine, 587
naloxone, 587
naltrexone, 587
pA_2, 587
Drug-induced discrimination
amphetamine, 1
antidepressants, 1
chlorpromazine, 1
clozapine, 1
desipramine, 1
fluphenazine, 1
haloperidol, 1
imipramine, 1
neuroleptics, 1
nortryptiline, 1
thioridazine, 1
trifluoperazine, 1
Drug interactions
amphetamine, 883
barbital, 577
p-chlorophenylalanine, 883
chronic morphine, 577
cinanserin, 883
conditioned avoidance response, 577
diazepam, 577
DRL, 883
ethanol, 577
naloxone, 577
pentobarbital, 577
phenobarbital, 577
response rate, 883
serotonin, 883
thiopental, 577
Drug self-administration
behaving animals, 815
fluid pump, 815
intracerebral drug administration, 815

Eating
amphetamine, 717
antagonism, 717
dopamine, 717
extinction, 917
fenfluramine, 717
methergoline, 717
operant behavior, 917
pimozide, 717, 917
reward, 917
serotonin, 717
Eating and drinking deficits
caudate nucleus, 371
6-hydroxydopamine, 371
lateral hypothalamus, 371
α-methylparatyrosine, 371
monoamine accumulation, 371
nigrostriatal dopamine, 371
post-synaptic supersensitivity, 371
ECS
amnesia, 377
anisomycin, 377
inhibitory avoidance, 377
long-term memory, 377
memory lability, 377
paradoxical sleep, 377
protein synthesis, 377
short-term memory, 377
slow-wave sleep, 377
EDTA
t-butanol, 651
calcium, 651
chloral hydrate, 651
EGTA, 651
ethanol, 651
ionophores, 651
pentobarbital, 651
sleeping time, 651
EEG
anticonvulsant, 747
behavior, 893
cat, 893
methadone, 893
neuromuscular coordination, 747
prolonged effects, 893
prostaglandin D_2, 747
sedation, 747
sleeping time, 747
spontaneous locomotor activity, 747
visual evoked potential, 893
EEG in sleep-waking behavior
cannabinoids, 99
hallucinogens, 99
long-term EEG frequency analysis, 99
LSD 99
mescaline, 99
psilocybin, 99
synhexyl, 99
Δ^9-tetrahydrocannabinol, 99
EGTA
t-butanol, 651
calcium, 651
chloral hydrate, 651
EDTA, 651
ethanol, 651
ionophones, 651
pentobarbital, 651
sleeping time, 651
Ejaculation
ambient temperature, 851
p-chloroamphetamine, 851
irritability, 851
salivation, 851
thermoregulation, 851
Electric shock
discrimination, 403
meperidine, 403
morphine, 403
SKF-525A, 403
squirrel monkey, 403
titration, 403
Electrical stimulation
anxiety, 41
chlordiazepoxide, 41
dorsal periaqueductal gray, 41
footshock, 41
punishment, 41
septal lesions, 41

Elfazepam
benzodiazepines, 195
cat, 195
chemically stimulated feeding, 195
diazepam, 195
dog, 195
food intake, 195
EMD 28422
benzodiazepine receptors, 685
diazepam, 685
purines, 685
Emotionality
p-chlorophenylalanine, 875
defecation, 875
5,6-dihydroxytryptamine, 875
5-hydroxytryptamine, 875
5-hydroxytryptophan, 875
open field, 875
reserpine, 875
shuttle box, 875
Endogenous opiate system
behavioral responsivity, 563
discriminant function analysis, 563
lesions, 563
limbic system, 563
morphine, 563
naloxone, 563
septal hyperreactivity, 563
Endorphin
dopamine, 389
17α-estradiol, 365
fluspirilene, 389
hypophysectomy, 365
luteinizing hormone releasing hormone, 365
naloxone, 365
naltrexone, 389
pituitary, 365
self-stimulation, 389
sexual behavior, 365
stress, 389
tail pinch, 389
Enkephalin
ACTH, 93
bombesin, 93
delta sleep-inducing peptide, 93
ethanol, 93
His-Pro diketopiperazine, 93
naloxone, 93
peptide, 93
stimulus properties of drugs, 93
substance P, 93
thyrotropin releasing hormone, 93
D-Ala^2-Met^5-Enkephalinamide
abstinence syndrome, 645
dependence, 645
D-Met^2-Pro^5-enkephalinamide, 645
hypothermia, 645
morphine, 645
naloxone, 645
D-Met^2-Pro^5-Enkephalinamide
abstinence syndrome, 645
dependence, 645
D-Ala^2-Met^5-enkephalinamide, 645
hypothermia, 645
morphine, 645
naloxone, 645
Estradiol
cyproterone acetate, 359
ewe, 359
receptivity, 359
sexual behavior, 359
testosterone, 359
17α-Estradiol
endorphin, 365
hypophysectomy, 365
luteinizing hormone releasing hormone, 365
naloxone, 365
pituitary, 365
sexual behavior, 365
Estradiol benzoate
angiotensin I, 131
angiotensin II, 131
urinary sodium, 131
urine output, 131
water intake, 131
Estrogen
apomorphine, 515
dopamine, 515
ovariectomy, 515
stereotypy, 515
Estrus
adrenergic system, 755
clonidine, 755
copulation, 755
Ethanol
acetaldehyde, 467
ACTH, 93
addiction, 909
adenylate cyclase, 509
β-adrenergic receptor, 509
alcohol, 297
alcohol preference, 293
analysis, 467
aversion therapy, 337
barbital, 577
behavioral teratology, 393
blocking, 337
blood levels, 223
blood pressure, 293
bombesin, 93
t-butanol, 651
calcium, 651
chloral hydrate, 651
chronic morphine, 577
conditioned avoidance response, 577
conditioned taste aversion, 707
delta sleep-inducing peptide, 93
dependence, 707
desalivation, 223
diazepam, 577
dopaminergic receptor, 509
drinking, 293
drug interaction, 577
EDTA, 651
EGTA, 651
ethanol intake, 223
ethanol preference, 223
expiration, 467
fetal alcohol, 393
fluid volume control, 293
genetics, 509
halothane, 691
His-Pro diketopiperazine, 93
hypertension, 293
ionophores, 651
latencies, 909
lithium chloride, 337
man, 297
mice strains, 467
muscarinic cholinergic receptor, 509
naloxone, 93, 577
neural hyperexcitability, 909
nutritionally complete liquid diets, 503
open field, 393

Ethanol (continued)
peak-to-peak amplitudes, 909
pentobarbital, 577, 651
peptide, 93
phenobarbital, 577
photic afterdischarge, 909
physical dependence, 503
prolactin, 297
rebound, 909
recovery time, 909
renin, 293
second-order conditioning, 337
selective breeding, 691
sleeping time, 651
stimulus properties of drugs, 93
strain differences, 293
substance P, 93
taste aversion conditioning, 337
thiopental, 577
thyrotropin releasing hormone, 93
visual evoked response, 909
withdrawal, 503, 909
withdrawal syndrome, 707
y-maze avoidance, 393
Ethanol intake
blood levels, 223
desalivation, 223
ethanol, 223
ethanol preference, 223
Ethanol preference
blood levels, 223
desalivation, 223
ethanol, 223
ethanol intake, 223
Ewe
cyproterone acetate, 359
estradiol, 359
receptivity, 359
sexual behavior, 359
testosterone, 359
Experimental hypertension
d-amphetamine, 53
apomorphine, 53
catecholamines, 53
serotonin, 53
SHR rat, 53
stereotypy, 53
WKY rat, 53
Expiration
acetaldehyde, 467
analysis, 467
ethanol, 467
mice strains, 467
Exploratory activity
5-hydroxytryptamine, 259
monoamine oxidase inhibition, 259
nialamide, 259
tube running activity, 259
Exploratory behavior
d-amphetamine, 453
arousal, 453
dopamine, 453
6-hydroxydopamine, 453
locomotion, 453
mesolimbic dopamine system, 453
open field, 453
Exteroceptive stimulus from conspecifics
body weight regulation, 43
cannabinol, 143
follicle-stimulating hormone, 143
luteinizing hormone, 143
perinatal exposure, 143
pheromones, 143
pituitary-gonadal axis, 143
sexual behavior, 143
sexual differentiation, 143
testis function, 143
testosterone, 143
Δ^9-tetrahydrocannabinol, 143
transfer of cannabinoids via milk, 143
Extinction
conditioned emotional response, 409
eating, 917
operant behavior, 409, 917
pimozide, 917
punishment, 409
reward, 917
scopolamine, 409
suppressed responding, 409
variable interval schedule, 409

Fat
carbohydrate, 427
dietary self-selection, 427
feeding behavior, 427
morphine, 427
protein, 427
Fear
chlordiazepoxide, 23
food familiarization, 23
food novelty, 23
food preference, 23
footshock, 23
neophobia, 23
Feeding
ambulatory activity, 773
amphetamine, 949
d-amphetamine, 723
anorexia, 723
apomorphine, 949
caffeine, 949
calcitonin, 609
2-deoxy-D-glucose, 949
drinking, 609
food deprivation, 723
hypertonic saline, 949
insulin, 949
interrelationship of drug effects, 723
lateral hypothalamic syndrome, 949
rearing, 723
recovery of function, 949
satiety, 609
urination, 609
weight loss, 609
zona incerta, 949
Feeding behavior
carbohydrate, 427
dietary self-selection, 427
fat, 427
morphine, 427
protein, 427
Female sexual behavior
ACTH, 201
adrenal, 201
adrenalectomy, 201
corticosterone, 201
dexamethasone, 201
lordosis, 201
ovariectomy, 201
Fenfluramine
activity, 265
amphetamine, 717
d-amphetamine, 265

antagonism, 717
p-chlorophenylalanine, 181
dopamine, 717
eating, 717
marking behavior, 181
meal patterns, 265
methengoline, 717
α-methyltyrosine, 181
pimozide, 717
serotonin, 717
testosterone, 181
zucker rat, 265
Fetal alcohol
behavioral teratology, 393
ethanol, 393
open field, 393
y-maze avoidance, 393
Fetal development
fighting, 213
lactation, 213
maternal aggression, 213
prednisone, 213
testosterone, 213
Fighting
fetal development, 213
lactation, 213
maternal aggression, 213
prednisone, 213
testosterone, 213
Fixed-interval performance
arylcyclohexylamines, 67
ketamine, 67
monkey, 67
phencyclidine, 67
schedule-controlled behavior, 67
Fixed-ratio schedule
d-amphetamine, 559, 865
interresponse-time-greater-than-t schedule, 559
ketamine, 865
lever press, 559
morphine, 865
operant history, 559
pentobarbital, 865
phenobarbital, 865
punishment, 865
rate-dependent effects, 559
variable-interval schedule, 559
Flow-thru
double channel, 463
infusions, 463
swivel, 463
unrestrained animals, 463
Fluid pump
behaving animals, 815
drug self-administration, 815
intracerebral drug administration, 815
Fluid volume control
alcohol preference, 293
blood pressure, 293
drinking, 293
ethanol, 293
hypertension, 293
renin, 293
strain differences, 293

α-Flupenthixol
behavioral arousal, 925
central catecholamine neurons, 925
development, 925
6-hydroxydopamine, 925
phenoxybenzamine, 925
TRH, 925

Fluphenazine
amphetamine, 1
antidepressants, 1
chlorpromazine, 1
clozapine, 1
desipramine, 1
drug-induced discrimination, 1
haloperidol, 1
imipramine, 1
neuroleptics, 1
nortryptiline, 1
thioridazine, 1
trifluoperazine, 1

Fluspirilene
dopamine, 389
endorphin, 389
naltrexone, 389
self-stimulation, 389
stress, 389
tail pinch, 389
Follicle-stimulating hormone
body weight regulation, 143
cannabinol, 143
exteroceptive stimulus from conspecifics, 143
luteinizing hormone, 143
perinatal exposure, 143
pheromones, 143
pituitary-gonadal axis, 143
sexual behavior, 143
sexual differentiation, 143
testis function, 143
testosterone, 143
Δ^9-tetrahydrocannabinol, 143
transfer of cannabinoids via milk, 143

Food deprivation
ambulatory activity, 723
d-amphetamine, 723
anorexia, 723
feeding, 723
interrelationship of drug effects, 723
rearing, 723
Food familiarization
chlordiazepoxide, 23
fear, 23
food novelty, 23
food preference, 23
footshock, 23
neophobia, 23

Food intake
amphetamine, 701
benzodiazepines, 195
body weight, 701
cat, 195
cathine, 701
cathinone, 701
chemically stimulated feeding, 195
cross tolerance, 701
diazepam, 195
dog, 195
elfazepam, 195
khat, 701
tolerance, 701
Food novelty
chlordiazepoxide, 23
fear, 23
food familiarization, 23
food preference, 23
footshock, 23
neophobia, 23

Food preference
chlordiazepoxide, 23
fear, 23
food familiarization, 23
food novelty, 23
footshock, 23
neophobia, 23
Footshock
anxiety, 41
avoidance conditioning, 277
chlordiazepoxide, 23, 41
cholinergic, 277
dorsal periaqueductal gray, 41
electrical stimulation, 41
fear, 23
food familiarization, 23
food novelty, 23
food preference, 23
high affinity choline uptake, 277
hippocampus, 277
neophobia, 23
punishment, 41
septal lesions, 41
septo-hippocampal pathway, 277
strain differences, 277
striatum, 277
Frontal cortex
aggression, 189
amygdala, 189
anterior colliculus, 189
dipropylacetate, 189
GABA, 189
gonadectomy, 189
hypothalamus, 189
lactation, 189
olfactory bulb, 189
posterior colliculus, 189
Frontal lobe
amphetamine, 861
delayed response, 861
monkey, 861
visual discrimination, 861
Fucose
apomorphine, 317
glycoprotein synthesis, 317
hippocampus, 317

GABA
aggression, 189
amygdala, 189
anterior colliculus, 189
dipropylacetate, 189
frontal cortex, 189
gonadectomy, 189
hypothalamus, 125, 189
lactation, 189
olfactory bulb, 189
picrotoxin, 125
posterior colliculus, 189
self-stimulation, 125
stimulation-induced feeding, 125
Genetics
adenylate cyclase, 509
β-adrenergic receptor, 509
dopaminergic receptor, 509
ethanol, 509
muscarinic cholinergic receptor, 509
Glutamate
conditioning, 533
memory trace, 533
l-proline, 533
l-proline analogs, 533
retrograde amnesia, 533
spreading depression, 533
Glycoprotein synthesis
apomorphine, 317
fucose, 317
hippocampus, 317
Goiter
hypothalamus, 837
knife cuts, 837
obesity, 837
paraventricular nucleus, 837
thyroid, 837
Gonadectomy
aggression, 189
amygdala, 189
anterior colliculus, 189
dipropylacetate, 189
frontal cortex, 189
GABA, 189
hypothalamus, 189
lactation, 189
olfactory bulb, 189
posterior colliculus, 189
Gryllicide
isolation-induced fighting, 675
tryptophan-free diet, 675

Habituation
hepatic encephalopathy, 739
portacaval shunt, 739
sensitization, 739
serotonin, 739
startle response, 739
tryptophan, 739
Hallucinogens
cannabinoids, 99
EEG in sleep-waking behavior, 99
long-term EEG frequency analysis, 99
LSD, 99
mescaline, 99
psilocybin, 99
synhexyl, 99
Δ^9-tetrahydrocannabinol, 99
Haloperidol
activity, 347
amphetamine, 1
antidepressants, 1
catalepsy, 347
chickens, 347
chlorpromazine, 1
clozapine, 1
desipramine, 1
dopaminergic system, 347
drug-induced discrimination, 1
fluphenazine, 1
imipramine, 1
neuroleptics, 1
nortryptiline, 1
quipazine, 347
raphe model, 347
serotonergic system, 347
stereotypy, 347
thioridazine, 1
tonic immobility, 347
trifluoperazine, 1
Halothane
ethanol, 691
selective breeding, 691
Heart rate
adrenaline, 449
catecholamines, 449

correlation, 449
cortisol, 449
humans, 449
noradrenaline, 449
response consistency, 449
sex differences, 449
Heart rate conditioning
β-adrenergic receptors, 419
amygdala central nucleus, 419
isoproterenol, 419
propranolol, 419
Hepatic encephalopathy
habituation, 739
portacaval shunt, 739
sensitization, 739
serotonin, 739
startle response, 739
tryptophan, 739
Heroin
analgesics, 983
human males, 163
naltrexone, 163
prolactin, 163
schedule, 983
self-injection, 983
tolerance, 163
Herpes simplex
amphetamine, 61
apomorphine, 61
locomotor activity, 61
Hexamethonium
intraperitoneal, 619
intraventricular, 619
mecamylamine, 619
mouse-killing, 619
nicotinic suppression, 619
shock-induced attack, 619
Hexobarbital
amobarbital, 613
barbital, 613
drinking, 613
lithium chloride, 613
pentobarbital, 613
taste aversion, 613
High affinity choline uptake
avoidance conditioning, 277
cholinergic, 277
footshock, 277
hippocampus, 277
septo-hippocampal pathway, 277
strain differences, 277
striatum, 277
High performance liquid chromatography
catecholamines, 959
indoles, 959
push-pull perfusion, 959
schedule dependent behavior, 959
Hippocampus
aggression, 855
alcohol, 333
alcohol dependence, 333
alcohol withdrawal, 333
apomorphine, 317
audiogenically induced seizures, 333
avoidance conditioning, 277, 481
brain, 481
brain distribution, 217
brain penetrability, 217
brightness discrimination, 319
^{3}H-cannabidiol, 217
^{3}H-cannabinol, 217
caudate nucleus, 481
cholinergic, 277
classical conditioning, 481
5,7-dihydroxytryptamine, 855
footshock, 277
fucose, 317
glycoprotein synthesis, 317
high affinity choline uptake, 277
liver, 481
locomotor activity, 855
membrane ATPase, 333
memory consolidation, 319
nuclear phosphoproteins, 481
protein synthesis, 319
raphe nuclei, 855
sensory stimulation, 481
septo-hippocampal pathway, 277
serotonin, 319, 855
social interaction, 855
strain differences, 277
striatum, 277, 855
^{3}H-Δ^9-tetrahydrocannabinol, 217
His-Pro diketopiperazine
ACTH, 93
bombesin, 93
delta sleep-inducing peptide, 93
enkephalin, 93
ethanol, 93
naloxone, 93
peptide, 93
stimulus properties of drugs, 93
substance P, 93
thyrotropin releasing hormone, 93
Histamine
circadian rhythm, 549
cortex, 35
corticosterone, 35, 549
hypothalamus, 35, 549
midbrain, 35
spontaneous locomotor activity, 549
stress, 35
temperature, 549
Hole-board
brain cytochrome c, 493
brain non-heme iron, 493
iron deficiency, 493
open field, 493
passive avoidance, 493
pituitary-adrenal system, 493
Hormone
ACTH, 93, 201, 711
angiotensin I, 131
angiotensin II, 131
calcitonin, 609
corticosterone, 35, 201, 207, 549
cortisol, 449
estradiol, 359
17α-estradiol, 365
estradiol benzoate, 131
estrogen, 515
follicle-stimulating hormone, 143
11-hydroxycorticosterone, 773
insulin, 949
luteinizing hormone, 143
luteinizing hormone releasing hormone, 365
lysine vasopressin, 343
MIF, 73
α-MSH, 773
prolactin, 163, 297
renin, 293
testosterone, 143, 181, 213, 359
thyrotropin releasing hormone, 93
TRH, 925

Human males
heroin, 163
naltrexone, 163
prolactin, 163
tolerance, 163
Human research
cigarette smoking, 811
interbout interval, 811
puff monitor, 811
puff rate, 811
puffing behavior, 811
Humans
adrenaline, 449
catecholamines, 449
correlation, 449
cortisol, 449
heart rate, 449
noradrenaline, 449
response consistency, 449
sex differences, 449
11-Hydroxycorticosterone
defecation, 773
hypophysectomy, 773
α-MSH, 773
novelty, 773
whole brain dopamine, 773
whole brain norepinephrine, 773
6-Hydroxydopamine
amphetamine, 185, 287
d-amphetamine, 453
apomorphine, 185, 281
arousal, 453
behavioral arousal, 925
catecholamines, 281, 287
caudate nucleus, 371
central catecholamine neurons, 925
circling behavior, 185
cocaine, 781
development, 281, 925
DOPA, 185
L-DOPA, 281
dopamine, 185, 453, 781
DRL, 287
eating and drinking deficits, 371
exploratory behavior, 453
α-flupenthixol, 925
lateral hypothalamus, 371
locomotion, 453
mesolimbic dopamine system, 453
α-methylparatyrosine, 371
monoamine accumulation, 371
nigrostriatal dopamine, 371
nigro-striatal neurons, 185
nucleus accumbens, 781
open field, 453
operant behavior, 281, 287
phenoxybenzamine, 925
post-synaptic supersensitivity, 371
self-administration, 781
substantia nigra, 185
TRH, 925
5-Hydroxytryptamine
d-amphetamine, 937
audiogenic seizures, 385
brain levels, 385
brain monoamines, 311
chlorimipramine, 255
p-chlorophenylalanine, 875
defecation, 875
5,6-dihydroxytryptamine, 875
5,7-dihydroxytryptamine, 937
dopamine, 311
emotionality, 875
exploratory activity, 259
5-hydroxytryptophan, 875
monoamine oxidase inhibition, 259
nialamide, 259
noradrenaline, 255
norepinephrine, 385
nucleus accumbens, 937
open field, 875
parachlorophenylalanine, 311
protryptyline, 255
reserpine, 875
self-administration, 937
shuttle box, 875
strain differences, 311
tube running activity, 255, 259
5-Hydroxytryptophan
audiogenic seizures, 119
chlorimipramine, 119
p-chlorophenylalanine, 875
defecation, 875
delayed responses, 229
5,6-dihydroxytryptamine, 875
L-DOPA, 229
dopamine, 229
emotionality, 875
5-hydroxytryptamine, 875
6-methoxy-1,2,3,4-tetrahydro-β-carboline, 119
open field, 875
pargyline, 119
reserpine, 875
R04-4602, 229
serotonin, 119, 229
shuttle box, 875
1,2,3,4-tetrahydro-β-carboline, 119
Hyperbaric pressure
avoidance behavior, 413
morphine, 413
Hypertension
alcohol preference, 293
blood pressure, 293
drinking, 293
ethanol, 293
fluid volume control, 293
renin, 293
strain differences, 293
Hypertonic saline
amphetamine, 949
apomorphine, 949
caffeine, 949
2-deoxy-D-glucose, 949
drinking, 987
feeding, 949
insulin, 949
lateral hypothalamic syndrome, 949
naloxone, 987
recovery of function, 949
zona incerta, 949
Hypodipsia
amphetamine, 107
anorexia, 107
body weight, 107
cross-tolerance, 107
ingestive effects, 107
nicotine, 107
tolerance, 107
Hypophysectomy
defecation, 773
endorphin, 365
17α-estradiol, 365
11-hydroxycorticosterone, 773
luteinizing hormone releasing hormone, 365

α-MSH, 773
naloxone, 365
novelty, 773
pituitary, 365
sexual behavior, 365
whole brain dopamine, 773
whole brain norepinephrine, 773
Hypothalamus
aggression, 189
amygdala, 189
anterior colliculus, 189
blood-brain barrier, 871
brain distribution, 217
brain penetrability, 217
^{7}H-cannabidiol, 217
^{3}H-cannabinol, 217
circadian rhythm, 549
cortex, 35
corticosterone, 35, 549
dipropylacetate, 189
frontal cortex, 189
GABA, 125, 189
goiter, 837
gonadectomy, 189
histamine, 35, 549
intraventricular injection, 871
knife cuts, 837
lactation, 189
metoclopramide, 871
midbrain, 35
neuroleptics, 871
obesity, 837
olfactory bulb, 189
paraventricular nucleus, 837
picrotoxin, 125
posterior colliculus, 189
schizophrenia, 871
self-stimulation, 125, 871
spiroperidol, 871
spontaneous locomotor activity, 549
stimulation-induced feeding, 125
stress, 35
temperature, 549
^{3}H-Δ^{9}-tetrahydrocannabinol, 217
thyroid, 837
Hypothermia
abstinence syndrome, 645
analgesic tolerance, 73
cyclo(Leu-Gly), 73
dependence, 645
D-Ala^{2}-Met^{5}-enkephalinamide, 645
D-Met^{2}-Pro^{5}-enkephalinamide, 645
jump threshold, 73
MIF, 73
morphine, 73, 645
naloxone, 73, 645
physical dependence, 73
Pro-Leu-Gly-NH_2, 73

Imipramine
amphetamine, 1
d-amphetamine, 899
antidepressants, 1
chlorpromazine, 1
clozapine, 1
cocaine, 899
desipramine, 1
drug-induced discrimination, 1
fluphenazine, 1
haloperidol, 1
neuroleptics, 1
nortryptiline, 1
operant behavior, 899
pentobarbital, 899
rate-dependent effects, 899
schedules of reinforcement, 899
thioridazine, 1
trifluoperazine, 1
Indoles
catecholamines, 959
high performance liquid chromatography, 959
push-pull perfusion, 959
schedule dependent behavior, 959
Information transfer
brain extracts, 7
learning, 7
memory consolidation, 7
passive avoidance, 7
Infrasound environment
avoidance learning, 767
brain catecholamine levels, 767
diazepam, 767
locomotor activity, 767
Infusions
double channel, 463
flow-thru, 463
swivel, 463
unrestrained animals, 463
Ingestion
deprivation, 431
drinking, 431
morphine, 431
naloxone, 431
opioids, 431
Ingestive effects
amphetamine, 107
anorexia, 107
body weight, 107
cross-tolerance, 107
hypodipsia, 107
nicotine, 107
tolerance, 107
Inhibitory avoidance
amnesia, 377
anisomycin, 377
ECS, 377
long-term memory, 377
memory lability, 377
paradoxical sleep, 377
protein synthesis, 377
short-term memory, 377
slow-wave sleep, 377
Insulin
amphetamine, 949
apomorphine, 949
caffeine, 949
2-deoxy-D-glucose, 949
feeding, 949
hypertonic saline, 949
lateral hypothalamic syndrome, 949
recovery of function, 949
zona incerta, 949
Interbout interval
cigarette smoking, 811
human research, 811
puff monitor, 811
puff rate, 811
puffing behavior, 811
Interrelationship of drug effects
ambulatory activity, 723
d-amphetamine, 723
anorexia, 723
feeding, 723

Interrelationship of drug effects (continued)
food deprivation, 723
rearing, 723
Interresponse-time-greater-than-t schedule
d-amphetamine, 559
fixed-ratio schedule, 559
lever-press, 559
operant history, 559
rate-dependent effects, 559
variable-interval schedule, 559
Interresponse-times
schedule-controlled behavior, 85
squirrel monkey, 85
Δ^9-tetrahydrocannabinol, 85
tolerance, 85
Intracerebral drug administration
behaving animals, 815
drug self-administration, 815
fluid pump, 815
Intracerebral microinjection
morphine, 965
naloxone, 965
positive reinforcement, 965
ventral tegmental area, 965
Intraperitoneal
hexamethonium, 619
intraventricular, 619
mecamylamine, 619
mouse-killing, 619
nicotinic suppression, 619
shock-induced attack, 619
Intraventricular
hexamethonium, 619
intraperitoneal, 619
mecamylamine, 619
mouse-killing, 619
nicotinic suppression, 619
shock-induced attack, 619
Intraventricular injection
blood-brain barrier, 871
hypothalamus, 871
metoclopramide, 871
neuroleptics, 871
schizophrenia, 871
self-stimulation, 871
spiroperidol, 871
Ionophores
t-butanol, 651
calcium, 651
chloral hydrate, 651
EDTA, 651
EGTA, 651
ethanol, 651
pentobarbital, 651
sleeping time, 651
Iron deficiency
brain cytochrome C, 493
brain non-heme iron, 493
hole-board, 493
open field, 493
passive avoidance, 493
pituitary-adrenal system, 493
Irritability
ambient temperature, 851
p-chloroamphetamine, 851
ejaculation, 851
salivation, 851
thermoregulation, 851
Isolation
aggregation, 313
catecholamines, 313
lethal dose, 313
morphine, 313
serotonin, 313
Isolation-induced fighting
gryllicide, 675
tryptophan free diet, 675
Isoproterenol
β-adrenergic receptors, 419
amygdala central nucleus, 419
chlordiazepoxide, 819
conflict behavior, 819
drinking, 819
heart rate conditioning, 419
propranolol, 419

Jump threshold
analgesic tolerance, 73
carbachol, 487
cholinergic mechanism, 487
cyclo(Leu-Gly), 73
hypothermia, 73
lateral hypothalamus, 487
MIF, 73
morphine, 73
naloxone, 73
physical dependence, 73
physostigmine, 487
Pro-Leu-Gly-NH_2, 73
scopolamine, 487
shock-induced defensive fighting, 487

Ketamine
d-amphetamine, 865
arylcyclohexylamines, 67
fixed-interval performance, 67
fixed-ratio schedule, 865
monkey, 67
morphine, 865
pentobarbital, 865
phencyclidine, 67, 865
punishment, 865
schedule-controlled behavior, 67
Khat
amphetamine, 701
body weight, 701
cathine, 701
cathinone, 701
cross tolerance, 701
food intake, 701
tolerance, 701
Knife cuts
goiter, 837
hypothalamus, 837
obesity, 837
paraventricular nucleus, 837
thyroid, 837

Lactation
aggression, 189
amygdala, 189
anterior colliculus, 189
bile, 555
cholic acid, 555
dipropylacetate, 189
fetal development, 213
fighting, 213
frontal cortex, 189
GABA, 189
gonadectomy, 189
hypothalamus, 189

maternal aggression, 213
maternal pheromone, 555
olfactory bulb, 189
posterior colliculus, 189
prednisone, 213
testosterone, 213
Latencies
addiction, 909
ethanol, 909
neural hyperexcitability, 909
peak-to-peak amplitudes, 909
photic afterdischarge, 909
rebound, 909
recovery time, 909
visual evoked response, 909
withdrawal, 909

Lateral hypothalamic syndrome
amphetamine, 949
apomorphine, 949
caffeine, 949
2-deoxy-D-glucose, 949
feeding, 949
hypertonic saline, 949
insulin, 949
recovery of function, 949
zona incerta, 949
Lateral hypothalamus
aggression, 681
atropine sulfate, 681
carbachol, 487
caudate nucleus, 371
cholinergic, 681
cholinergic mechanism, 487
eating and drinking deficits, 371
6-hydroxydopamine, 371
jump threshold, 487
lidocaine, 681
α-methylparatyrosine, 371
monoamine accumulation, 371
mouse killing, 681
nigrostriatal dopamine, 371
physostigmine, 487
post-synaptic supersensitivity, 371
scopolamine, 487
shock-induced defensive fighting, 487
Learning
brain extracts, 7
caudate nucleus, 249
cholinergic blockade, 249
information transfer, 7
memory consolidation, 7
overtraining, 249
passive avoidance, 7
potassium chloride, 249
scopolamine, 249

Lesions
A10, 603
activity, 603
amphetamine, 603
behavioral responsivity, 563
discriminant function analysis, 563
dopamine, 603
endogenous opiate system, 563
limbic system, 563
morphine, 563
naloxone, 563
norepinephrine, 603
septal hyperreactivity, 563
serotonin, 603
ventral medial tegmentum, 603

Lethal dose
aggregation, 313
catecholamines, 313
isolation, 313
morphine, 313
serotonin, 313
Lever-press
d-amphetamine, 559
fixed-ratio schedule, 559
interresponse-time-greater-than-t schedule, 559
operant history, 559
rate-dependent effects, 559
variable-interval schedule, 559
Lidocaine
aggression, 681
atropine sulfate, 681
cholinergic, 681
lateral hypothalamus, 681
mouse killing, 681
Limbic system
behavioral responsivity, 563
discriminant function analysis, 563
endogenous opiate system, 563
lesions, 563
morphine, 563
naloxone, 563
septal hyperreactivity, 563
Lithium chloride
alcoholism, 239
amobarbital, 613, 803
aversion therapy, 337
barbital, 613, 803, 807
biogenic amines, 239
blocking, 337
conditioned responses, 789
conditioned taste aversion, 239
drinking, 613, 789
drug conditioning, 789
ethanol, 337
hexobarbital, 613
pentobarbital, 613, 803
phenobarbital, 803, 807
secobarbital, 803
second-order conditioning, 337
taste aversion, 613, 803, 807
taste aversion conditioning, 337, 789
voluntary alcohol intake, 239
Liver
avoidance conditioning, 481
brain, 481
caudate nucleus, 481
classical conditioning, 481
hippocampus, 481
nuclear phosphoproteins, 481
sensory stimulation, 481
Locomotion
aggression, 525
amino acids, 525
d-amphetamine, 453
arousal, 453
diet, 525
dopamine, 453
exploratory behavior, 453
6-hydroxydopamine, 453
mesolimbic dopamine system, 453
monoamines, 525
open field, 453
tolerance, 525
Locomotor activity
aggression, 855
amphetamine, 61
apomorphine, 61

Locomotor activity (continued)
avoidance learning, 767
brain catecholamine levels, 767
diazepam, 767
5,7-dihydroxytryptamine, 855
herpes simplex, 61
hippocampus, 855
infrasound environment, 767
raphe nuclei, 855
serotonin, 855
social interaction, 855
striatum, 855
Locomotor stimulation
γ-acetylenic GABA, 113
aminooxyacetic acid, 113
d-amphetamine, 113
baclofen, 113
muscimol, 113
phencyclidine, 113
surgical anesthesia, 113
Lofexidine
body shakes, 573
clonidine, 573
diarrhea, 573
morphine, 573
naloxone, 573
withdrawal, 573
Long-term EEG frequency analysis
cannabinoids, 99
EEG in sleep-waking behavior, 99
hallucinogens, 99
LSD, 99
mescaline, 99
psilocybin, 99
synhexyl, 99
Δ^9-tetrahydrocannabinol, 99
Long-term memory
amnesia, 377
anisomycin, 377
ECS, 377
inhibitory avoidance, 377
memory lability, 377
paradoxical sleep, 377
protein synthesis, 377
short-term memory, 377
slow-wave sleep, 377
Lordosis
ACTH, 201
adrenal, 201
adrenalectomy, 201
corticosterone, 201
dexamethasone, 201
female sexual behavior, 201
ovariectomy, 201
LSD
cannabinoids, 99
EEG in sleep-waking behavior, 99
hallucinogens, 99
long-term EEG frequency analysis, 99
mescaline, 99
psilocybin, 99
synhexyl, 99
Δ^9-tetrahydrocannabinol, 99
Luteinizing hormone
body weight regulation, 143
cannabinol, 143
exteroceptive stimulus from conspecifics, 143
follicle-stimulating hormone, 143
perinatal exposure, 143
pheromones, 143
pituitary-gonadalaxis, 143
sexual behavior, 143
sexual differentiation, 143
testis function, 143
testosterone, 143
Δ^9-tetrahydrocannabinol, 143
transfer of cannabinoids via milk, 143
Luteinizing hormone releasing hormone
endorphin, 365
17α-estradiol, 365
hypophysectomy, 365
naloxone, 365
pituitary, 365
sexual behavior, 365
Lysine vasopressin
attenuation, 343
diethyldithiocarbamate-induced amnesia, 343
passive avoidance, 343

Man
alcohol, 297
ethanol, 297
prolactin, 297
Marking behavior
p-chlorophenylalanine, 181
fenfluramine, 181
α-methyltyrosine, 181
testosterone, 181
Maternal aggression
fetal development, 213
fighting, 213
lactation, 213
prednisone, 213
testosterone, 213
Maternal pheromone
bile, 555
cholic acid, 555
lactation, 555
Meal patterns
activity, 265
d-amphetamine, 265
fenfluramine, 265
Zucker rat, 265
Mecamylamine
hexamethonium, 619
intraperitoneal, 619
intraventricular, 619
mouse-killing, 619
nicotinic suppression, 619
shock-induced attack, 619
Medulla
brain distribution, 217
brain penetrability, 217
^{3}H-cannabidiol, 217
^{3}H-cannabinol, 217
^{3}H-Δ^9-tetrahydrocannabinol, 217
Melanin
albinism, 969
catecholamines, 969
tyrosinase, 969
tyrosine, 969
Membrane ATPase
alcohol, 333
alcohol dependence, 333
alcohol withdrawal, 333
audiogenically induced seizures, 333
hippocampus, 333
Memory
amnesia, 79
amphetamine, 595
anisomycin, 79
cycloheximide, 79
discrimination learning, 595

methylscopolamine, 595
pentobarbital, 595
protein synthesis inhibition, 79
radial arm maze, 595
scopolamine, 595
short-term memory, 595
spatial discrimination, 595
spatial memory, 595

Memory consolidation
brain extracts, 7
brightness discrimination, 319
hippocampus, 319
information transfer, 7
learning, 7
passive avoidance, 7
protein synthesis, 319
serotonin, 319
Memory lability
amnesia, 377
anisomycin, 377
ECS, 377
inhibitory avoidance, 377
long-term memory, 377
paradoxical sleep, 377
protein synthesis, 377
short-term memory, 377
slow-wave sleep, 377
Memory trace
conditioning, 533
glutamate, 533
l-proline, 533
l-proline analogs, 533
retrograde amnesia, 533
spreading depression, 533

Meperidine
alphaprodine, 797
anileridine, 797
discrimination, 403
electric shock, 403
morphine, 403, 797
naloxone, 797
schedule-controlled responding, 797
SKF-525A, 403
squirrel monkey, 403
titration, 403
Mescaline
cannabinoids, 99
EEG in sleep-waking behavior, 99
hallucinogens, 99
long-term EEG frequency analysis, 99
LSD, 99
psilocybin, 99
synhexyl, 99
Δ^9-tetrahydrocannabinol, 99

Mesolimbic dopamine system
d-amphetamine, 453
arousal, 453
dopamine, 453
exploratory behavior, 453
6-hydroxydopamine, 453
locomotion, 453
open field, 453
Methadone
behavior, 893
cat, 893
EEG, 893
prolonged effects, 893
visual evoked potential, 893
Methaqualone
d-amphetamine, 657
cocaine, 657
diazepam, 657
schedule-controlled behavior, 657
Methergoline
amphetamine, 717
antagonism, 717
dopamine, 717
eating, 717
fenfluramine, 717
pimozide, 717
serotonin, 717
Method
tube running activity as a measure of drug effects on behavior, 255, 259

6-Methoxy-1,2,3,4-tetrahydro-β-carboline
audiogenic seizures, 119
chlorimipramine, 119
5-hydroxytryptophan, 119
pargyline, 119
serotonin, 119
1,2,3,4-tetrahydro-β-carboline, 119
α-Methylparatyrosine
caudate nucleus, 371
eating and drinking deficits, 371
6-hydroxydopamine, 371
lateral hypothalamus, 371
monoamine accumulation, 371
nigrostriatal dopamine, 371
post-synaptic supersensitivity, 371
Methylscopolamine
amphetamine, 595
discrimination learning, 595
memory, 595
pentobarbital, 595
radial arm maze, 595
scopolamine, 595
short-term memory, 595
spatial discrimination, 595
spatial memory, 595

α-Methyltyrosine
p-chlorophenylalanine, 181
fenfluramine, 181
marking behavior, 181
testosterone, 181
Metoclopramide
blood-brain barrier, 871
hypothalamus, 871
intraventricular injection, 871
neuroleptics, 871
schizophrenia, 871
self-stimulation, 871
spiroperidol, 871
Mice strains
acetaldehyde, 467
analysis, 467
ethanol, 467
expiration, 467

Midbrain
brain distribution, 217
brain penetrability, 217
^{3}H-cannabidiol, 217
^{3}H-cannabinol, 217
cortex, 35
corticosterone, 35
histamine, 35
hypothalamus, 35
stress, 35
^{3}H-Δ^9-tetrahydrocannabinol, 217

MIF
analgesic tolerance, 73
cyclo(Leu-Gly), 73
hypothermia, 73
jump threshold, 73
morphine, 73
naloxone, 73
physical dependence, 73
Pro-Leu-Gly-NH_2, 73
Monkey
amphetamine, 861
arylcyclohexylamines, 67
delayed response, 861
fixed-interval performance, 67
frontal lobe, 861
ketamine, 67
phencyclidine, 67
schedule-controlled behavior, 67
visual discrimination, 861
Monoamine accumulation
caudate nucleus, 371
eating and drinking deficits, 371
6-hydroxydopamine, 371
lateral hypothalamus, 371
α-methylparatyrosine, 371
nigrostriatal dopamine, 371
post-synaptic supersensitivity, 371
Monoamine oxidase
β-adrenergic receptor, 943
antidepressants, 943
dihydroalprenolol binding, 943
monoamine uptake inhibition, 943
receptor sensitivity, 943
Monoamine oxidase inhibition
exploratory activity, 259
5-hydroxytryptamine, 259
nialamide, 259
tube running activity, 259
Monoamine uptake inhibition
β-adrenergic receptor, 943
antidepressants, 943
dihydroalprenolol binding, 943
monoamine oxidase, 943
receptor sensitivity, 943
Monoamines
aggression, 525
amino acids, 525
diet, 525
locomotion, 525
tolerance, 525
Morphine
abstinence syndrome, 645
aggregation, 313
alphaprodine, 797
d-amphetamine, 865
analgesic tolerance, 73
anileridine, 797
avoidance behavior, 413
bar test, 743
behavioral responsivity, 563
body shakes, 573
carbohydrate, 427
catalepsy, 743
catecholamines, 313
clonidine, 573
cyclo(Leu-Gly), 73
dependence, 645
deprivation, 431
diarrhea, 573
dietary self-selection, 427
discriminant function analysis, 563
discrimination, 403
discriminative stimulus, 587
drinking, 431
drug discrimination, 587
electric shock, 403
endogenous opiate system, 563
D-Ala^2-Met^5-enkephalinamide, 645
D-Met^2-Pro^5-enkephalinamide, 645
fat, 427
feeding behavior, 427
fixed-ratio schedule, 865
hyperbaric pressure, 413
hypothermia, 73, 645
ingestion, 431
isolation, 313
intracerebral microinjection, 965
jump threshold, 73
ketamine, 865
lesions, 563
lethal dose, 313
limbic system, 563
lofexidine, 573
meperidine, 403, 797
MIF, 73
naloxone, 73, 431, 563, 573, 587, 645, 743, 797, 965
naloxone-precipitated withdrawal, 625
naltrexone, 587
opioids, 431
pA_2, 587
pentobarbital, 865
phencyclidine, 865
phenytoin, 743
phenytoin-morphine antagonism, 743
physical dependence, 73, 625
positive reinforcement, 965
Pro-Leu-Gly-NH_2, 73
protein, 427
punishment, 865
schedule-controlled responding, 797
septal hyperreactivity, 563
serotonin, 313
SKF-525A, 403
squirrel monkey, 403
titration, 403
tolerance, 625
ventral tegmental area, 965
withdrawal, 573
Motor activity
aggressive behavior, 667
aging, 667
diet supplement, 667
dopamine, 667
norepinephrine, 667
precursor amino acids, 667
serotonin, 667
stress, 667
tyrosine, 667
Mouse killing
aggression, 681
atropine sulfate, 681
cholinergic, 681
hexamethonium, 619
intraperitoneal, 619
intraventricular, 619
lateral hypothalamus, 681
lidocaine, 681
mecamylamine, 619
nicotinic sppression, 619
shock-induced attack, 619
α-MSH
defecation, 773
11-hydroxycorticosterone, 773
hypophysectomy, 773

novelty, 773
whole brain dopamine, 773
whole brain norepinephrine, 773
Muricide
pain sensitivity, 173
shock-induced fighting, 173
tryptophan-free diet, 173
Muscarinic cholinergic receptor
adenylate cyclase, 509
β-adrenergic receptor, 509
dopaminergic receptor, 509
ethanol, 509
genetics, 509
Muscimol
γ-acetylenic GABA, 113
aminooxyacetic acid, 113
d-amphetamine, 113
baclofen, 113
locomotor stimulation, 113
phencyclidine, 113
surgical anesthesia, 113

Naloxone
abstinence syndrome, 645
ACTH, 93
alphaprodine, 797
analgesic tolerance, 73
anileridine, 797
bar test, 743
barbital, 577
behavioral responsivity, 563
body shakes, 573
bombesin, 93
brain rewarding system, 729
catalepsy, 743
chronic morphine, 577
clonidine, 573
conditioned avoidance response, 577
cyclo(Leu-Gly), 73
delta sleep-inducing peptide, 93
dependence, 645
deprivation, 431
diarrhea, 573
diazepam, 577
discriminant function analysis, 563
discriminative stimulus, 587
drinking, 431, 987
drug discrimination, 587
drug interaction, 577
endogenous opiate system, 563
endorphin, 365
enkephalin, 93
D-Ala^2-Met^5-enkephalinamide, 645
D-Met^2-Pro^5-enkephalinamide, 645
17α-estradiol, 365
ethanol, 93, 577
His-Pro diketopiperazine, 93
hypertonic saline, 987
hypophysectomy, 365
hypothermia, 73, 645
ingestion, 431
intracerebral microinjection, 965
jump threshold, 73
lesions, 563
limbic system, 563
lofexidine, 573
luteinizing hormone releasing hormone, 365
meperidine, 797
MIF, 73
morphine, 73, 431, 563, 573, 587, 645, 743, 797, 965
naltrexone, 587
opiate systems, 729
opioids, 431
pA_2, 587
pain modulation system, 729
pentobarbital, 577
peptide, 93
phenobarbital, 577
phenytoin, 743
phenytoin-morphine antagonism, 743
physical dependence, 73
pituitary, 365
positive reinforcement, 965
Pro-Leu-Gly-NH_2, 73
schedule-controlled responding, 797
septal hyperreactivity, 563
sexual behavior, 365
stimulus properites of drugs, 93
substance P, 93
taste aversion, 729
taste preference, 729
thiopental, 577
thyrotropin releasing hormone, 93
ventral tegmental area, 965
withdrawal, 573
Naloxone-precipitated withdrawal
morphine, 625
physical dependence, 625
tolerance, 625
Naltrexone
discriminative stimulus, 587
dopamine, 389
drug discrimination, 587
endorphin, 389
fluspirilene, 389
heroin, 163
human males, 163
morphine, 587
naloxone, 587
pA_2, 587
prolactin, 163
self-stimulation, 389
stress, 389
tail pinch, 389
tolerance, 163
α-Naphthoxyacetic acid
apomorphine, 735
dopaminergic neurons, 735
protoveratrine-A, 735
retching, 735
vomiting, 735
Neophobia
chlordiazepoxide, 23
fear, 23
food familiarization, 23
food novelty, 23
food preference, 23
footshock, 23

Neostigmine
cholinesterase inhibition, 847
physostigmine, 847
shuttle-box avoidance, 847
Neural hyperexcitability
addiction, 909
ethanol, 909
latencies, 909
peak-to-peak amplitudes, 909
photic afterdischarge, 909
rebound, 909
recovery time, 909
visual evoked response, 909
withdrawal, 909

Neuroleptics
amphetamine, 1
anhedonia, 93
antidepressants, 1
apomorphine, 29
associative learning, 445
blood-brain barrier, 871
chlorpromazine, 1
clozapine, 1
defensive burying, 445
desipramine, 1
dopamine, 445
dopamine receptor sensitivity, 29
drug-induced discrimination, 1
fluphenazine, 1
haloperidol, 1
hypothalamus, 871
imipramine, 1
intraventricular injection, 871
metoclopramide, 871
nortryptiline, 1
operant behavior, 931
pimozide, 445, 931
reward, 931
schizophrenia, 871
self-stimulation, 871
spiroperidol, 29, 871
stereotypic activity, 29
thioridazine, 1
trifluoperazine, 1
Neuromuscular coordination
anticonvulsant, 747
EEG, 747
prostaglandin D_2, 747
sedation, 747
sleeping time, 747
spontaneous locomotor activity, 747
Nialamide
exploratory activity, 259
5-hydroxytryptamine, 259
monoamine oxidase inhibition, 259
tube running activity, 259
Nicotine
amphetamine, 107
anorexia, 107
body weight, 107
cross-tolerance, 107
hypodipsia, 107
ingestive effects, 107
tolerance, 107
Nicotinic suppression
hexamethonium, 619
intraperitoneal, 619
intraventricular, 619
mecamylamine, 619
mouse-killing, 619
shock-induced attack, 619
Nigrostriatal dopamine
caudate nucleus, 371
eating and drinking deficits, 371
6-hydroxydopamine, 371
lateral hypothalamus, 371
α-methylparatyrosine, 371
monoamine accumulation, 371
post-synaptic supersensitivity, 371
Nigro-striatal neurons
amphetamine, 185
apomorphine, 185
circling behavior, 185
DOPA, 185
dopamine, 185
6-hydroxydopamine, 185
substantia nigra, 185
Noradrenaline
adrenaline, 449
catecholamines, 449
chlorimipramine, 255
correlation, 449
cortisol, 449
heart rate, 449
5-hydroxytryptamine, 255
humans, 449
protriptyline, 255
response consistency, 449
sex differences, 449
tube running activity, 255
Norepinephrine
A 10, 603
acetylcholine, 437
activity, 603
aggressive behavior, 667
aging, 667
amphetamine, 603
audiogenic seizures, 385
brain levels, 385
chlordiazepoxide, 437
diet supplement, 667
distress vocalizations, 437
dopamine, 603, 667
5-hydroxytryptamine, 385
lesions, 603
motor activity, 667
opiates, 437
precursor amino acids, 667
serotonin, 437, 603, 667
stress, 667
tyrosine, 667
ventral medial tegmentum, 603
Nortryptiline
amphetamine, 1
antidepressants, 1
chlorpromazine, 1
clozapine, 1
desipramine, 1
drug-induced discrimination, 1
fluphenazine, 1
haloperidol, 1
imipramine, 1
neuroleptics, 1
thioridazine, 1
trifluoperazine, 1
Novelty
defecation, 773
11-hydroxycorticosterone, 773
hypophysectomy, 773
α-MSH, 773
whole brain dopamine, 773
whole brain norepinephrine, 773
Nuclear phosphoproteins
avoidance conditioning, 481
brain, 481
caudate nucleus, 481
classical conditioning, 481
hippocampus, 481
liver, 481
sensory stimulation, 481
Nucleus accumbens
d-amphetamine, 937
cocaine, 781
5,7-dihydroxytryptamine, 937
dopamine, 781
6-hydroxydopamine, 781
5-hydroxytryptamine, 937
self-administration, 781, 937

Nutritionally complete liquid diets
ethanol, 503
physical dependence, 503
withdrawal, 503

Obesity
goiter, 837
hypothalamus, 837
knife cuts, 837
paraventricular nucleus, 837
thyroid, 837
Olfactory bulb
aggression, 189
amygdala, 189
anterior colliculus, 189
dipropylacetate, 189
frontal cortex, 189
GABA, 189
gonadectomy, 189
hypothalamus, 189
lactation, 189
posterior colliculus, 189
Open field
d-amphetamine, 453
arousal, 453
behavioral teratology, 393
brain cytochrome c, 493
brain non-heme iron, 493
p-chlorophenylalanine, 875
defecation, 875
5,6-dihydroxytryptamine, 875
dopamine, 453
emotionality, 875
ethanol, 393
exploratory behavior, 453
fetal alcohol, 393
hole-board, 493
6-hydroxydopamine, 453
5-hydroxytryptamine, 875
5-hydroxytryptophan, 875
iron deficiency, 493
locomotion, 453
mesolimbic dopamine system, 453
passive avoidance, 493
pituitary-adrenal system, 493
reserpine, 875
shuttle box, 875
y-maze avoidance, 393
Operant behavior
amphetamine, 287
d-amphetamine, 899
anhedonia, 931
apomorphine, 281
catecholamines, 281, 287
cocaine, 899
conditioned emotional response, 409
development, 281
L-DOPA, 281
DRL, 287
eating, 917
extinction, 409, 917
6-hydroxydopamine, 281, 287
imipramine, 899
neuroleptics, 931
pentobarbital, 899
pimozide, 917, 931
punishment, 409
rate-dependent effects, 899
reward, 917, 931
schedules of reinforcement, 899
scopolamine, 409
suppressed responding, 409
variable interval schedule, 409
Operant history
d-amphetamine, 559
fixed-ratio schedule, 559
interresponse-time-greater-than-t schedule, 559
lever press, 559
rate dependent effects, 559
variable-interval schedule, 559

Opiate systems
brain rewarding system, 729
naloxone, 729
pain modulating system, 729
taste aversion, 729
taste preference, 729
Opiates
acetylcholine, 437
chlordiazepoxide, 437
distress vocalizations, 437
norepinephrine, 437
serotonin, 437

Opioids
deprivation, 431
drinking, 431
ingestion, 431
morphine, 431
naloxone, 431
Ouabain
arrythmias, 235
digitalis, 235
stress, 235
toxicity, 235

Ovariectomy
ACTH, 201
adrenal, 201
adrenalectomy, 201
apomorphine, 515
corticosterone, 201
dexamethasone, 201
dopamine, 515
estrogen, 515
female sexual behavior, 201
lordosis, 201
stereotypy, 515
Overtraining
caudate nucleus, 249
cholinergic blockade, 249
learning, 249
potassium chloride, 249
scopolamine, 249
Oxotremorine
catecholamines, 353
rostral pons, 353
sleep, 353
tyrosine hydroxylase, 353

pA_2
discriminative stimulus, 587
drug discrimination, 587
morphine, 587
naloxone, 587
naltrexone, 587
Pain modulating system
brain rewarding system, 729
naloxone, 729
opiate systems, 729
taste aversion, 729
taste preference, 729

Pain sensitivity
muricide, 173
shock-induced fighting, 173
tryptophan-free diet, 173
Parachlorophenylalanine
brain monoamines, 311
dopamine, 311
5-hydroxytryptamine, 311
strain differences, 311
Paradoxical sleep
amnesia, 377
anisomycin, 377
ECS, 377
inhibitory avoidance, 377
long-term memory, 377
memory lability, 377
protein synthesis, 377
short-term memory, 377
slow-wave sleep, 377
Paranoid psychosis
apomorphine, 979
β-carbolines, 979
phenylethylamine, 979
schizophrenia, 979
stereotypy, 979
tryptolines, 979
Paraventricular nucleus
goiter, 837
hypothalamus, 837
knife cuts, 837
obesity, 837
thyroid, 837
Pargyline
audiogenic seizures, 119
chlorimipramine, 119
5-hydroxytryptophan, 119
6-methoxy-1,2,3,4-tetrahydro-β-carboline, 119
serotonin, 119
1,2,3,4-tetrahydro-β-carboline, 119
Passive avoidance
attenuation, 343
brain cytochrome c, 493
brain extracts, 7
brain non-heme iron, 493
diethyldithiocarbamate-induced amnesia, 343
hole-board, 493
information transfer, 7
iron deficiency, 493
learning, 7
lysine vasopressin, 343
memory consolidation, 7
open field, 493
pituitary-adrenal system, 493
Peak-to-peak amplitudes
addiction, 909
ethanol, 909
latencies, 909
neural hyperexcitability, 909
photic afterdischarge, 909
rebound. 909
recovery time, 909
visual evoked response, 909
withdrawal, 909
Pentobarbital
amobarbital, 613, 803
amphetamine, 595
d-amphetamine, 865, 899
barbital, 577, 613, 803
t-butanol, 651
calcium, 651
chloralhydrate, 651
chronic morphine, 577
cocaine, 899
conditioned avoidance response, 577
diazepam, 577
discrimination learning, 595
drinking, 613
drug interaction, 577
EDTA, 651
EGTA, 651
ethanol, 577, 651
fixed-ratio schedule, 865
hexobarbital, 613
imipramine, 899
ionophores, 651
ketamine, 865
lithium chloride, 613, 803
memory, 595
methylscopolamine, 595
morphine, 865
naloxone, 577
operant behavior, 899
phencyclidine, 865
phenobarbital, 577, 803
punishment, 865
radial arm maze, 595
rate-dependent effects, 899
schedules of reinforcement, 899
scopolamine, 595
secobarbital, 803
short-term memory, 595
sleeping time, 651
spatial discrimination, 595
spatial memory, 595
taste aversion, 613, 803
thiopental, 577
Peptide
ACTH, 93
bombesin, 93
delta sleep-inducing peptide, 93
enkephalin, 93
ethanol, 93
His-Pro diketopiperazine, 93
naloxone, 93
stimulus properties of drugs, 93
substance P, 93
thyrotropin releasing hormone, 93
Perinatal exposure
body weight regulation, 143
cannabinol, 143
exteroceptive stimulus from conspecifics, 143
follicle-stimulating hormone, 143
luteinizing hormone, 143
pheromones, 143
pituitary-gonadal axis, 143
sexual behavior, 143
sexual differentiation, 143
testis function, 143
testosterone, 143
Δ^9-tetrahydrocannabinol, 143
transfer of cannabinoids via milk, 143
Pharmacokinetics
behavioral effects, 761
body weight, 761
^{3}H-cannabidiol, 217
^{3}H-cannabinol, 217
phencyclidine, 761
^{3}H-Δ^9-tetrahydrocannabinol, 217
tissue localization, 761
tolerance, 761
Phencyclidine
α-acetylenic GABA, 113
aminooxyacetic acid, 117
d-amphetamine, 113, 865

arylcyclohexylamines, 67
baclofen, 113
behavioral effects, 761
body weight, 761
fixed-interval performance, 67
fixed-ratio schedule, 865
ketamine, 67, 865
locomotor stimulation, 113
monkey, 67
morphine, 865
muscimol, 113
pentobarbital, 865
pharmacokinetics, 761
punishment, 865
schedule-controlled behavior, 67
surgical anesthesia, 113
tissue localization, 761
tolerance, 761
Phenobarbital
amobarbital, 803
d-amphetamine, 47
barbital, 577, 803, 807
chronic morphine, 577
conditioned avoidance response, 577
diazepam, 577
drug interaction, 577
ethanol, 577
lithium chloride, 803, 807
naloxone, 577
pentobarbital, 577, 803
schedule-controlled behavior, 47
secobarbital, 803
taste aversion, 803, 807
thiopental, 577
tolerance, 47
Phenoxybenzamine
behavioral arousal, 925
central catecholamine neurons, 925
development, 925
α-flupenthixol, 925
6-hydroxydopamine, 925
TRH, 925
Phenylethylamine
apomorphine, 979
β-carbolines, 979
paranoid psychosis, 979
schizophrenia, 979
stereotypy, 979
tryptolines, 979
Phenytoin
bar test, 743
catalepsy, 743
morphine, 743
naloxone, 743
phenytoin-morphine antagonism, 743
Phenytoin-morphine antagonism
bar test, 743
catalepsy, 743
morphine, 743
naloxone, 743
phenytoin, 743
Pheromones
body weight regulation, 143
cannabinol, 143
exteroceptive stimulus from conspecifics, 143
follicle-stimulating hormone, 143
luteinizing hormone, 143
perinatal exposure, 143
pituitary-gonadal axis, 143
sexual behavior, 143
sexual differentiation, 143
testis function, 143
testosterone, 143
Δ^9-tetrahydrocannabinol, 143
transfer of cannabinoids via milk, 143
Phospholipids
platelets, 697
Δ^9-tetrahydrocannabinol, 697
Photic afterdischarge
addiction, 909
ethanol, 909
latencies, 909
neural hyperexcitability, 909
peak-to-peak amplitides, 909
rebound, 909
recovery time, 909
visual evoked response, 909
withdrawal, 909

Physical dependence
analgesic tolerance, 73
cyclo(Leu-Gly), 73
dependence potential, 155
ethanol, 503
hypothermia, 73
jump threshold, 73
MIF, 73
morphine, 73, 625
naloxone, 73
naloxone-precipitated withdrawal, 625
nutritionally complete liquid diets, 503
Pro-Leu-Glu-NH_2, 73
rhesus monkey, 155
self-administration, 155
tolerance, 625
viloxazine, 155
withdrawal, 503
Physostigmine
carbachol, 487
cholinergic mechanism, 487
cholinesterase inhibition, 847
jump threshold, 487
lateral hypothalamus, 487
neostigmine, 847
scopolamine, 487
shock-induced defensive fighting, 487
shuttle-box avoidance, 847
Picrotoxin
GABA, 125
hypothalamus, 125
self-stimulation, 125
stimulation-induced feeding, 125
Pimozide
amphetamine, 717
anhedonia, 931
antagonism, 717
associative learning, 445
defensive burying, 445
dopamine, 445, 717
eating, 717, 917
extinction, 917
fenfluramine, 717
methergoline, 717
neuroleptics, 445, 931
operant behavior, 917, 931
reward, 917, 931
serotonin, 717
Pituitary
endorphin, 365
17α-estradiol, 365
hypophysectomy, 365
luteinizing hormone releasing hormone, 365
naloxone, 365
sexual behavior, 365

Pituitary-adrenal system
brain cytochrome c, 493
brain non-heme iron, 493
hole-board, 493
iron deficiency, 493
open field, 493
passive avoidance, 493
Pituitary-gonadal axis
body weight regulation, 143
cannabinol, 143
exteroceptive stimulus from conspecifics, 143
follicle-stimulating hormone, 143
luteinizing hormone, 143
perinatal exposure, 143
pheromones, 143
sexual behavior, 143
sexual differentiation, 143
testis function, 143
testosterone, 143
Δ^9-tetrahydrocannabinol, 143
transfer of cannabinoids via milk, 143

Platelets
phospholipids, 697
Δ^9-tetrahydrocannabinol, 697
Portacaval shunt
habituation, 739
hepatic encephalopathy, 739
sensitization, 739
serotonin, 739
startle response, 739
tryptophan, 739
Positive reinforcement
intracerebral microinjection, 965
morphine, 965
naloxone, 965
ventral tegmental area, 965
Post-synaptic supersensitivity
caudate nucleus, 371
eating and drinking deficits, 371
6-hydroxydopamine, 371
lateral hypothalamus, 371
α-methylparatyrosine, 371
monoamine accumulation, 371
nigrostriatal dopamine, 371
Posterior colliculus
aggression, 189
amygdala, 189
anterior colliculus, 189
dipropylacetate, 189
frontal cortex, 189
GABA, 189
gonadectomy, 189
hypothalamus, 189
lactation, 189
olfactory bulb, 189
Potassium chloride
caudate nucleus, 249
cholinergic blockade, 249
learning, 249
overtraining, 249
scopolamine, 249
Precursor amino acids
aggressive behavior, 667
aging, 667
diet supplement, 667
dopamine, 667
motor activity, 667
norepinephrine, 667
serotonin, 667
stress, 667
tyrosine, 667

Prednisone
fetal development, 213
fighting, 213
lactation, 213
maternal aggression, 213
testosterone, 213
Pro-Leu-Gly-NH_2
analgesic tolerance, 73
cyclo(Leu-Gly), 73
hypothermia, 73
jump threshold, 73
MIF, 73
morphine, 73
naloxone, 73
physical dependence, 73
Prolactin
alcohol, 297
ethanol, 297
heroin, 163
human males, 163
man, 297
naltrexone, 163
tolerance, 163
l-Proline
conditioning, 533
glutamate, 533
memory trace, 533
l-proline analogs, 533
retrograde amnesia, 533
spreading depression, 533
l-Proline analogs
conditioning, 533
glutamate, 533
memory trace, 533
l-proline, 533
retrograde amnesia, 533
spreading depression, 533
Prolonged effects
behavior, 893
cat, 893
EEG, 893
methadone, 893
visual evoked potential, 893
Propranolol
β-adrenergic receptors, 419
amygdala central nucleus, 419
heart rate conditioning, 419
isoproterenol, 419
Prostaglandin D_2
anticonvulsant, 747
EEG, 747
neuromuscular coordination, 747
sedation, 747
sleeping time, 747
spontaneous locomotor activity, 747
Protein
carbohydrate, 427
dietary self-selection, 427
fat, 427
feeding behavior, 427
morphine, 427
Protein synthesis
amnesia, 377, 663
anisomycin, 377, 663
brightness discrimination, 319, 663
ECS, 377
hippocampus, 319
inhibitory avoidance, 377
long-term memory, 377
memory consolidation, 319
memory lability, 377
paradoxical sleep, 377

sensitive periods, 663
serotonin, 319
short-term memory, 377
slow-wave sleep, 377
Protein synthesis inhibition
amnesia, 79
anisomycin, 79
cycloheximide, 79
memory, 79
Protoveratrine-A
apomorphine, 735
dopaminergic neurons, 735
α-naphthoxyacetic acid, 735
retching, 735
vomiting, 735
Protriptyline
chlorimipramine, 255
5-hydroxytryptamine, 255
noradrenaline, 255
tube running activity, 255
Psilocybin
cannabinoids, 99
EEG in sleep-waking behavior, 99
hallucinogens, 99
long-term EEG frequency analysis, 99
LSD, 99
mescaline, 99
synhexyl, 99
Δ^9-tetrahydrocannabinol, 99
Puff monitor
cigarette smoking, 811
human research, 811
interbout interval, 811
puff rate, 811
puffing behavior, 811

Puff rate
cigarette smoking, 811
human research, 811
interbout interval, 811
puff monitor, 811
puffing behavior, 811
Puffing behavior
cigarette smoking, 811
human research, 811
interbout interval, 811
puff monitor, 811
puff rate, 811
Punishment
d-amphetamine, 865
anxiety, 41
chlordiazepoxide, 41
conditioned emotional response, 409
dorsal periaqueductal gray, 41
electrical stimulation, 41
extinction, 409
fixed-ratio schedule, 865
footshock, 41
ketamine, 865
morphine, 865
operant behavior, 409
pentobarbital, 865
phencyclidine, 865
scopolamine, 409
septal lesions, 41
suppressed responding, 409
variable interval schedule, 409

Purines
benzodiazepine receptors, 865
diazepam, 685
EMD 28422, 685

Push-pull perfusion
catecholamines, 959
high performance liquid chromatography, 959
indoles, 959
schedule dependent behavior, 959

Quipazine
activity, 347
catalepsy, 347
chickens, 347
dopaminergic system, 347
haloperidol, 347
raphe model, 347
serotonergic system, 347
stereotypy, 347
tonic immobility, 347

Radial arm maze
amphetamine, 595
discrimination learning, 595
memory, 595
methylscopolamine, 595
pentobarbital, 595
scopolamine, 595
short-term memory, 595
spatial discrimination, 595
spatial memory, 595
Raphe model
activity, 347
catalepsy, 347
chickens, 347
dopaminergic system, 347
haloperidol, 347
quipazine, 347
serotonergic system, 347
stereotypy, 347
tonic immobility, 347
Raphe nuclei
aggression, 855
animal hypnosis, 519
biphasic effects, 519
5,7-dihydroxytryptamine, 855
hippocampus, 855
locomotor activity, 855
serotonin, 519, 855
social interaction, 855
striatum, 855
tonic immobility, 519

Rate-dependent effects
d-amphetamine, 559, 899
cocaine, 899
fixed-ratio schedule, 559
imipramine, 899
interresponse-time-greater-than-t schedule, 559
lever-press, 559
operant behavior, 899
operant history, 559
pentobarbital, 899
schedules of reinforcement, 899
variable-interval schedule, 559
Rearing
ambulatory activity, 723
d-amphetamine, 723
anorexia, 723
feeding, 723
food deprivation, 723
interrelationship of drug effects, 723

Rebound
addiction, 909
ethanol, 909
latencies, 909
neural hyperexcitability, 909
peak-to-peak amplitudes, 909
photic after discharge, 909
recovery time, 909
visual evoked response, 909
withdrawal, 909
Receptivity
cyproterone acetate, 359
estradiol, 359
ewe, 359
sexual behavior, 359
testosterone, 359
Receptor sensitivity
β-adrenergic receptor, 943
antidepressants, 943
dihydroalprenolol binding, 943
monoamine oxidase, 943
monoamine uptake inhibition, 943
Recovery of function
amphetamine, 949
apomorphine, 949
caffeine, 949
2-deoxy-D-glucose, 949
feeding, 949
hypertonic saline, 949
insulin, 949
lateral hypothalamic syndrome, 949
zona incerta, 949
Recovery time
addiction, 909
ethanol, 909
latencies, 909
neural hyperexcitability, 909
peak-to-peak amplitudes, 909
photic after discharge, 909
rebound, 909
visual evoked response, 909
withdrawal, 909
Renin
alcohol preference, 293
blood pressure, 293
drinking, 293
ethanol, 293
fluid volume control, 293
hypertension, 293
strain differences, 293
Reserpine
p-chlorophenylalanine, 875
defecation, 875
5,6-dihydroxytryptamine, 875
emotionality, 875
5-hydroxytryptamine, 875
5-hydroxytryptophan, 875
open field, 875
shuttle box, 875
Response consistency
adrenaline, 449
catecholamines, 449
correlation, 449
cortisol, 449
heart rate, 449
humans, 449
noradrenaline, 449
sex differences, 449
Response rate
amphetamine, 883
p-chlorophenylalanine, 883
cinanserin, 883
DRL, 883
drug interactions, 883
serotonin, 883
Response sensitization
adipose tissue, 543
d-amphetamine, 543
chronic administration, 543
conditioning factors, 543
self-stimulation, 543
substantia nigra, 543
Retching
apomorphine, 735
dopaminergic neurons, 735
α-naphthoxyacetic acid, 735
protoveratrine-A, 735
vomiting, 735
Retrograde amnesia
conditioning, 533
glutamate, 533
memory trace, 533
l-proline, 533
l-proline analogs, 533
spreading depression, 533
Reward
S(+)-amphetamine, 137
anhedonia, 931
brain disappearance, 137
eating, 917
extinction, 917
neuroleptics, 931
operant behavior, 917, 931
pimozide, 917, 931
self-administration, 137
tolerance, 137
Rhesus monkey
dependence potential, 155
physical dependence, 155
self-administration, 155
viloxazine, 155
Rostral pons
catecholamines, 353
oxotremorine, 353
sleep, 353
tyrosine hydroxylase, 353
R04-4602
delayed responses, 229
L-DOPA, 229
dopamine, 229
5-hydroxytryptophan, 229
serotonin, 229

Salivation
ambient temperature, 851
p-chloroamphetamine, 851
ejaculation, 851
irritability, 851
thermoregulation, 851
Satiety
calcitonin, 609
drinking, 609
feeding, 609
urination, 609
weight loss, 609
Schedule
analgesics, 983
heroin, 983
self-injection, 983
Schedule-controlled behavior
d-amphetamine, 47, 657
arylcyclohexylamines, 67
cocaine, 657
diazepam, 657

fixed-interval performance, 67
interresponse-times, 85
ketamine, 67
methaqualone, 657
monkey, 67
phencyclidine, 67
phenobarbital, 47
squirrel monkey, 85
Δ^9-tetrahydrocannabinol, 85
tolerance, 47, 85
Schedule-controlled responding
alphaprodine, 797
anileridine, 797
meperidine, 797
morphine, 797
naloxone, 797
Schedule dependent behavior
catecholamines, 959
high performance liquid chromatography, 959
indoles, 959
push-pull perfusion, 959
Schedule-induced behavior
aggressive behavior, 305
chronic administration, 305
Δ^9-tetrahydrocannabinol, 305
Schedules of reinforcement
d-amphetamine, 899
cocaine, 899
imipramine, 899
operant behavior, 899
pentobarbital, 899
rate-dependent effects, 899
Schizophrenia
apomorphine, 979
blood-brain barrier, 871
β-carbolines, 979
hypothalamus, 871
intraventricular injection, 871
metoclopramide, 871
neuroleptics, 871
paranoid psychosis, 979
phenylethylamine, 979
self-stimulation, 871
spiroperidol, 871
stereotypy, 979
tryptolines, 979
Scopolamine
amphetamine, 595
carbachol, 487
caudate nucleus, 249
cholinergic blockade, 249
cholinergic mechanism, 487
conditioned emotional response, 409
discrimination learning, 595
extinction, 409
jump threshold, 487
lateral hypothalamus, 487
learning, 249
memory, 595
methylscopolamine, 595
operant behavior, 409
overtraining, 249
pentobarbital, 595
physostigmine, 487
potassium chloride, 249
punishment, 409
radial arm maze, 595
shock-induced defensive fighting, 487
short-term memory, 595
spatial discrimination, 595
spatial memory, 595
suppressed responding, 409
variable interval schedule, 409
Secobarbital
amobarbital, 803
barbital, 803
lithium chloride, 803
pentobarbital, 803
phenobarbital, 803
taste aversion, 803
Second-order conditioning
aversion therapy, 337
blocking, 337
ethanol, 337
lithium chloride, 337
taste aversion conditioning, 337
Sedation
anticonvulsant, 747
EEG, 747
neuromuscular coordination, 747
prostaglandin D_2, 747
sleeping time, 747
spontaneous locomotor activity, 747
Selective breeding
ethanol, 691
halothane, 691
Self-administration
d-amphetamine, 937
S(+)-amphetamine, 137
brain disappearance, 137
cocaine, 781
dependence potential, 155
5,7-dihydroxytryptamine, 937
dopamine, 781
6-hydroxydopamine, 781
5-hydroxytryptamine, 937
nucleus accumbens, 781, 937
physical dependence, 155
reward, 137
rhesus monkey, 155
tolerance, 137
viloxazine, 155
Self-injection
analgesics, 983
heroin, 983
schedule, 983
Self-stimulation
adipose tissue, 543
d-amphetamine, 543
blood-brain barrier, 871
chronic administration, 543
conditioning factors, 543
dopamine, 389
endorphin, 389
fluspirilene, 389
GABA, 125
hypothalamus, 125, 871
intraventricular injection, 871
metoclopramide, 871
naltrexone, 389
neuroleptics, 871
picrotoxin, 125
response sensitization, 543
schizophrenia, 871
spiroperidol, 871
stimulation-induced feeding, 125
stress, 389
substantia nigra, 543
tail pinch, 389
Sensitive periods
amnesia, 663
anisomycin, 663
brightness discrimination, 663
protein synthesis, 663

Sensitization
habituation, 739
hepatic encephalopathy, 739
portacaval shunt, 739
serotonin, 739
startle response, 739
tryptophan, 739
Sensory stimulation
avoidance conditioning, 481
brain, 481
caudate nucleus, 481
classical conditioning, 481
hippocampus, 481
liver, 481
nuclear phosphoproteins, 481
Septal hyperreactivity
behavioral responsivity, 563
discriminant function analysis, 563
endogenous opiate system, 563
lesions, 563
limbic system, 563
morphine, 563
naloxone, 563
Septal lesions
anxiety, 41
chlordiazepoxide, 41
dorsal periaqueductal gray, 41
electrical stimulation, 41
footshock, 41
punishment, 41
Septo-hippocampal pathway
avoidance conditioning, 277
cholinergic, 277
footshock, 277
high affinity choline uptake, 277
hippocampus, 277
strain differences, 277
striatum, 277
Serotonergic system
activity, 347
catalepsy, 347
chickens, 347
dopaminergic system, 347
haloperidol, 347
quipazine, 347
raphe model, 347
stereotypy, 347
tonic immobility, 347
Serotonin
A10, 603
acetylcholine, 437
activity, 603
aggregation, 313
aggression, 855
aggressive behavior, 667
aging, 667
amphetamine, 603, 717, 883
d-amphetamine, 53
animal hypnosis, 519
antagonism, 717
apomorphine, 53
audiogenic seizures, 119
biphasic effects, 519
brightness discrimination, 319
catecholamines, 53, 313
chlordiazepoxide, 437
chlorimipramine, 119
p-chlorophenylalanine, 883
cinanserin, 883
delayed responses, 229
diet supplement, 667
5,7-dihydroxytryptamine, 855
distress vocalizations, 437
L-DOPA, 229
dopamine, 229, 603, 667, 717
DRL, 883
drug interactions, 883
eating, 717
experimental hypertension, 53
fenfluramine, 717
habituation, 739
hepatic encephalopathy, 739
hippocampus, 319, 855
5-hydroxytryptophan, 119, 229
isolation, 313
lesions, 603
lethal doses, 313
locomotor activity, 855
memory consolidation, 319
methergoline, 717
6-methoxy-1,2,3,4-tetrahydro-β-carboline, 119
morphine, 313
motor activity, 667
norepinephrine, 437, 603, 667
opiates, 437
pargyline, 119
pimozide, 717
portacaval shunt, 739
precursor amino acids, 667
protein synthesis, 319
raphe nuclei, 519, 855
response rate, 883
R04-4602, 229
sensitization, 739
SHR rat, 53
social interaction, 855
startle response, 739
stereotypy, 53
stress, 667
striatum, 855
1,2,3,4-tetrahydro-β-carboline, 119
tonic immobility, 519
tryptophan, 739
tyrosine, 667
ventral medial tegmentum, 603
WKY rat, 53
Sex differences
adrenaline, 449
catecholamines, 449
correlation, 449
cortisol, 449
heart rate, 449
humans, 449
noradrenaline, 449
response consistency, 449
Sexual behavior
body weight regulation, 143
cannabinol, 143
cyproterone acetate, 359
endorphin, 365
estradiol, 359
17α-estradiol, 365
ewe, 359
exteroceptive stimulus from conspecifics, 143
follicle-stimulating hormone, 143
hypophysectomy, 365
luteinizing hormone, 143
luteinizing hormone releasing hormone, 365
naloxone, 365
perinatal exposure, 143
pheromones, 143
pituitary, 365
pituitary-gonadal axis, 143
receptivity, 359
sexual differentiation, 143
testis function, 143

testosterone, 143, 359
Δ^9-tetrahydrocannabinol, 143
transfer of cannabinoids via milk, 143
Sexual differentiation
body weight regulation, 143
cannabinol, 143
exteroceptive stimulus from conspecifics, 143
follicle-stimulating hormone, 143
luteinizing hormone, 143
perinatal exposure, 143
pheromones, 143
pituitary-gonadal axis, 143
sexual behavior, 143
testis function, 143
testosterone, 143
Δ^9-tetrahydrocannabinol, 143
transfer of cannabinoids via milk, 143
Shock-induced attack
hexamethonium, 619
intraperitoneal, 619
intraventricular, 619
mecamylamine, 619
mouse-killing, 619
nicotinic suppression, 619
Shock-induced defensive fighting
carbachol, 487
cholinergic mechanism, 487
jump threshold, 487
lateral hypothalamus, 487
physostigmine, 487
scopolamine, 487
Shock-induced fighting
muricide, 173
pain sensitivity, 173
tryptophan-free diet, 173
Short-term memory
amnesia, 377
amphetamine, 595
anisomycin, 377
discrimination learning, 595
ECS, 377
inhibitory avoidance, 377
long-term memory, 377
memory, 595
memory lability, 377
methylscopolamine, 595
paradoxical sleep, 377
pentobarbital, 595
protein synthesis, 377
radial arm maze, 595
scopolamine, 595
slow-wave sleep, 377
spatial discrimination, 595
spatial memory, 595
SHR rat
d-amphetamine, 53
apomorphine, 53
catecholamines, 53
experimental hypertension, 53
serotonin, 53
stereotypy, 53
WKY rat, 53
Shuttle box
p-chlorophenylalanine, 875
defecation, 875
5,6-dihydroxytryptamine, 875
emotionality, 875
5-hydroxytryptamine, 875
5-hydroxytryptophan, 875
open field, 875
reserpine, 875
Shuttle-box avoidance
cholinesterase inhibition, 847
neostigmine, 847
physostigmine, 847
SKF-525A
discrimination, 403
electric shock, 403
meperidine, 403
morphine, 403
squirrel monkey, 403
titration, 403
Sleep
catecholamines, 353
oxotremorine, 353
rostral pons, 353
tyrosine hydroxylase, 353
Sleeping time
anticonvulsant, 747
t-butanol, 651
calcium, 651
chloral hydrate, 651
EDTA, 651
EEG, 747
EGTA, 651
ethanol, 651
ionophores, 651
neuromuscular coordination, 747
pentobarbital, 651
prostaglandin D2, 747
sedation, 747
spontaneous locomotor activity, 747
Slow-wave sleep
amnesia, 377
anisomycin, 377
ECS, 377
inhibitory avoidance, 377
long-term memory, 377
memory lability, 377
paradoxical sleep, 377
protein synthesis, 377
short-term memory, 377
Social interaction
ACTH, 711
aggression, 855
anxiety, 711
5,7-dihydroxytryptamine, 855
hippocampus, 855
locomotor activity, 855
raphe nuclei, 855
serotonin, 855
striatum, 855
Spatial discrimination
amphetamine, 595
discrimination learning, 595
memory, 595
methylscopolamine, 595
pentobarbital, 595
radial armmaze, 595
scopolamine, 595
short-term memory, 595
spatial memory, 595
Spatial memory
amphetamine, 595
discrimination learning, 595
memory, 595
methylscopolamine, 595
pentobarbital, 595
radial armmaze, 595
scopolamine, 595
short-term memory, 595
spatial discrimination, 595
Spiroperidol
apomorphine, 29
audiogenic seizures, 823
blood-brain barrier, 871

Spiroperidol (continued)
bromocryptine, 823
dopamine receptor sensitivity, 29
dopaminergic pathways, 823
hypothalamus, 871
intraventricular injection, 871
metoclopramide, 871
neuroleptics, 29, 871
schizophrenia, 871
self-stimulation, 871
stereotypic activity, 29
Spontaneous locomotor activity
anticonvulsant, 747
circadian rhythm, 549
corticosterone, 549
EEG, 747
histamine, 549
hypothalamus, 549
neuromuscular coordination, 747
prostaglandin D_2, 747
sedation, 747
sleeping time, 747
temperature, 549
Spreading depression
conditioning, 533
glutamate, 533
memory trace, 533
l-proline, 533
l-proline analogs, 533
retrograde amnesia, 533
Squirrel monkey
discrimination, 403
electric shock, 403
interresponse-times, 85
meperidine, 403
morphine, 403
schedule-controlled behavior, 85
SKF-525A, 403
Δ^9-tetrahydrocannabinol, 85
titration, 403
tolerance, 85
Startle response
habituation, 739
hepatic encephalopathy, 739
portacaval shunt, 739
sensitization, 739
serotonin, 739
tryptophan, 739
Stereotypic activity
apomorphine, 29
dopamine receptor sensitivity, 29
neuroleptics, 29
spiroperidol, 29
Stereotypy
activity, 347
d-amphetamine, 53
apomorphine, 53, 459, 515, 979
β-carbolines, 979
catalepsy, 347
catecholamines, 53
chickens, 347
chronopharmacology, 459
circadian rhythm, 459
dopamine, 515
dopaminergic system, 347
estrogen, 515
experimental hypertension, 53
haloperidol, 347
ovariectomy, 515
paranoid psychosis, 979
phenylethylamine, 979
quipazine, 347
raphe model, 347
schizophrenia, 979
serotonergic system, 347
serotonin, 53
SHR rat, 53
tonic immobility, 347
tryptolines, 979
WKY rat, 53
Stimulation-induced feeding
GABA, 125
hypothalamus, 125
picrotoxin, 125
self-stimulation, 125
Stimulus properties of drugs
ACTH, 93
bombesin, 93
delta sleep-inducing peptide, 93
enkephalin, 93
ethanol, 93
His-Pro diketopiperazine, 93
naloxone, 93
peptide, 93
substance P, 93
thyrotropin releasing hormone, 93
Strain differences
alcohol preference, 293
avoidance conditioning, 277
blood pressure, 293
brain monoamines, 311
cholinergic, 277
dopamine, 311
drinking, 293
ethanol, 293
fluid volume control, 293
footshock, 277
high affinity choline uptake, 277
hippocampus, 277
5-hydroxytryptamine, 311
hypertension, 293
parachlorophenylalanine, 311
renin, 293
septo-hippocampal pathway, 277
striatum, 277
Stress
aggressive behavior, 667
aging, 667
arrythmias, 235
cortex, 35
corticosterone, 35
diet supplement, 667
digitalis, 235
dopamine, 389, 667
endorphin, 389
fluspirilene, 389
histamine, 35
hypothalamus, 35
midbrain, 35
motor activity, 667
naltrexone, 389
norepinephrine, 667
ouabain, 235
precursor amino acids, 667
self-stimulation, 389
serotonin, 667
tail pinch, 389
toxicity, 235
tyrosine, 667
Striatum
aggression, 855
avoidance conditioning, 277
brain distribution, 217
brain penetrability, 217
^{3}H-cannabidiol, 217
^{3}H-cannabinol, 217

cholinergic, 277
5,7-dihydroxytryptamine, 855
footshock, 277
high affinity choline uptake, 277
locomotor activity, 855
raphe nuclei, 855
hippocampus, 277, 855
septo-hippocampal pathway, 277
serotonin, 855
social interaction, 855
strain differences, 277
^{3}H-Δ^9-tetrahydrocannabinol, 217
Subcutaneous gastric cannula
chronic preparation, 629
Substance P
ACTH, 93
bombesin, 93
delta sleep-inducing peptide, 93
enkephalin, 93
ethanol, 93
His-Pro diketopiperazine, 93
naloxone, 93
peptide, 93
stimulus properties of drugs, 93
thyrotropin releasing hormone, 93
Substantia nigra
adipose tissue, 543
amphetamine, 185
d-amphetamine, 543
apomorphine, 185
chronic administration, 543
circling behavior, 185
conditioning factors, 543
DOPA, 185
dopamine, 195
6-hydroxydopamine, 185
nigro-striatal neurons, 185
response sensitization, 543
self-stimulation, 543
Suppressed responding
conditioned emotional response, 409
extinction, 409
operant behavior, 409
punishment, 409
scopolamine, 409
variable interval schedule, 409
Surgical anesthesia
γ-acetylenic GABA, 113
aminooxyacetic acid, 113
d-amphetamine, 113
baclofen, 113
locomotor stimulation, 113
muscimol, 113
phencyclidine, 113
Swivel
double channel, 463
flow-thru, 463
infusions, 463
unrestrained animals, 463
Synhexyl
cannabinoids, 99
EEG in sleep-waking behavior, 99
hallucinogens, 99
long-term EEG frequency analysis, 99
LSD, 99
mescaline, 99
psilocybin, 99
Δ^9-tetrahydrocannabinol, 99

Tail pinch
dopamine, 389
endorphin, 389
fluspirilene, 389
naltrexone, 389
self-stimulation, 389
stress, 389
Taste aversion
amobarbital, 613, 803
barbital, 613, 803, 807
brain rewarding system, 729
drinking, 613
hexobarbital, 613
lithium chloride, 613, 803, 807
naloxone, 729
opiate systems, 729
pain modulating system, 729
pentobarbital, 613, 803
phenobarbital, 803, 807
secobarbital, 803
taste preference, 729
Taste aversion conditioning
aversion therapy, 337
blocking, 337
conditioned responses, 789
drinking, 789
drug conditioning, 789
ethanol, 337
lithium chloride, 337, 789
second-order conditioning, 337
Taste preference
brain rewarding system, 729
naloxone, 729
opiate systems, 729
pain modulating system, 729
taste aversion, 729
Temperature
circadian rhythm, 549
corticosterone, 549
histamine, 549
hypothalamus, 549
spontaneous locomotor activity, 549
Template active region
brain chromatin, 207
corticosterone, 207
development, 207
Testis function
body weight regulation, 143
cannabinol, 143
exteroceptive stimulus from conspecifics, 143
follicle-stimulating hormone, 143
luteinizing hormone, 143
perinatal exposure, 143
pheromones, 143
pituitary-gonadal axis, 143
sexual behavior, 143
sexual differentiation, 143
testosterone, 143
Δ^9-tetrahydrocannabinol, 143
transfer of cannabinoids via milk, 143
body weight regulation, 143
cannabinol, 143
p-chlorophenylalanine, 181
cyproterone acetate, 359
estradiol, 359
ewe, 359
exteroceptive stimulus from conspecifics, 143
fenfluramine, 181
fetal development, 213
fighting, 213
follicle-stimulating hormone, 143
lactation, 213
luteinizing hormone, 143
marking behavior, 181
maternal aggression, 213
α-methyltyrosine, 181

Testis function
perinatal exposure, 143
pheromones, 143
pituitary-gonadal axis, 143
prednisone, 213
receptivity, 359
sexual behavior, 143, 359
sexual differentiation, 143
testis function, 143
Δ^9-tetrahydrocannabinol, 143
transfer of cannabinoids via milk, 143
1,2,3,4-tetrahydro-β-carboline
audiogenic seizures, 119
chlorimipramine, 119
5-hydroxytryptophan, 119
6-methoxy-1,2,3,4-tetrahydro-β-carboline, 119
pargyline, 119
serotonin, 119
Δ^9-Tetrahydrocannabinol
aggressive behavior, 305
body weight regulation, 143
cannabinoids, 99
cannabinol, 143
chronic administration, 305
EEG in sleep-waking behavior, 99
exteroceptive stimulus from conspecifics, 143
follicle-stimulating hormone, 143
hallucinogens, 99
interresponse-times, 85
long-term EEG frequency analysis, 99
LSD, 99
luteinizing hormone, 143
mescaline, 99
perinatal exposure, 143
pheromones, 143
phospholipids, 697
pituitary-gonadal axis, 143
platelets, 697
psilocybin, 99
schedule-controlled behavior, 85
schedule-induced behavior, 305
sexual behavior, 143
sexual differentiation, 143
squirrel monkey, 85
synhexyl, 99
testis function, 143
testosterone, 143
tolerance, 85
transfer of cannabinoid via milk, 143
^{3}H-Δ^9-Tetrahydrocannabinol
brain distribution, 217
brain penetrability, 217
pharmacokinetics, 217
Theophylline
behavioral thermoregulation, 843
circadian rhythm, 843
Thermoregulation
ambient temperature, 851
p-chloroamphetamine, 851
ejaculation, 851
irritability, 851
salivation, 851

Thiopental
barbital, 577
chronic morphine, 577
conditioned avoidance response, 577
diazepam, 577
drug interaction, 577
ethanol, 577
naloxone, 577
pentobarbital, 577
phenobarbital, 577

Thioridazine
amphetamine, 1
antidepressants, 1
chlorpromazine, 1
clozapine, 1
desipramine, 1
drug-induced discrimination, 1
fluphenazine, 1
haloperidol, 1
imipramine, 1
neuroleptics, 1
trifluoperazine, 1
Thyroid
goiter, 837
hypothalamus, 837
knife cuts, 837
obesity, 837
paraventricular nucleus, 837
Thyrotropin releasing hormone
ACTH, 93
bombesin, 93
delta sleep-inducing peptide, 93
enkephalin, 93
ethanol, 93
His-Pro-diketopiperazine, 93
naloxone, 93
peptide, 93
stimulus properties of drugs, 93
substance P, 93
Tissue localization
behavioral effects, 761
body weight, 761
pharmacokinetics, 761
phencyclidine, 761
tolerance, 761
Titration
discrimination, 403
electric shock, 403
meperidine, 403
morphine, 403
SKF-525A, 403
squirrel monkey, 403
Tolerance
aggression, 525
amino acids, 525
amphetamine, 107, 701
d-amphetamine, 47
S(+)-amphetamine, 137
anorexia, 107
behavioral effects, 761
body weight, 107, 701, 761
brain disappearance, 137
cathine, 701
cathinone, 701
cross-tolerance, 107, 701
diet, 525
food intake, 701
heroin, 163
human males, 163
hypodipsia, 107
ingestive aeffects, 107
interresponse-times, 85
khat, 701
locomotion, 525
monoamines, 525
morphine, 625
naloxone-precipitated withdrawal, 625
naltrexone, 163
nicotine, 107
pharmacokinetics, 761
phencyclidine, 761
phenobarbital, 47
physical dependence, 625

prolactin, 163
reward, 137
schedule-controlled behavior, 47, 85
self-administration, 137
squirrel monkey, 85
Δ^9-tetrahydrocannabinol, 85
tissue localization, 761
Tonic immobility
activity, 347
animal hypnosis, 519
biphasic effects, 519
catalepsy, 347
chickens, 347
dopaminergic system, 347
haloperidol, 347
quipazine, 347
raphe model, 347
raphe nuclei, 519
serotonergic system, 347
serotonin, 519
stereotypy, 347
Toxicity
arrythmias, 235
digitalis, 235
ouabain, 235
stress, 235
Transfer of cannabinoids via milk
body weight regulation, 143
cannabinol, 143
exteroceptive stimulus from conspecifics, 143
follicle-stimulating hormone, 143
luteinizing hormone, 143
perinatal exposure, 143
pheromones, 143
pituitary-gonadal axis, 143
sexual behavior, 143
sexual differentiation, 143
testis function, 143
testosterone, 143
Δ^9-tetrahydrocannabinol, 143
TRH
behavioral arousal, 925
central catecholaminergic neurons, 925
development, 925
α-flupenthixol, 925
6-hydroxydopamine, 925
phenoxybenzamine, 925
Trifluoperazine
amphetamine, 1
antidepressants, 1
chlorpromazine, 1
clozapine, 1
desipramine, 1
drug-induced discrimination, 1
fluphenazine, 1
haloperidol, 1
imipramine, 1
neuroleptics, 1
nortryptiline, 1
thioridazine, 1
Tryptolines
apomorphine, 979
β-carbolines, 979
paranoid psychosis, 979
phenylethylamine, 979
schizophrenia, 979
stereotypy, 979
Tryptophan
habituation, 739
hepatic encephalopathy, 739
portacaval shunt, 739
sensitization, 739
serotonin, 739
startle response, 739
Tryptophan-free diet
gryllicide, 675
isolation-induced fighting, 675
muricide, 173
pain sensitivity, 173
shock-induced fighting, 173
Tube running activity
chlorimipramine, 255
exploratory activity, 259
5-hydroxytryptamine, 255, 259
monoamine oxidase inhibition, 259
nialamide, 259
noradrenaline, 255
protriptyline, 255
Tyrosinase
albinism, 969
catecholamines, 969
melanin, 969
tyrosine, 969
Tyrosine
aggressive behavior, 667
aging, 667
albinism, 969
catecholamines, 969
diet supplement, 667
dopamine, 667
melanin, 969
motor activity, 667
norepinephrine, 667
precursor amino acids, 667
serotonin, 667
stress, 667
tyrosinase, 969
Tyrosine hydroxylase
catecholamines, 353
oxotremorine, 353
rostral pons, 353
sleep, 353

Unrestrained animals
double channel, 463
flow-thru, 463
infusions, 463
swivel, 463
Urinary sodium
angiotensin I, 131
angiotensin II, 131
estradiol benzoate, 131
urine output, 131
water intake, 131
Urination
calcitonin, 609
drinking, 609
feeding, 609
satiety, 609
weight loss, 609
Urine output
angiotensin I, 131
angiotensin II, 131
estradiol benzoate, 131
urinary sodium, 131
water intake, 131

Variable-interval schedule
d-amphetamine, 559
conditioned emotional response, 409
extinction, 409
fixed-ratio schedule, 559
interresponse
time-greater-than-t schedule, 559

Variable-interval schedule (continued)
lever press, 559
operant behavior, 409
operant history, 559
punishment, 409
rate-dependent effects, 559
scopolamine, 409
suppressed responding, 409
Ventral medial tegmentum
A10, 603
activity, 603
amphetamine, 603
dopamine, 603
lesions, 603
norepinephrine, 603
serotonin, 603
Ventral tegmental area
intracerebral microinjection, 965
morphine, 965
naloxone, 965
positive reinforcement, 965
Viloxazine
dependence potential, 155
physical dependence, 155
rhesus monkey, 155
self-administration, 155
Visual discrimination
amphetamine, 861
delayed response, 861
frontal lobe, 861
monkey, 861
Visual evoked potential
behavior, 893
cat, 893
EEG, 893
methadone, 893
prolonged effects, 893
Visual evoked response
addiction, 909
ethanol, 909
latencies, 909
neural hyperexcitability, 909
peak-to-peak amplitudes, 909
photic afterdischarge, 909
rebound, 909
recovery time, 909
withdrawal, 909
Voluntary alcohol intake
alcoholism, 239
biogenic amines, 239
conditioned taste aversion, 239
lithium chloride, 239
Vomiting
apomorphine, 735
dopaminergic neurons, 735
α-naphthoxyacetic acid, 735
protoveratrine-A, 735
retching, 735

Water intake
angiotensin I, 131
angiotensin II, 131
estradiol benzoate, 131
urinary sodium, 131
urine output, 131
Weight loss
calcitonin, 609
drinking, 609
feeding, 609
satiety, 609
urination, 609
Whole brain dopamine
defecation, 773
11-hydroxycorticosterone, 773
hypophysectomy, 773
α-MSH, 773
novelty, 773
whole brain norepinephrine, 773
Whole brain norepinephrine
defecation, 773
11-hydroxycorticosterone, 773
hypophysectomy, 773
α-MSH, 773
novelty, 773
whole brain dopamine, 773
Withdrawal
addiction, 909
body shakes, 573
clonidine, 573
diarrhea, 573
ethanol, 503, 909
latencies, 909
lofexidine, 573
morphine, 573
naloxone, 573
neural hyperexcitability, 909
nutritionally complete liquid diets, 503
peak-to-peak amplitudes, 909
photic aferdischarge, 909
physical dependence, 503
rebound, 909
recovery time, 909
visual evoked potential, 909
Withdrawal syndrome
conditioned taste aversion, 707
dependence, 707
ethanol, 707
WKY rat
d-amphetamine, 53
apomorphine, 53
catecholamines, 53
experimental hypertension, 53
serotonin, 53
SHR rat, 53
stereotypy, 53

Y-maze avoidance
behavioral teratology, 393
ethanol, 393
fetal alcohol, 393
open field, 393

Zona incerta
amphetamine, 949
apomorphine, 949
caffeine, 949
2-deoxy-D-glucose, 949
feeding, 949
hypertonic saline, 949
insulin, 949
lateral hypothalamic syndrome, 949
recovery of function, 949
Zucker rat
activity, 265
d-amphetamine, 265
fenfluramine, 265
meal patterns, 265

AUTHOR INDEX

ADAMCHUK, C. A., 837
AIRAKSINEN, M. M., 979
ALBERT, D. J., 681
ALOZIE, S. O., 217
ALTAR, A., 629
ALTSHULER, H. L., 847
AMIT, Z., 463
ANDERSON, J. A., 29
ANGELUCCI, L., 7
APRISON, M. H., 959
ASIN, K. E., 343

BAETTIG, K., 107
BAILE, C. A., 195
BAKER, H. F., 861
BAKER, R., 691
BALSTER, R. L., 67, 761
BARRETT, R. J., 137, 277
BARONE, F. C., 803, 807
BARRETT, J. E., 899
BATTY, J., 181
BAUM, J. J., 365
BEAN, N. J., 437
BECK, E. C., 893
BECK, L. K., 651
BELL, R., 487
BENINGER, R. J., 445, 917
BHARGAVA, H. N., 73, 645
BIERLEY, R. A., 909
BLAIR, R., 463
BLUNDELL, J. E., 717
BOISVERT, C., 229
BOLAND, F. J., 239
BOLT, M., 555
BORISON, R. L., 515
BRADY, K., 67, 667
BRANCH, M. N., 85
BROWN, H., 207
BROWN, J. W., 525, 667
BROWN, K., 487
BUCKHOLTZ, N. S., 119
BURCH, L. S., 413

CAGIN, N. A., 235
CAMERON, W. R., 563
CANNON, D. S., 909
CAPLAN, M. A., 883
CARDEAL, J. O., 333
CARLINI, E. A., 701
CARMAN, J. S., 609
CAUL, W. F., 393
CAVALHEIRO, E. A., 333
CHANNABASAVAIAH, K., 93
CHAPMAN, L., 559
CHEREK, D. R., 305
CHERKIN, A., 533
CHIPKIN, R. E., 93
CHIUEH, C. C., 53
CLARK, W. G., 113
CLARKE, A., 711
CLASSEN, W., 107
COLE, S. O., 723
COOKSON, S. L., 743
COONS, E. E., 125
COOPER, D. O., 277
COOPER, S. J., 23
COWAN, C. M., 333
CRAIGMILL, A. L., 313
CREEL, D., 969
CUNNINGHAM, C. L., 337
CURLEY, M. D., 413
CZECH, D. A., 987

DALLMAN, P. R., 493
DALTERIO, S. L., 143
DATTA, P. C., 773
DAVIS, G. A., 755
DAVIS, J. L., 533
DEAKIN, J. F. W., 855
DE CATANZARO, D., 201
DEITRICH, R., 691
DELLA-FERA, M. A., 195
DEVOS, M., 729
DEWEY, W. L., 217
DIAMOND, B. I., 515
DIBNER, M. D., 509
DOMJAN, M., 789
DREGITS, D. P., 281
DREWNOWSKI, A., 265
DUENSING, K. L., 651
DUSTMAN, R. E., 893, 909
DYKSTRA, L. A., 403

ECKERMAN, D. A., 595
EDWARDS, J. D., 595
EICHELMAN, B., 173, 675
ELISABETSKY, E., 481
ELLINGBOE, J., 163, 297
ELLIS, D. B., 943
EMERY, D., 311
ENGEL, J., 311
ENNS, M., 265
ERICKSON, C. K., 503, 651
ERINOFF, L., 281
EVANS, S., 563
EVERETT, J., 229

FABRE-NYS, C., 359
FAIRCHILD, M. D., 99
FERNANDEZ, K., 393
FIBIGER, H. C., 781, 917
FILE, S. E., 711, 855
FIORIGLIO, C., 467
FISCHER, J. E., 739
FISHBEIN, W., 377
FISHMAN, B., 463
FLEXNER, L. B., 79
FOLEY, T. L., 431
FORD, R. D., 657
FORSMAN, L., 449
FREED, W. J., 609
FREGLY, M. J., 131
FRIEDLE, N. M., 937
FRYSINGER, R. C., 419
FURUKAWA, T., 735
FYHRQUIST, F., 293

GAGE, F. H., 563
GAGE, M. I., 595
GALBICKA, G., 85
GALLAGHER, M., 419
GANDELMAN, R., 213
GEMBERLING, G. A., 789
GETSOVA, V. M., 319
GEYER, M. A., 739
GILLAN, D. J., 789
GOLD, R. M., 837
GOLDMAN, M. E., 503
GONZALEZ, L. P., 847
GONZÁLEZ PÉREZ, J. N., 823
GONZÁLEZ-QUEVEDO, A., 823
GORDON, J. H., 515
GORDON, W. A., 595
GORSKI, R. A., 515
GORZALKA, B. B., 201
GOY, R. W., 755
GRAEFF, F. G., 41
GRAY, T., 931
GRECKSCH, G., 317, 663
GRIFFITHS, R. R., 811
GRINKER, J. A., 265
GROSSMAN, S. P., 949
GUTWEIN, B. M., 377

HARA, C., 459
HARRIS, L. S., 217, 747
HARRIS, R. A., 47
HARTLINE, R. A., 467
HAUG, M., 189
HEFFNER, T. G., 287
HEFTI, F., 185
HEGSTRAND, L. R., 173, 675
HENNIG, C. W., 519
HENNINGFIELD, J. E., 811
HERBERG, L. J., 871
HINGTGEN, J. N., 959
HO, B. T., 303
HOFFMAN, P. L., 79
HOFFMAN, S. L., 235
HOLTZMAN, S. G., 587
HOTCHIN, J., 61
HOWD, R. A., 577
HOWES, J. F., 625
HUMPHRIES, C. R., 851

IRVING, S. M., 755
IZQUIERDO, I., 481

JENDEN, D. J., 99
JEPPSSON, B., 739
JESTE, D. V., 453
JIRKA, M., 317
JOHNSON, D. N., 747
JOLICOEUR, F. B., 613
JORK, R., 317, 319

KALOFOUTIS, A., 697
KAMEYAMA, T., 875
KANAREK, R. B., 427
KANT, G. J., 603
KANTAK, K. M., 173, 675
KAPP, B. S., 419
KARI, I., 979
KATZ, R. J., 389
KAUFMANN, P., 249
KAVALIERS, M., 843
KELLY, T., 305
KILPATRICK, S. J., 555
KIM, L., 189
KING, M. G., 773
KISSILEFF, H., 265
KIYOHARA, H., 155
KLONOFF, P., 781
KOKKINIDIS, L., 543
KOOB, G. F., 603, 781
KOPIN, I. J., 53
KOSERSKY, D. S., 625
KOUTSELINIS, A., 697
KOWOLENKO, M. D., 625
KRAFFT, K., 559
KRAMARCY, N. R., 525
KUEHNLE, J. C., 163, 297

LAL, H., 573
LARSSON, K., 311
LASLEY, S. M., 525
LATHAM, C. J., 717
LAYCHOCK, S. G., 747
LEANDER, J. D., 797
LEE, D. M., 85
LEKAKIS, J., 697
LE MAGNEN, J., 707, 729
LE PIANE, F. G., 965
LEVINE, S., 493
LEVINE, T. E., 281, 287
LINAKIS, J. G., 337
LIND, M. D., 431
LINKOLA, J., 293
LINTS, C. E., 385
LOCK, K.-L., 685
LÖSSNER, B., 317
LOULLIS, C. C., 959
LOWELL, B. B., 837
LUNDBERG, U., 449
LYNESS, W. H., 937

McCARTY, R., 53
McCLELLAND, A., 23
McCOWN, T. J., 137
McDERMOTT, L. J., 949
McGUIRE, P. S., 287
McKIM, W. A., 409
McLAUGHLIN, C. L., 195

MacLENNAN, A. J., 445
MacPHAIL, R. C., 595
MADDEN, C., 983
MALICK, J. B., 819
MANDEL, P., 189
MANN, J. D., 743
MARANGOS, P., 685
MARFAING-JALLAT, P., 709, 729
MARKS-KAUFMAN, R., 427
MARTIN, B. R., 217, 761
MARTIN, J. R., 107
MARTIN, L. L., 943
MASON, S. T., 917
MATTHIES, H., 317, 319, 663
MAZURKIEWICZ-KWILECKI, I. M., 35, 549
MEEKER, R., 437
MELAMED, E., 185
MELCHIOR, C., 691
MELE, P. C., 883
MELTZER, L. T., 67
MENDELSON, J. H., 163, 297
MENON, M. K., 113
MERKEL, A. D., 613
MEYERHOFF, J. L., 603
MEYERSON, B. J., 181
MEYERSON, L. R., 943
MICELI, D., 707, 729
MICKEY, M. R., 99
MILLER, K. D., 297
MILLER, S. S., 503
MINTZ, R. B., 613
MOHRLAND, J. S., 313
MOLINOFF, P. B., 509
MOLTZ, H., 555
MOORE, K. E., 937
MOSCONA, R., 249
MYERS, B. M., 365

NABESHIMA, T., 875
NAKANO, S., 459
NATELSON, B. H., 235
NENJA, L. H., 385
NOMURA, Y., 925

O'BRIEN, M., 851
OEI, T. P. S., 983
OGAWA, N., 459
OKI, K., 925
ONG, H. H., 943
OSBORNE, G. L., 393
OSTROWSKI, N. L., 431

PANKSEPP, J., 437
PAPADOPOULOU, Z., 767
PATEL, J. B., 819
PAUGH, B., 685
PAUL, S., 685
PAXINOS, G., 851
PERLOW, M. J., 609
PERSSON, S.-Å., 255, 259
PHILLIPS, A. G., 917, 965
PICKENS, R., 811
PINEL, J. P. J., 445
POLING, A., 559
PORRINO, L. J., 125
PRADO-ALCALA, R. A., 249
PRELL, G. D., 549
PRYOR, G. T., 577

RABIN, R. A., 509
RAINBOW, T. C., 79
RAMM, P., 353
RAPAKKO, S., 979
RAPP, P. R., 419
RAWLINS, J. N. P., 41
RECH, R. H., 657
REID, L. D., 431
REINISCH, J. M., 213
RIDLEY, R. M., 861
RIFFEE, W. H., 29
RITZMANN, R. F., 73
ROBERGE, A. G., 229
ROBERTS, D. C. S., 781
RODD, D., 815
ROEHRS, T. A., 223
RONDEAU, D. B., 613
ROTH, K. A., 389
RUSI, M., 293

SAHAKIAN, B. J., 185
SALE, P., 7
SAMSON, H. H., 223
SCHECHTER, M. D., 1
SCHLEHUBER, C., 893
SCHMALTZ, K., 389
SCHMIDT, D. E., 277
SCHNEIDER, C. W., 467
SCHWERTZ, D., 67
SEEGAL, R. F., 61
SEIDEN, L. S., 281, 287
SESSIONS, G. R., 603
SHEA, P. A., 959
SHEARER, D. E., 893
SHEARMAN, G. T., 573
SHIROMANI, P. J., 377
SHOREY, R. L., 503
SIGNORET, J. P., 359
SIKORA, E., 61
SILVERMAN, P. B., 303
SIMLER, S., 189
SIMON, N. G., 213
SINGER, G., 371, 803, 807, 983
SKOLNICK, P., 685
SKUPNY, A. S. T., 297
SMITH, G. P., 453
SMITH, R. V., 29
SNELL, D., 47
SNYDER, E. W., 893
SOUZA, D. O., 481
SPARKS, D. L., 119
SPYRAKI, C., 767
STEIN, E. A., 815, 987
STERN, M. H., 239
STEWART, J. M., 93
SUZUKI, M., 875
SZE, P. Y., 385

TAUB, H., 353
TEAL, J. J., 587
THOMPSON, T., 305
THURMOND, J. B., 525, 667
TIKKANEN, I., 293
TOBIN, D., 657
TOZZI, W., 7
TYLER, T. D., 651

UPHOUSE, L., 207
URSILLO, R. C., 573

VALDES, J. J., 563
VAN HARREVELD, A., 533
VARONOS, D., 767
VIVONIA, C., 113

WAHLSTRÖM, G., 259
WAKASA, Y., 155

WALDBILLIG, R. J., 619
WALLNAU, L. B., 347
WALSH, J. M., 413
WALTER, R., 73
WARBRITTON, J. D., III, 739
WAYNER, E. A., 803, 807
WAYNER, M. J., 613, 803, 807
WEEKS, J. R., 463
WEHL, C. K., 909
WEIGHT, M. L., 861
WEINBERG, J., 493
WENGER, G. R., 865
WETZEL, W., 319
WHITMAN, J., 173
WILCOX, R. E., 29
WILLIS, G. L., 371
WILLOTT, J. F., 385
WINDSOR, R., 685
WISE, R. A., 931
WISHART, T. B., 871
WOLFE, B. B., 509
WOOD, J., 467
WOOLVERTON, W. L., 761
WURTMAN, R. J., 185
WYATT, R. J., 609

YALE, C., 99
YAMADA, K., 735
YANAGITA, T., 155
YINGLING, J., 811

ZACHARUKO, R. M., 543
ZAHNISER, N. R., 509
ZELGER, J. L., 701
ZIS, B., 767
ZUCCARELLI, R. R., 899

VOLUME 13 1980

PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR

Editor-in-Chief

MATTHEW J. WAYNER

Published by

ANKHO International Inc

Fayetteville, New York

PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR

Editor-in-Chief

MATTHEW J. WAYNER

Brain Research Laboratory, Syracuse University, 601 University Avenue, Syracuse, N. Y. 13210 U.S.A.

Regional Editors

R. L. BALSTER, Department of Pharmacology, Medical College of Virginia, Virginia Commonwealth University, Richmond, Virginia 23298

A. BARBEAU, Department of Neurobiology, Clinical Research Institute of Montreal, 110 West Pine Avenue, Montreal (130), Quebec, Canada

J. R. BOISSIER, Faculté de Médecine de Paris, Unité de Neuropsychopharmacologie, 2 rue d'Alésia, 75014 Paris, France

G. R. BREESE, Department of Psychiatry, University of North Carolina School of Medicine, Chapel Hill, North Carolina 27514

E. A. CARLINI, Department of Psychobiology, Escola Paulista de Medicina, Rua Botucatu, 862, 04023 – São Paulo, Brasil

J. COCHIN, Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, 80 East Concord Street, Boston, Massachusetts 02118

D. V. COSCINA, Section of Neurochemistry, Clarke Institute of Psychiatry, 250 College Street, Toronto, Ontario M5T 1R8, Canada

B. COX, Pharmaceuticals Division, Imperial Chemical Industries, Ltd., Mereside, Alderly Park, Macclesfield, Cheshire, United Kingdom SK10 4TG

G. ELLMAN, Brain Behavior Research Center, Sonoma State Hospital, Eldridge, CA 95431

K. ERIKSSON, Research Laboratories of State Alcohol Monopoly, Box 350, 00101 Helsinki 10, Finland

J. L. FALK, Department of Psychology, Rutgers University, New Brunswick, New Jersey 08903

E. GELLER, Neurobiochemistry Laboratory, T-85 Veterans Administration, Brentwood Hospital, Los Angeles, California 90073

S. P. GROSSMAN, Department of Psychology, University of Chicago, Chicago, Illinois 60637

Y. GUTMAN, Department of Pharmacology, The Hebrew University, Hadassah Medical School, P.O. Box 1172, Jerusalem, Israel

J. HANO, Polish Academy of Sciences, Institute of Pharmacology, 52, Ojcowska Street, 31 344 Krakow, Poland

J. A. HARVEY, Department of Psychology, University of Iowa, Iowa City, Iowa 52242

P. JANSSEN, Research Laboratoria, Janssen Pharmaceutica, 2340-Beerse, Belgium

D. A. KHARKEVICH, Department of Pharmacology, First Medical Institute, 2/6, Bolshaja Pirogovhkaja Street, Moscow, G-435, USSR

J. KNOLL, Director, Department of Pharmacology, Semmelweis University of Medicine,1445 Budapest, VIII, Nagyvárad tér 4

I. P. LAPIN, Laboratory of Psychopharmacology, Bekhterev Institute, Bekhtereva ul., 3, 193019 Leningrad, USSR

A. E. LEBLANC, Biological Studies Research Division, Alcoholism and Drug Addiction Research Foundation, 33 Russell Street, Toronto, Ontario M5S 2S1, Canada

V. G. LONGO, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 Roma, Italy

H. MATTHIES, Institut für Pharmakologie und Toxikologie, Medizinische Akademie Magdeburg, 301 Magdeburg, Leipziger Strasse 44, German Democratic Republic

N. K. MELLO, Alcohol and Drug Abuse Research Center, Harvard Medical School, McLean Hospital, Belmont, Massachusetts 02178

R. D. MYERS, Departments of Psychiatry and Pharmacology, University of North Carolina School of Medicine, Chapel Hill, NC 27514

R. H. RECH, Department of Pharmacology, Michigan State University, B440 Life Sciences, East Lansing, Michigan 48824

C. R. SCHUSTER, Department of Psychiatry, University of Chicago, 950 East 59th Street, Chicago, Illinois 60637

D. S. SEGAL, Department of Psychiatry, School of Medicine, University of California, San Diego, La Jolla, California 92037

L. S. SEIDEN, Department of Pharmacology, University of Chicago, Chicago, Illinois 60637

E. B. SIGG, Wyeth Laboratories Inc., P.O. Box 8299, Philadelphia, PA 19101

G. SINGER, Department of Psychology, La Trobe University, Bundoora, Victoria 3083, Australia

T. L. SOURKES, Allan Memorial Institute of Psychiatry, 1025 Pine Avenue West, Montreal 112, P.Q., Canada

W. C. STERN, Medical Division, Burroughs Wellcome Co., 3030 Cornwallis Road, Research Triangle Park, NC 27709

S. TADOKORO, Behavior Research Institute, School of Medicine, Gunma University, 3-39-22, Showamachi Maebashi 371, Japan

T. THOMPSON, Department of Psychiatry, University of Minnesota, Research Unit, Medical School, Box 392, Mayo Memorial Building, Minneapolis, Minnesota 55455

U. UNGERSTEDT, Department of Pharmacology, Karolinska Institutet, S-104 01 Stockholm 60, Sweden

W. L. VEALE, Division of Medical Physiology, Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada

J. E. VILLARREAL, Department of Behavioral Pharmacology, Instituto Miles de Terepeutica Experimental, Division de Laboratorios Miles de Mexico, S.A. de C.V., Apartado Postal 22026, Mexico 22, D.F.

Z. VOTAVA, Department of Pharmacology, Research Institute of Pharmacy and Biochemistry, Praha 3, Kouřimská 17, Czechoslovakia

W. WUTTKE, Institut für Pharmakologie, Farbenfabriken Bayer AG, 56 Wuppertal-Elberfeld, Friederich-Ebert-Straße 217, Germany

T. YANAGITA, Central Institute for Experimental Animals, 1433 Nogawa, Kawasaki 211, Japan

Editorial Advisory Board

B. AGRANOFF (*Ann Arbor*)
B. BEER (*Pearl River*)
M. H. APRISON (*Indianapolis*)
E. F. DOMINO (*Ann Arbor*)
D. X. FREEDMAN (*Chicago*)
E. GLASSMAN (*Chapel Hill*)
H. KALANT (*Toronto*)
A. J. MANDELL (*San Diego*)
J. MENDELSON (*Boston*)
J. ROSECRANS (*Richmond*)
P. A. SHORE (*Dallas*)
S. H. SNYDER (*Baltimore*)
E. USDIN (*Rockville*)
R. J. WURTMAN (*Cambridge*)

PHARMACOLOGY BIOCHEMISTRY & BEHAVIOR
ISSN 0091-3057

Subscription, postpaid $250 per year for Libraries, Research Establishments and all other multiple user Institutions. Private individuals whose departmental libraries subscribe may obtain this Journal for their personal use at a reduced rate of $30 per year.

Publishing and Advertising Offices:
ANKHO International Inc.
7374 Highbridge Terrace, P.O. Box 426, Fayetteville, New York 13066 U.S.A.

Back issues are available. Write for Back Issue Price List.

Published monthly. Copyright © 1980 ANKHO International Inc.

Second class postage paid at Fayetteville, NY 13066

Postmaster: If undeliverable send POD Form 3579 to P.O. Box 426, Fayetteville NY 13066

Printed at SALINA PRESS, Syracuse, New York, U.S.A.

PHARMACOLOGY BIOCHEMISTRY & BEHAVIOR

VOLUME 13 NUMBER 1 JULY 1980

CONTENTS

Facilitatory effect of ketamine on punished behavior. BRANDÃO, M. L., J. C. S. FONTES and F. G. GRAEFF 1

Strain differences in dopamine receptor function and the initiation of movement. WOLF, M. D., R. E. WILCOX, W. H. RIFFEE and L. D. ABRAHAM 5

Kynurenines and audiogenic excitement in mice. LAPIN, I. P. 9

Effect of kynurenine and quinolinic acid on the action of convulsants in mice. LAPIN, I. P. 17

Choline uptake and permanent memory storage. RAUCA, CH., E. KAMMERER and H. MATTHIES 21

Effects of diazepam on extinction induced aggression in pigs. ARNONE, M. and R. DANTZER . 27

Learned taste aversion to saccharin produced by orally consumed d-amphetamine. SANGER, D. J., A. J. GREENSHAW, I. P. THOMPSON and J. D. MERCER 31

MSH and MIF-I in animal models of tardive dyskinesia. DAVIS, K. L., A. J. KASTIN, B. A. BEILSTEIN and A. L. VENTO 37

Studies of zinc and histamine on lysosomal fragility: Possible role in stress ulceration. CHO, C. H., C. J. PFEIFFER and A. CHEEMA 41

Ontogenesis of morphine-induced behavior in the rat. CAZA, P. A. and L. P. SPEAR 45

Elimination of REM sleep rebound in rats by α-adrenoreceptor blockers, phentolamine and phenoxybenzamine. RADULOVACKI, M., W. J. WOJCIK, C. FORNAL and R. MILETICH .. 51

Inhibition of sexual behavior by dopamine antagonist or serotonin agonist drugs in castrated male rats given estradiol or dihydrotestosterone. BAUM, M. J. and M. S. STARR 55

Comparative behavioral profile of cocaine and norcocaine in rats and monkeys. BEFORD, J. A., R. F. BORNE and M. C. WILSON 69

Total avoidance of saccharin consumption by rats after repeatedly paired injections of ethanol or LiCl. KULKOSKY, P. J., J. L. SICKEL and A. L. RILEY 77

Cholinergic brain mechanisms and the hormonal regulation of female sexual behavior in the rat. CLEMENS, L. G., R. R. HUMPHRYS and G. P. DOHANICH 81

Inhibition of lordotic behavior in female rats following intracerebral infusion of anticholinergic agents. CLEMENS, L. G. and G. P. DOHANICH 89

Facilitation of the suppressing effect of dopamine upon a motor conditioned response by 6-hydroxydopamine applied into the caudate nucleus in cats. REYES-VÁZQUEZ, C. and H. BRUST-CARMONA 97

The role of the nucleus accumbens and nigrostriatum in enkephalin-induced myoclonus. DZOLJIC, M. R. and A. L. V.D. POEL-HEISTERKAMP 103

Abnormal sympatho-adrenal function and plasma catecholamines in obese Zucker rats. LEVIN, B. E., J. TRISCARI and A. C. SULLIVAN 107

Narcotic abstinence in dependent rats: EEG and behavioral correlates. YOUNG, G. A., G. F. STEINFELS and N. KHAZAN 115

BRIEF COMMUNICATIONS

The spacing of rhesus monkey troops changes when a few group members receive Δ9THC or D-amphetamine. BURGESS, J. W., P. N. WITT, E. PHOEBUS and C. WEISBARD 121

Rotational syndrome after central injection of C-terminal 7-peptide of cholecystokinin. MANN, J. F. E., R. BOUCHER and P. W. SCHILLER 125

Factors influencing plasma catecholamine levels in rats during immobilization. DETURCK, K. H. and W. H. VOGEL 129

Conditioned taste aversion as an index of lead toxicity. DANTZER, R. 133

TRH on rat conditioned avoidance behavior: Interaction with brain catecholamines. MORA, S., A. G. NASELLO and L. FIESCHI 137

ANNOUNCEMENTS 141

PHARMACOLOGY BIOCHEMISTRY & BEHAVIOR

VOLUME 13 NUMBER 2 AUGUST 1980

CONTENTS

Effects of chronic administration of antidepressant drugs on aggressive behavior induced by clonidine in mice. MAJ, J., E. MOGILNICKA and A. KORDECKA-MAGIERA 153

The effects of l-, d-, and parahydroxy-amphetamine on locomotor activity and wall climbing in rats of different ages. BAUER, R. H. 155

Preliminary report of a simple animal behavior model for the anxiolytic effects of benzodiazepines. CRAWLEY, J. and F. K. GOODWIN 167

Reversal of stress-induced analgesia by apomorphine, but not by amphetamine. BODNAR, R. J., D. D. KELLY, M. BRUTUS, C. B. GREENMAN and M. GLUSMAN 171

Effects of d-amphetamine and diazepam on paired and grouped primate food competition. LOVELL, D. K., J. A. BEDFORD, L. GROVE and M. C. WILSON 177

Task-dependent development of tolerance to scopolamine. ROSIC, N., D. BOKONJIC and D. H. OVERSTREET 183

Muscarinic receptor binding and behavioral effects of atropine following chronic catecholamine depletion or acetylcholinesterase inhibition in rats. SCHALLERT, T., D. H. OVERSTREET and H. I. YAMAMURA 187

Effect of cycloheximide and *d*-amphetamine on brain catecholamines in two mouse strains. CARR, L. A. and S. M. WEHRY 193

Levels of processing and acute effects of marijuana on memory. BELMORE, S. M. and L. L. MILLER 199

Lithium distribution ratios in psychiatrically normal subjects. LIEBERMAN, K. W. and P. STOKES 205

Effects of changing dosage and urinary pH in rats self-administering nicotine on a food delivery schedule. LATIFF, A. A., L. A. SMITH and W. J. LANG 209

Changes occurring in self administration of nicotine by rats over a 28-day period. SMITH, L. A. and W. J. LANG 215

Sociopharmacology of d-amphetamine in *Macaca arctoides*. BELLAROSA, A., J. A. BEDFORD and M. C. WILSON 221

Dipsogenic effect of angiotensin II, bombesin and tachykinins in the duck. DE CARO, G., M. MARIOTTI, M. MASSI and L. G. MICOSSI 229

Metabolism of ^{3}H-dopamine continuously perfused through push-pull cannulas in rats' brains: Modification by amphetamine or prostaglandin $F_{2\alpha}$. NIELSEN, J. A., L. H. FOSSOM and S. B. SPARBER 235

The use of human observers in psychopharmacological research. POLING, A., J. CLEARY and M. MONAGHAN 243

Evidence that respiratory depression by serotonin agonists may be exerted in the central nervous system. MUELLER R. A., D. LUNDBERG and G. R. BREESE 247

Brain noradrenergic responses to training and to amnestic frontal cortex stimulation. GOLD, P. E. and J. M. MURPHY 257

A critical evaluation of tetrahydroisoquinoline induced ethanol preference in rats. DUNCAN, C. and R. A. DEITRICH 265

Para-halogenated phenethylamines: Similar serotonergic effects in rats by different mechanisms. SLOVITER, R. S., J. D. CONNOR, B. P. DAMIANO and E. G. DRUST 283

BRIEF COMMUNICATIONS

An automated device for screening the effects of psychotropic drugs on aggression and motor activity in mice. PUGLISI-ALLEGRA, S. and P. RENZI 287

Schedule-induced ethanol polydipsia: Function of ethanol concentration. ROEHRS, T. A. and H. H. SAMSON 291

Correlation between human erythrocyte aldehyde dehydrogenase activity and sensitivity to alcohol. INOUE, K., M. FUKUNAGA and K. YAMASAWA 295

Protection from shock-induced seizures as a measure of hypnotic potency of drugs. HALPERIN, J. M. and L. C. IORIO 299

The influence of dopamine on the incorporation of different sugars into total proteins of hippocampal slices. JORK, R., B. LÖSSNER and H. MATTHIES 303

Effect of S-adenosylhomocystein on color avoidance behavior. SATAKE, N. 305

Caffeine potentiation of apomorphine discrimination. SCHECHTER, M. D. 307

NEWSLETTER & ABSTRACTS, **Society for Stimulus Properties of Drugs** 311

ANNOUNCEMENTS 315

PHARMACOLOGY BIOCHEMISTRY & BEHAVIOR

VOLUME 13 NUMBER 3 SEPTEMBER 1980

CONTENTS

Effects of iron-loading and ethanol treatment on rat porphyrin metabolism. KÓSZÓ, F., CS. SIKLÓSI and N. SIMON 325

Apomorphine: Effects on the timing and sequencing of pecking behavior in chicks. MACHLIS, L. E. 331

Dissimilar effects of nicotinamide and inosine, putative endogenous ligands of the benzodiazepine receptors, on pentylenetetrazol seizures in four strains of mice. LAPIN, I. P. 337

Pro- and anticonvulsant action of morphine in rats. URCA, G. and H. FRENK 343

Joint effects of *d*-amphetamine and ethanol or pentobarbital in pigeons. HEALEY, M. L. and L. A. DYKSTRA 349

Evidence of a direct action of angiotensin II on neurones in the septum and in the medial preoptic area. SIMONNET, G., B. BIOULAC, F. RODRIGUEZ and J. D. VINCENT 359

5HT blockade and the stimulant effects of d- and l-amphetamine: No interaction in self-stimulation of prefrontal cortex, hypothalamus, or dorsal tegmentum. Unexpected lethality in hippocampal sites. FRANKLIN, K. B. J. and A. ROBERTSON 365

Effects of apomorphine on escape performance and activity in developing rat pups treated with 6-hydroxydopamine (6-OHDA). LIPTON, S. V., J. P. McGOUGH and B. A. SHAYWITZ . 371

Post-amphetamine depression of self-stimulation responding from the substantia nigra: Reversal by tricyclic antidepressants. KOKKINIDIS, L., R. M. ZACHARKO and P. A. PREDY . 379

***n*-Pentylamine: Effect on motor activity of mice.** WIDY-TYSZKIEWICZ, E. and T. L. SOURKES . 385

Effects of 6-hydroxydopamine and amphetamine on rat mothering behavior and offspring development. PICCIRILLO, M., J. E. ALPERT, D. J. COHEN and B. A. SHAYWITZ 391

Effects of thioridazine on apomorphine-elicited stereotypic behavior and motor activity. LAI, H., M. A. CARINO, R. SPERRY and A. HORITA 397

The anorexic and actometric effects of cocaine and two coca extracts. BEDFORD, J. A., D. K. LOVELL, C. E. TURNER, M. A. ELSOHLY and M. C. WILSON 403

The effects of dopaminergic agents on the locomotor activity of rats after high doses of methylamphetamine. LUCOT, J. B., G. C. WAGNER, C. R. SCHUSTER and L. S. SEIDEN 409

Central excitatory actions of flurazepam. ROSENBERG, H. C. 415

The effect of morphine on purine and acetylcholine release from rat cerebral cortex: Evidence for a purinergic component in morphine's action. PHILLIS, J. W., Z. G. JIANG, B. J. CHELACK and P. H. WU 421

Retinotoxic effects of diaminodiphenoxybutane in rats. NOGUCHI, Y., S. SATO, T. ANDO and S. CHIBA 429

Effects of morphine, β-endorphin and naloxone on catecholamine levels and sexual behavior in the male rat. McINTOSH, T. K., M. L. VALLANO and R. J. BARFIELD 435

Strain dependent effects of ketamine on locomotor activity and antinociception in mice. FILIBECK, U. and C. CASTELLANO 443

Blood ethanol and free-choice ethanol intake in rats and their progeny. KULKOSKY, P. J. 449

BRIEF COMMUNICATIONS

A rapid method for the regional dissection of the rat brain. HEFFNER, T. G., J. A. HARTMAN and L. S. SEIDEN 453

Reversal of schedule-induced self-injection of heroin by naloxone. OEI, T. P. S. 457

Reduced forebrain norepinephrine in rhesus monkeys made obese by hypothalamic lesions. KEMNITZ, J. W., G. W. KRAEMER and G. R. BREESE 461

Differential effects of methylphenidate on signalled and non-signalled reinforcement. EMMETT-OGLESBY, M. W., K. E. TAYLOR and R. E. DAFTER 467

Use of the catheterized rat in studies on social interactions and plasma catecholamines. PASHKO, S., K. H. DeTURCK and W. H. VOGEL 471

Possible mechanism for the enhanced lethality of morphine in aggregated mice. MOHRLAND, J. S. and A. L. CRAIGMILL 475

Post-swim grooming in mice inhibited by dopamine receptor antagonists and by cannabinoids. CHESHER, G. B. and D. M. JACKSON 479

ANNOUNCEMENTS 483

PHARMACOLOGY BIOCHEMISTRY & BEHAVIOR

VOLUME 13 NUMBER 4 OCTOBER 1980

CONTENTS

Different dopaminergic mechanisms for amfonelic acid, amphetamine and apomorphine. SCHECHTER, M. D. 497

Rewarding and aversive effects of morphine: Temporal and pharmacological properties. SHERMAN, J. E., C. PICKMAN, A. RICE, J. C. LIEBESKIND and E. W. HOLMAN 501

Using profiles of saccharin and water drinking to detect and discriminate actions of drugs and toxicants. YAMAMOTO, B. K. and C. L. KUTSCHER 507

Evidence that a preferred substrate for type B monoamine oxidase mediates stimulus properties of MAO inhibitors: A possible role for β-phenylethylamine in the cocaine cue. COLPAERT, F. C., C. J. E. NIEMEGEERS and P. A. J. JANSSEN 513

Cholinergic mechanisms in scent marking behavior by Mongolian gerbils *(Meriones unguiculatus)*. YOSHIMURA, H. 519

On the neurochemical basis of self-stimulation with midbrain raphe electrode placements. DEAKIN, J. F. W. 525

***In utero* alcohol heightens juvenile reactivity.** ANANDAM, N., W. FELEGI and J. M. STERN . 531

Changes in distribution of mercury and selenium in soluble fractions of rabbit tissues after simultaneous administration. NAGANUMA, A. and N. IMURA 537

Tolerance to suppressive effects of chlordiazepoxide on operant behavior: Lack of cross tolerance to pentobarbital. CESARE, D. A. and J. W. McKEARNEY 545

LSD-25 as a discriminative stimulus for response selection by pigeons. JÄRBE, T. U. C. 549

Reward system depression following chronic amphetamine: Antagonism by haloperidol. BARRETT, R. J. and D. K. WHITE 555

Rotation induced by intranigral injections of GABA agonists and antagonists: Zone-specific effects. KOZLOWSKI, M. R. and J. F. MARSHALL 561

The effect of serotonin depletion on the discriminability of LSD. WHITE, F. J., M. A. SIMMONS, K. B. WEST, A. M. HOLOHEAN and J. B. APPEL 569

Pre- and postsynaptic serotonergic manipulations in an animal model of depression. NAGAYAMA, H., J. N. HINGTGEN and M. H. APRISON 575

BRIEF COMMUNICATIONS

Intracranial injection parameters which affect angiotensin II-induced drinking. SELLECK, S. B. and J. B. SIMPSON 581

Stereospecific, dose-dependent antagonism by naloxone of non-opiate behavior in mice. JACQUET, Y. F. 585

Differences in activity in cerebral methyltransferases and monoamine oxidases between audiogenic seizure susceptible and resistant mice and deermice. DOYLE, R. L. and O. Z. SELLINGER ... 589

A drug dispenser to measure individual drinking in rat colonies. COAMBS, R. B., B. K. ALEXANDER, C. M. DAVIS, P. F. HADAWAY and W. R. TRESSEL ... 593

Temporal properties of the rewarding and aversive effects of amphetamine in rats. SHERMAN, J. E., T. ROBERTS, S. E. ROSKAM and E. W. HOLMAN 597

Naloxone potentiates the disruptive effects of mescaline on operant responding in the rat. COMMISSARIS, R. L., K. E. MOORE and R. H. RECH 601

Enhancement of the behavioral effects of 2,5-dimethoxy-4-methyl-amphetamine (DOM) by pretreatment with *p*-chlorophenylalanine. COMMISSARIS, R. L., W. H. LYNESS, K. E. MOORE and R. H. RECH 605

ANNOUNCEMENTS 609

PHARMACOLOGY BIOCHEMISTRY & BEHAVIOR

VOLUME 13 NUMBER 5 NOVEMBER 1980

CONTENTS

The effects of *d*-lysergic acid diethylamide (LSD), 2,5-dimethoxy-4-methylamphetamine (DOM) and *d*-amphetamine on operant responding in control and 6-hydroxydopamine-treated rats. COMMISSARIS, R. L., W. H. LYNESS, J. J. CORDON, K. E. MOORE and R. H. RECH 621

Pemoline-induced self-biting in rats and self-mutilation in the deLange syndrome. MUELLER, K. and S. HSIAO 627

Inhibition of neuroleptic-induced dopamine receptor supersensitivity by cyclo(Leu-Gly). BHARGAVA, H. N. and R. F. RITZMANN 633

Light-dark and feeding regimens affect circadian phasing of blood-ethanol decay rates. STURTEVANT, R. P. and S. L. GARBER 637

Serotonin-mimetic and antidepressant drugs on passive avoidance learning by olfactory bulbectomised rats. BROEKKAMP, C. L., D. GARRIGOU and K. G. LLOYD 643

Cumulative dose-response curves in behavioral pharmacology. WENGER, G. R. 647

Titration procedure with rats using a nose poke response and tail shock. BURNE, T. A. and H. A. TILSON 653

Effects of psychotropic drugs on FI responding and adjunctive drinking in rats. KURIBARA, H. and S. TADOKORO 657

Behavioural and endocrine effects of naltrexone in male talapoin monkeys. MELLER, R. E., E. B. KEVERNE and J. HERBERT 663

Opioid blockade and social comfort in chicks. PANKSEPP, J., N. J. BEAN, P. BISHOP, T. VILBERG and T. L. SAHLEY 673

Chronic administration of haloperidol during development: Later psychopharmacological responses to apomorpine and arecoline. SHALABY, I. A. and L. P. SPEAR 685

Differential effects of imipramine in rats as a function of DRL schedule value. McGUIRE, P. S. and L. S. SEIDEN 691

Differential effects of cocaine on limbic excitability. LESSE, H. and J. P. COLLINS 695

Effects of raphe magnus and raphe pallidus lesions on morphine-induced analgesia and spinal cord monoamines. PROUDFIT, H. K. 705

An inhibitor of opioid peptide degradation produces analgesia in mice. SIMMONS, W. H. and R. F. RITZMANN 715

Caffeine as an intensifier of stress-induced hormonal and pathophysiologic changes in mice. HENRY, J. P. and P. M. STEPHENS 719

BRIEF COMMUNICATIONS

Reduction of heroin intake in baboons by an economic constraint. ELSMORE, T. F., G. V. FLETCHER, D. G. CONRAD and F. J. SODETZ 729

Lack of influence of brain catecholamines on acute effects of barbiturates. BOURN, W. M. and C. E. REIGEL 733

Olfactory influences on the human menstrual cycle. RUSSELL, M. J., G. M. SWITZ and K. THOMPSON 737

Naloxone and shuttlebox self-stimulation in the rat. STILWELL, D. J., R. A. LEVITT, C. A. HORN, M. D. IRVIN, K. GROSS, D. S. PARSONS, R. H. SCOTT and E. L. BRADLEY 739

Postural asymmetry and directionality of rotation in rats. MYSLOBODSKY, M. S. and H. BRAUN 743

ANNOUNCEMENTS 747

PHARMACOLOGY BIOCHEMISTRY & BEHAVIOR

VOLUME 13 NUMBER 6 DECEMBER 1980

CONTENTS

Modulation of conditioned taste aversion by sodium pentobarbital. CONCANNON, J. T. and J. FREDA 761

Effect of L-fucose on brain protein metabolism and retention of a learned behavior in rats. WETZEL, W., N. POPOV, B. LÖSSNER, S. SCHULZECK, R. HONZA and H. MATTHIES 765

Ethanol-induced analgesia in rats selectively bred for ethanol sensitivity. FRIEDMAN, H. J., M. B. BASS and D. LESTER 773

The excitatory component of ethanol in mice: A chronic study. MASUR, J. and R. BOERNGEN 777

Subcutaneous silastic implants: Maintenance of high blood ethanol levels in rats drinking a liquid diet. ERICKSON, C. K., K. I. KOCH and J. W. McGINITY 781

Effect of prostaglandin E_1 and its biosynthesis inhibitor indomethacin on drinking in the rat. PÉREZ GUAITA, M. F. and E. CHIARAVIGLIO 787

Apparent tolerance to some aspects of amphetamine steroetypy with long-term treatment. REBEC, G. V. and D. S. SEGAL 793

Effects of Pavlovian conditioning and MIF-I on the development of morphine tolerance in rats. LAHOSTE, G. J., R. D. OLSON, G. A. OLSON and A. J. KASTIN 799

Comparisons of the effects of guanethidine, 6-hydroxydopamine and diethyldithiocarbamate on retention of passive avoidance. PALFAI, T. and T. J. WALSH 805

Acute effects of ethanol *in vivo* on neuromuscular transmission. REED, T. E. 811

Circling produced by serotonin and dopamine agonists in raphe lesioned rats: A serotonin model. SLATER, P. 817

Corticotropin-induced changes in protein labelling: Lack of molecular specificity. DUNN, A. J. and N. B. GILDERSLEEVE 823

Antagonism of stress-induced analgesia by D-phenylalanine, an anti-enkephalinase. BODNAR, R. J., M. LATTNER and M. M. WALLACE 829

Effects of phencyclidine and methylphenidate on *d*-amphetamine-induced behaviors in reserpine pre-treated rats. FESSLER, R. G., R. D. STURGEON and H. Y. MELTZER 835

Effects of branched-chain fatty acids on GABA-degradation and behavior: Further evidence for a role of GABA in quasi-morphine abstinence behavior. VAN DER LAAN, J. W., A. W. C. M. JACOBS and J. BRUINVELS 843

Hexamethonium modification of cardiovascular adjustments during combined static-dynamic arm exercise in monkeys. GAIDE, M. S., K. J. KLOSE, W. J. GAVIN, N. SCHNEIDERMAN, T. W. ROBERTSON, M. SILBRET and M. V. FALETTI 851

Effects of pimozide on accuracy of performance and distribution of correct responding on a simultaneous discrimination task in the rat. TOMBAUGH, T. N., M. A. RITCH and D. T. SHEPHERD 859

Effects of neonatal 6-hydroxydopa on behavior in female rats. McLEAN, J. H., R. S. GLASSER, R. M. KOSTRZEWA and J. G. MAY 863

Structure-activity relationships among some *d*-N-alkylated amphetamines. WOOLVERTON, W. L., G. SHYBUT and C. E. JOHANSON 869

Effects of body weight levels on cannabis self-injection. TAKAHASHI, R. N. and G. SINGER 877

Neonatal administration of Met-enkephalin facilitates maze performance of adult rats. KASTIN, A. J., R. M. KOSTRZEWA, A. V. SCHALLY and D. H. COY 883

Effects of phencyclidine, pentobarbital, and *d*-amphetamine on the acquisition and performance of conditional discriminations in monkeys. MOERSCHBAECHER, J. M. and D. M. THOMPSON 887

Thermoregulatory and locomotor effects of DSIP: Paradoxical interaction with d-amphetamine. YEHUDA, S., A. J. KASTIN and D. H. COY 895

Radioimmunoassay of MIF-1/Tyr-MIF-1-like material in rat pineal. KASTIN, A. J., S. P. LAWRENCE and D. H. COY 901

Naloxone-like actions of MIF-1 do not require the presence of the pituitary. KASTIN, A. J., C. NISSEN, J. E. ZADINA, A. V. SCHALLY and R. H. EHRENSING 907

Dissociation of effects of LH-RH analogs on pituitary regulation and reproductive behavior. KASTIN, A. J., D. H. COY, A. V. SCHALLY and J. E. ZADINA 913

Effects of nomifensine and desipramine on the sequelae of intracerebrally-injected 6-OHDA and 5,6-DHT WADDINGTON, J. L. 915

Facilitation of self-stimulation in rats by methadone. STUTZ, R. M., A. N. MAROLI, W. K. TSANG and P. A. HARVAN 919

ERRATUM 925

ANNOUNCEMENTS 926

AIMS AND SCOPE

Pharmacology Biochemistry & Behavior will publish original reports of systematic studies in the areas of pharmacology, biochemistry, toxicology and behavior in which the primary emphasis and theoretical context are behavioral; and brief communications which describe a new method, technique or apparatus and results of experiments which can be reported briefly with limited figures and tables. Behavioral studies as such will not be published unless they are obviously pertinent and make a significant contribution to pharmacology, biochemistry or toxicology. A limited number of relevant reviews and theoretical articles, results of symposia, and more comprehensive studies as monograph supplements will also be published. Articles will be published in English.

The accepted abbreviation for *Pharmacology Biochemistry & Behavior* for bibliographic citation is *Pharmac. Biochem. Behav.*

INSTRUCTIONS TO AUTHORS

Manuscripts should be sent directly to the Editor-in-Chief or to the most proximal Regional Editor for review and will be published within three months or less after formal acceptance.

STYLE OF MANUSCRIPT

General Form. (1) Manuscripts should be submitted in duplicate and should be typewritten, double spaced with wide margins on good quality paper. (2) The title page should contain: title of paper; author(s); laboratory or institution of origin with city, state, zip code, and country; complete address for mailing proofs; a running head not to exceed 50 characters including spaces between words. (3) References, footnotes, and legends for illustrations should be typed on separate sheets, double spaced. (4) Illustrations (unmounted photographs) should be identified on the reverse with figure number and author(s) name; when necessary the top should be clearly marked. (5) Each table should be typed on a separate sheet and double spaced. (6) All dimensions and measurements must be specified in the metric system. Standard nomenclature, abbreviations and symbols, as specified by Royal Society Conference of Editors. Metrication in Scientific Journals, *Am. Scient.* **56**: 159–164, 1968, should be used throughout. (7) Italics should not be used for the purpose of emphasis.

Title. The title should not be longer than 85 characters, including spaces between words.

Papers in a series such as: "Studies on . . . I." will not be accepted.

Length of Paper. The Editors insist upon clear, concise statement of facts and conclusions. Fragmentation of material into numerous short reports is discouraged.

Abstract. Each paper submitted must be accompanied by an abstract, which does not exceed 170 words and must be suitable for use by abstracting journals. Abstracts should be prepared as follows:

> EVANS, B. K., S. ARMSTRONG, G. SINGER, R. D. COOK AND G. BURNSTOCK. *Intracranial injection of drugs: comparison of diffusion of* . . . PHARMAC. BIOCHEM. BEHAV. Marked differences in extent of diffusion have been . . .

A list of from 3–12 (or more) words or short phrases suitable for indexing terms should be typed at the bottom of the abstract page accompanying the manuscript. These terms will be printed with the paper at the end of the abstract.

Drugs. Proprietary (trademarked) names should be capitalized. The chemical name should precede the trade, popular name, or abbreviation of a drug the first time it occurs.

Footnotes. Title page footnotes should be numbered consecutively. Text footnotes should not be used, the material should be incorporated into the text. Table footnotes: see *Tables* (b).

References. Literature cited should be numbered in brackets in text (only one reference to a number) and listed in alphabetical order on a separate sheet at the end of the manuscript. *Do not recite names of authors within the text.* Journal citations in the reference list should contain the following: (a) surnames and initials of all authors (surname of first author precedes initials; initials precede surnames of all co-authors); (b) title of article; (c) journal title abbreviated as listed in the 4th edition of the *World List of Scientific Periodicals;* (d) volume, inclusive pages, and year. Example:

1. Abrams, R. and H. T. Hammel. Hypothalamic temperature in unanesthetized albino rats during feeding and sleeping. *Am. J. Physiol.* **206**: 641–646, 1964.

Book references should be in the following order: author, title, city of publication, publisher, year, and pages. Example:

1. Thompson, T. and C. R. Schuster. *Behavioral Pharmacology.* Englewood, New Jersey: Prentice-Hall, Inc., 1968, p. 297.

Citations such as "Unpublished observations," "Personal communication," "Manuscript in preparation," "To be published," should not be entered in the list of References, but may be noted in the text without serial numbers, in parentheses.

Illustrations. (a) Prepare for use in a single column width whenever possible. (b) All drawings for reduction to a given size should be drawn and lettered to the same scale. (c) All illustrations should be referred to as figures and numbered in Arabic numerals. (d) Lettering should be done in India ink or other suitable material and must be proportionate to the size of the illustrations if it is to be legible after reduction. Lettering should be sized so that its smallest elements (subscripts or superscripts) will be readable when reduced. (e) When possible all lettering should be within the framework of the illustration; likewise the key to symbols should be on the face of the chart. The following standard symbols should be used as they are easily available to the printer. ○ ● △ ▲ □ ■ + (f) Actual magnification of all photomicrographs should be given. Dimension scale should be indicated. (g) Sharply contrasting unmounted photographs of figures on glossy paper are required.

Tables. (a) Each table should have a brief heading; explanatory matter should be in footnotes, not as part of the title. (b) Table footnotes should be indicated in the body of the table in order of their appearance with the following symbols: * † ‡ § ¶ # **, etc. (c) Tables must not duplicate material in text or illustrations. (d) Vertical rules should be omitted. (e) Short or abbreviated column heads should be used. (f) Statistical measures of variation, SD, SE, etc., should be identified. (g) Analysis of Variance Tables should not be submitted but significant F's should be incorporated where appropriate within the text. The appropriate form for reporting F values is: $F(11,20) = 3.05$, $p < 0.01$.

Formulas and Equations. Structural chemical formulas, process flow-diagrams, and complicated mathematical expressions should be kept to a minimum. Usually chemical formulas and flow-diagrams should be drawn in India ink for reproduction as line cuts.

All subscripts, superscripts, Greek letters, and unusual characters must be clearly identified.

Anesthesia. In describing surgical procedures on animals, the type and dosage of the anesthetic agent should be specified. Curarizing agents are not anesthetics; if these were used, evidence must be provided that anesthesia of suitable grade and duration was employed.

Proofs. Corrections to the proofs must be restricted to printer's errors only. Other than these, any other alterations will be charged to the author.

Reprints. Each author will receive with his galley proofs a reprint order form which must be completed and returned with the proofs. Late orders cannot be filled since reprints are run at the time the Journal is printed. Senior author receives 25 reprints free.

Pharmacology Biochemistry & Behavior, Vol. 13. Copyright © by ANKHO International Inc. Printed in the U.S.A.

PHARMACOLOGY BIOCHEMISTRY & BEHAVIOR

VOLUME 13 1980

SUBJECT INDEX

Abstinence
  DNLAAM, 115
  head shakes, 115
  LAAM, 115
  lever pressing, 115
  methadone, 115
  morphine, 115
  NLAAM, 115
  REM sleep, 115
  self-administration, 115
Acetaldehyde
  aversion to alcohol, s269, s291
  blood levels after ethanol ingestion, s101
  blood levels and ethanol elimination, s119
  disulfiram implantation, s73
  genetic markers of alcoholism, s9
  liver injury and protein metabolism, s17
  protein secretion, s31
  protein synthesis, s31
Acetylcholine
  adenosine, 421
  atropine sulfate, 89
  bethanechol, 81
  brightness discrimination, 21
  caffeine, 421
  carbachol, 81
  cerebral cortex, 421
  choline, 21
  hemicholinium-3, 89
  hippocampus, 21
  incorporation, 21
  intracerebral infusion, 89
  long-term memory, 21
  medial preoptic area, 81
  mesencephalic reticular formation, 81
  morphine, 421
  muscarinic receptors, 81
  naloxone, 421
  neocortex, 81
  sexual behavior, 81, 89
  theophylline, 421
  uptake, 21
Acetylcholinesterase
  choline acetyltransferase, 519
  Mongolian gerbil, 519
  scent marking behavior, 519
  scopolamine, 519
Acoustic startle reflex
  activity, 531
  ethanol, 531
  fetal alcohol syndrome, 531
  prenatal, 531
Acquisition
  active avoidance, 183
  scopolamine, 183
  spontaneous locomotor activity, 183
  task dependent, 183
  tolerance development, 183
ACTH
  brain protein synthesis, 823
  brain specific protein, 823
  NSP, 823
  S-100, 823
Active avoidance
  acquisition, 183
  scopolamine, 183
  spontaneous locomotor activity, 183
  task dependent, 183
  tolerance development, 183
Activity
  acoustic startle reflex, 531
  antinociception, 443
  apomorphine, 371
  coca, 403
  cocaine, 403
  development, 371
  eating, 403
  equilibrium, 863
  escape performance, 371
  ethanol, 531
  female rat, 863
  fetal alcohol syndrome, 531
  habituation, 863
  6-hydroxydopa, 863
  6-hydroxydopamine, 371
  inbred mice, 443
  ketamine, 443
  neonatal, 863
  norepinephrine, 863
  prenatal, 531
  sexual behavior, 863
Acute alcohol intoxication
  glutathione levels, s53
Acute response
  animal model, 811
  ataxia, 811
  ethanol, 811
  neuromuscular junction, 811
  residual latency, 811
  synaptic delay, 811
Acute tolerance
  analgesia, 773
  ethanol, 773
  pharmacogenetics, 773
  shock response, 773
  startle response, 773
Adenosine
  acetylcholine, 421
  caffeine, 421
  cerebral cortex, 421
  morphine, 421
  naloxone, 421
  theophylline, 421
S-Adenosylhomocystein
  color avoidance conditioning, 305

Adjunctive behavior
amphetamine, 657
chlorpromazine, 657
diazepam, 657
drinking, 657
fixed interval, 657
heroin, 457
interpellet distributions, 657
naloxone, 457
schedule, 457
self-administration, 457
Adoption studies
hereditary aspects of alcoholism, s9
ADP translocation
ethanol and liver mitochondria, s63
Affective disorders
erythrocytes, 205
lithium, 205
manic-depressives, 205
potassium, 250
sodium, 205
Afterdischarge thresholds
amygdala, 695
cocaine, 695
focal brain stimulation, 695
hippocampus, 695
kindling, 695
limbic system, 695
sensitization, 695
septum, 695
temporal lobe epilepsy, 695
Age
chronic indwelling catheter, 129
epinephrine, 129
estrous cycle, 129
immobilization stress, 129
norepinephrine, 129
Aggregation
convulsions, 475
lethality, 475
morphine, 475
stress, 475
Aggression
amphetamine, 221
anorexia, 221
behavioral toxicity, 221
clonidine, 153
competition, 221
corticosteroids, 27
diazepam, 27
dominance hierarchy, 221
extinction, 27
frustration, 27
imipramine, 153
iprindole, 153
mianserin, 153
mice, 287
motor activity, 287
pig, 27
n-D-propylacetate, 287
psychotropic drugs, 287
response persistence, 27
sexual behavior, 221
social behavior, 221
Aging
amphetamine, 155
catecholamines, 155
development, 155
motor activity, 155
Alanine aminotransferase
regenerating liver and ethanol, 83
Alcohol consumption
decrease during pregnancy and lactation, s149
Alcohol preference
decrease during pregnancy and lactation, s149
Alcohol tolerance
change in EEG, s233
Alcoholism detection
biological markers, s1
Aldehyde dehydrogenase
blood acetaldehyde, 295
ethanol sensitivity, 295
human erythrocytes, 295
peroxisomes in normal liver, s111
Amfonelic acid
amphetamine, 497
apomorphine, 497
dopamine, 497
drug-induced stimuli, 497
n-propylnoraporphine, 497
Amitriptyline
animal model of depression, 575
chronic amphetamine treatment, 379
fluoxetine, 575
5-hydroxytryptophan, 575
imipramine, 379
methysergide, 575
receptors, 575
response depression, 379
self-stimulation, 379
serotonin, 575
substantia nigra, 379
Amnesia
antiadrenergic, 805
avoidance training, 257
biogenic amines, 805
diethyldithiocarbamate, 805
electroshock, 257
guanethidine, 805
memory, 805
memory storage processes, 257
norepinephrine, 257
stress, 257
Amphetamine
adjunctive behavior, 657
aggression, 221
aging, 155
amfonelic acid, 497
analgesia, 171
animal models, 555
anorexia, 221
apomorphine, 171, 497, 793, 817
ataxia, 835
behavioral toxicity, 221
brain perfusion, 235
catecholamines, 155, 471, 621
chlorpromazine, 657
chronic indwelling catheter, 471
cold-water swims, 171
competition, 177, 221
conditional discrimination, 887
conditioned flavor aversion, 597
conditioned location preference, 597
conditioned taste aversion, 31
cumulative dose-response, 647
cycloheximide, 193
2-deoxy-D-glucose, 171
development, 155
developmental disturbances, 391
diazepam, 177, 657
DOM, 621
dominance hierarchy, 177, 221
dopamine, 193, 235, 391, 497

Amphetamine (continued)
drinking, 657
drug-induced depression, 555
drug-induced stimuli, 497
drug interaction, 349
DSIP, 895
fenfluramine, 817
fixed interval, 657
fixed ratio, 647
food-getting, 177
guinea pig atrium, 869
hallucinogens, 621
haloperidol, 555
6-hydroxydopamine, 391, 621
interpellet distributions, 657
ketamine, 1, 647
kinesics, 121
lateral hypothalamus, 555
lesions, 817
lever pressing, 887
locomotion, 895
locomotor activity, 835
LSD, 621
maternal behavior, 391
memory, 193
5-methoxy-N,N-dimethyltryptamine, 817
methylphenidate, 835
monkey, 177, 887
morphine, 647
motor activity, 155
mouse strains, 193
multiple schedule, 887
nigrostriatal system, 743
norepinephrine, 193, 235
operant behavior, 1, 235, 621
oral administration, 31
pain, 171
pentobarbital, 1, 349, 647, 887
phencyclidine, 647, 835, 887
pigeon, 1, 349
plasma levels, 471
postural asymmetry, 743
n-propylnoraporphine, 497
prostaglandin, 235
proximics, 121
punishment, 1
quipazine, 817
raphe nuclei, 817
repeated acquisition, 887
reserpine, 835
rhesus monkey, 121, 869
ripple effect, 121
rotation, 743, 817
schedule-controlled behavior, 349
self-administration, 869
self-stimulation, 555
sexual behavior, 221
signal detection analysis, 887
sleep, 895
social behavior, 121, 177, 221
social interactions, 471
sociopharmacology, 471
spacing, 121
stereotypy, 793, 835
stress, 171
structure-activity, 869
temperature, 895
Δ^9-tetrahydrocannabinol, 121
tolerance, 793
Amphetamine isomers
dorsal tegmentum, 365
hippocampus, 365
lateral hypothalamus, 365
locomotor activity, 365
methysergide, 365
prefrontal cortex, 365
self-stimulation, 365
serotonin, 365
Amygdala
afterdischarge thresholds, 695
cocaine, 695
focal brain stimulation, 695
hippocampus, 695
kindling, 695
limbic system, 695
sensitization, 695
septum, 695
temporal lobe epilepsy, 695
Analgesia
acute tolerance, 773
amphetamine, 171
apomorphine, 171
bacitracin, 715
cold-water swims, 171, 829
collateral inhibition, 829
2-deoxy-D-glucose, 171
endorphin, 715
enkephalin, 715, 829
enkephalinase, 715
ethanol, 773
frog righting, 907
glutamic acid, 705
guinea pig ileum, 907
MIF-I, 907
morphine, 705, 829
naloxone, 715, 907
norepinephrine, 705
pain, 171, 829
pharmacogenetics, 773
D-phenylalanine, 829
pituitary, 907
raphe nuclei, 705
serotonin, 705
shock response, 773
spinal cord, 705
startle response, 773
Straub tail, 907
stress, 171
tail-flick, 907
withdrawal, 907
Angiotensin II
bombesin, 229
drinking, 229, 581
duck, 229
eledoisin, 229
intracranial injection, 581
iontophoresis, 359
lateral preoptic area, 581
medial preoptic area, 359
septum, 359
substance P, 229
Animal model
acute response, 811
amphetamine, 555
ataxia, 811
drug-induced depression, 555
ethanol, 811
haloperidol, 555
lateral hypothalamus, 555
neuromuscular junction, 811
residual latency, 811
self-stimulation, 555
synaptic delay, 811

Animal model of alcoholism
blood ethanol, 449
conditioned taste aversion, 77
ethanol, 77, 449
ethanol dose-response, 77
free-choice ethanol intake, 449
LiCl, 77
repeated aversion conditioning trials, 77
saccharin, 77
selective breeding, 449
Animal model of depression
amitriptyline, 575
fluoxetine, 575
5-hydroxytryptophan, 575
methysergide, 575
receptors, 575
serotonin, 575
Animal model of parkinsonism
atropine sulfate, 187
diisopropylfluorophosphate, 187
dopamine receptor binding, 187
6-hydroxydopamine, 187
locomotion, 187
muscarinic receptor binding, 187
stereotypy, 187
subsensitivity, 187
supersensitivity, 187
thermoregulation, 187
Anorexia
aggression, 221
amphetamine, 221
behavioral toxicity, 221
competition, 221
dominance hierarchy, 221
sexual behavior, 221
social behavior, 221
Antiadrenergic
amnesia, 805
biogenic amines, 805
diethyldithiocarbamate, 805
guanethidine, 805
memory, 805
Antidepressants
antihistamines, 299
electroconvulsive shock, 299
hypnotics, 299
tonic seizures, 299
Anti-epileptic opiates
convulsions, 343
morphine, 343
pentamethylenetetrazol, 343
Antihistamines
antidepressants, 299
electroconvulsive shock, 299
hypnotics, 299
tonic seizures, 299
Antinociception
activity, 443
inbred mice, 443
ketamine, 443
Anxiolytic drugs
benzodiazepines, 167
chlordiazepoxide, 167
clonazepam, 167
conditioned taste aversion, 761
conflict tests, 761
exploration, 167
LiCl, 761
light⇌dark chamber transitions, 167
locomotion, 167
pentobarbital, 761
sedation, 167

Apomorphine
activity, 371
amfonelic acid, 497
amphetamine, 171, 497, 793, 817
analgesia, 171
arecoline, 685
autoreceptor, 37
behavioral teratology, 685
caffeine, 307
chicks, 331
chronic haloperidol, 685
cold-water swims, 171
cyclic AMP, 307
cyclo(Leu-Gly), 633
2-deoxy-D-glucose, 171
development, 371
developmental psychopharmacology, 685
L-DOPA, 409
dopamine, 307, 497, 633
dopamine depletion, 409
dopaminergic-cholinergic interactions, 685
drug-induced stimuli, 497
escape performance, 371
ethological analysis, 331
fenfluramine, 817
haloperidol, 307, 409, 633
6-hydroxydopamine, 371
hypothermia, 633
lesions, 817
locomotor activity, 409, 633
5-methoxy-N,N-dimethyltryptamine, 817
methylamphetamine, 409
MIF, 37
motor behavior, 397
MSH, 37
neuroleptics, 633
pain, 171
pecking, 331
n-propylnoraporphine, 497
quipazine, 817
raphe nuclei, 817
receptors, 633
rotation, 817
stereotypy, 397, 793
stimulus preference, 331
stimulus properties of drugs, 307
stress, 171
striatum, 397
supersensitivity, 633
tardive dyskinesia, 37, 633
thioridazine, 397
tolerance, 793
Apparatus
automated device for screening the effects of psychotropic drugs on aggression and motor activity in mice, 287
drug dispenser to measure individual drinking in rat colonies, 593
Arecoline
apomorphine, 685
behavioral teratology, 685
chronic haloperidol, 685
developmental psychopharmacology, 685
dopaminergic-cholinergic interactions, 685
Ataxia
acute response, 811
amphetamine, 835
animal model, 811
ethanol, 811
locomotor activity, 835
methylphenidate, 835
neuromuscular junction, 811
phencyclidine, 835
reserpine, 835

Ataxia (continued)
residual latency, 811
stereotypy, 835
synaptic delay, 811
ATP synthesis
ethanol and liver mitochondria, s63
Atropine
acetylcholine, 89
animal model of parkinsonism, 187
barbital tolerance, s249
diisopropylfluorophosphate, 187
dopamine receptor binding, 187
hemicholinium-3, 89
6-hydroxydopamine, 187
imprinting, 673
intracerebral infusion, 89
locomotion, 187
methysergide, 673
morphine, 673
muscarinic receptor binding, 187
naloxone, 673
opioids, 673
pilocarpine, 673
quipazine, 673
sexual behavior, 89
social comfort, 673
stereotypy, 187
subsensitivity, 187
supersensitivity, 187
thermoregulation, 187
Audiogenic excitement
convulsants, 9
kynurenines, 9
tryptophan metabolites, 9
Audiogenic seizures
brain methyltransferases, 589
MAO, 589
mouse strains, 589
Auditory brainstem
response in alcoholics, s241
Autoreceptor
apomorphine, 37
MIF, 37
MSH, 37
tardive dyskinesia, 37
Aversion to alcohol
acetaldehyde and ethanol preference, s291
underlying factors, s269
Avoidance training
amnesia, 257
electroshock, 257
memory storage processes, 257
norepinephrine, 257
stress, 257

Baboon
choice, 729
drug abuse, 729
eating, 729
economics, 729
heroin, 729
Bacitracin
analgesia, 715
endorphin, 715
enkephalin, 715
enkephalinase, 715
naloxone, 715
Bacteria
E. coli and ethanol tolerance, s191
Barbital
atropine effect on tolerance, s249

Barbiturate sensitivity
desipramine, 733
dopamine, 733
EEG, 733
6-hydroxydopamine, 733
methohexital, 733
α-methyltyrosine, 733
norepinephrine, 733
Behavior
branched chain fatty acids, 843
GABA, 843
metabolic compartmentation, 843
di-n-propylacetate, 843
quasi-morphine abstinence, 843
Behavioral activation
morphine, 585
naloxone antagonism, 585
Behavioral inhibitory actions
catecholamines, 97
caudate nucleus, 97
6-hydroxydopamine, 97
inhibitory motor conditioning, 97
learning, 97
Behavioral teratology
apomorphine, 685
arecoline, 685
chronic haloperidol, 685
developmental psychopharmacology, 685
dopaminergic-cholinergic interactions, 685
Behavioral toxicity
aggression, 221
amphetamine, 221
anorexia, 221
competition, 221
dominance hierarchy, 221
sexual behavior, 221
social behavior, 221
Benzodiazepine receptor
inosine, 337
nicotinamide, 337
pentylenetetrazol, 337
Benzodiazepines
anxiolytic, 167
chlordiazepoxide, 167
clonazepam, 167
CNS stimulation, 415
drug abuse, 415
drug overdose, 415
exploration, 167
flurazepam, 415
light⇌dark chamber transitions, 167
locomotion, 167
pentylenetetrazol, 415
sedation, 167
Bethanechol
acetylcholine, 81
carbachol, 81
medial preoptic area, 81
mesencephalic reticular formation, 81
muscarinic receptors, 81
neocortex, 81
sexual behavior, 81
Bicuculline methiodide
GABA, 561
6-hydroxydopamine, 561
picrotoxin, 561
rotational behavior, 561
substantia nigra, 561
Biogenic amines
amnesia, 805
antiadrenergic, 805
diethyldithiocarbamate, 805

Biogenic amines (continued)
guanethidine, 805
memory, 805
Biological markers
alcoholism detection, s1
blood acetaldehyde after ethanol ingestion, s101
gamma glutamyltranspeptidase and alcoholism, s95
glutamate dehydrogenase and liver injury, s107
hereditary aspects of alcoholism, s9
Blind observer
data-recording procedures, 243
interobserver agreement, 243
observational dependent variable, 243
pharmacological independent variable, 243
Blood acetaldehyde
aldehyde dehydrogenase, 295
ethanol sensitivity, 295
human erythrocytes, 295
Blood ethanol
animal models of alcoholism, 449
ethanol, 449
free-choice ethanol intake, 449
selective breeding, 449
Blood ethanol concentration
ethanol concentration, 291
ethanol intake, 291
schedule induced polydipsia, 291
Blood levels
ethanol, 781
liquid diet, 781
physical dependence, 781
silastic, 781
Sustacal, 781
sustained release, 781
Blood pressure
exercise, 851
heart rate, 851
hexamethonium, 851
monkey, 851
Blood urea nitrogen
caffeine, 719
chronic interstitial nephritis, 719
corticosterone, 719
plasma renin, 719
population cage, 719
psychosocial stress, 719
Body weight
deprivation-induced, 877
dopamine, 461
environmental conditions, 877
hypothalamus, 461
lesions, 461
norepinephrine, 461
obesity, 461
rhesus monkey, 461
schedule-induced, 877
self-injection, 877
Δ^9-tetrahydrocannabinol, 877
Bombesin
angiotensin II, 229
drinking, 229
duck, 229
eledoisin, 229
substance P, 229
Brain
amygdala, 695
caudate nucleus, 5, 97, 103
cerebral cortex, 421
dorsal tegmentum, 365
hippocampus, 21, 303, 365, 695, 765
hypothalamus, 461, 913
lateral hypothalamus, 365, 555, 739
lateral preoptic area, 581
limbic system, 695
medial preoptic area, 81, 359
median raphe nucleus, 525
mesencephalic reticular formation, 81
neocortex, 81
nigrostriatal system, 743
nucleus accumbens, 103
olfactory bulb, 643
periaqueductal gray, 739
pineal gland, 901
pituitary, 907, 913
prefrontal cortex, 365
raphe nuclei, 705, 817
septum, 359, 695
striatum, 397
substantia nigra, 379, 561
substantia nigra compacta, 103
Brain dissection
catecholamines, 453
Brain methyltransferases
audiogenic seizures, 589
MAO, 589
mouse strains, 589
Brain perfusion
amphetamine, 235
dopamine, 235
norepinephrine, 235
operant behavior, 235
prostaglandins, 235
Brain protein synthesis
ACTH, 823
brain specific protein, 823
NSP, 823
S-100, 823
Brain specific protein
ACTH, 823
brain protein synthesis, 823
NSP, 823
S-100, 823
Branched chain fatty acids
behavior, 843
GABA, 843
metabolite compartmentation, 843
di-n-propylacetate, 843
quasi-morphine abstinence, 843
Brightness discrimination
acetylcholine, 21
choline, 21
hippocampus, 21
incorporation, 21
long-term memory, 21
uptake, 21

Caffeine
acetylcholine, 421
adenosine, 421
apomorphine, 307
blood urea nitrogen, 719
cerebral cortex, 421
chronic interstitial nephritis, 719
corticosterone, 719
cyclic AMP, 307
dopamine, 307
haloperidol, 307
morphine, 421
naloxone, 421
plasma renin, 719
population cage, 719
psychosocial stress, 719

Caffeine (continued)
stimulus properties of drugs, 307
theophylline, 421
Cannabinol
cannabidiol, 479
dopamine receptor antagonists, 479
grooming, 479
Δ^9-tetrahydrocannabinol, 479
Carbachol
acetylcholine, 81
bethanechol, 81
medial preoptic area, 81
mesencephalic reticular formation, 81
muscarinic receptors, 81
neocortex, 81
sexual behavior, 81
Catalepsy
developmental psychopharmacology, 45
locomotor activity, 45
morphine, 45
stereotyped gnawing/mouthing, 45
Catecholamines
aging, 155
amphetamine, 155, 471, 621
behavioral inhibitory actions, 97
brain dissection, 453
caudate nucleus, 97
chronic indwelling catheter, 471
conditioned avoidance behavior, 137
development, 155
disulfiram, 137
DOM, 621
L-DOPA, 137
electrode placement, 525
β-endorphin, 435
hallucinogens, 621
6-hydroxydopamine, 97, 621
inhibitory motor conditioning, 97
learning, 97
LSD, 621
median raphe nucleus, 525
α-methyltyrosine, 137
morphine, 435
motor activity, 155
naloxone, 435
neurochemical basis, 525
operant behavior, 621
plasma levels, 471
self-stimulation, 525
serotonin, 525
sexual behavior, 435
social interactions, 471
sociopharmacology, 471
TRH, 137
Caudate nucleus
behavioral inhibitory actions, 97
catecholamines, 97
conditioned avoidance, 5
dopamine, 5
enkephalin, 103
D-Ala^2-Met^5-enkephalinamide, 103
haloperidol, 103
6-hydroxydopamine, 97
inhibitory motor conditioning, 97
learning, 97
movement initiation, 5
myoclonus, 103
naloxone, 103
nucleus accumbens, 103
receptor, 5
substantia nigra compacta, 103
Cerebral cortex
acetylcholine, 421
adenosine, 421
caffeine, 421
morphine, 421
naloxone, 421
theophylline, 421
Change in dosage
food delivery schedule, 209
nicotine, 209
self-administration, 209
urinary pH, 209
Chicks
apomorphine, 331
ethological analysis, 331
pecking, 331
stimulus preference, 331
Chlordiazepoxide
anxiolytic, 167
benzodiazepines, 167
clonazepam, 167
cross-tolerance, 545
exploration, 167
light⇌dark chamber transitions, 167
locomotion, 167
pentobarbital, 545
pigeon, 545
schedule-controlled behavior, 545
sedation, 167
tolerance, 545
p-Chloroamphetamine
p-chlorophenylalanine, 569
depletion, 569
5,7-dihydroxytryptamine, 569
drug discrimination, 569
halogenated phenethylamines, 283
LSD, 569
serotonin, 569
serotonin behavioral syndrome, 283
supersensitivity, 569
zimelidine, 283
p-Chlorophenylalanine
p-chloroamphetamine, 569
depletion, 569
5,7-dihydroxytryptamine, 569
2,5-dimethoxy-4-methylamphetamine, 605
drug discrimination, 569
LSD, 569
operant behavior, 605
serotonin, 569, 605
supersensitivity, 569
Chlorpromazine
adjunctive behavior, 657
amphetamine, 657
diazepam, 657
drinking, 657
fixed interval, 657
interpellet distributions, 657
Choice
baboon, 729
drug abuse, 729
eating, 729
economics, 729
heroin, 729
Cholecystokinin
intracerebroventricular injection, 125
labyrinthectomy, 125
rotation, 125
toxicity, 125
Choline
acetylcholine, 21
brightness discrimination, 21

Choline (continued)
hippocampus, 21
incorporation, 21
long-term memory, 21
uptake, 21
Choline acetyltransferase
acetylcholinesterase, 519
Mongolian gerbil, 519
scent marking behavior, 519
scopolamine, 519
Cholinergic-dopaminergic balance
dopaminergic mechanisms, 385
motor activity, 385
pentylamine, 385
Chronic alcohol intoxication
glutathione levels, s53
Chronic alcoholism
auditory brainstem response, s241
Chronic amphetamine treatment
amitriptyline, 379
imipramine, 379
response depression, 379
self-stimulation, 379
substantia nigra, 379
Chronic haloperidol
apomorphine, 685
arecoline, 685
behavioral teratology, 685
developmental psychopharmacology, 685
dopaminergic-cholinergic interactions, 685
Chronic indwelling catheter
age, 129
amphetamine, 471
catecholamines, 471
epinephrine, 129
estrous cycle, 129
immobilization stress, 129
plasma levels, 471
norepinephrine, 129
social interactions, 471
sociopharmacology, 471
Chronic interstitial nephritis
blood urea nitrogen, 719
caffeine, 719
corticosterone, 719
plasma renin, 719
population cage, 719
psychosocial stress, 719
Chronopharmacokinetics
circadian rhythms, 637
clearance rates, 637
eating, 637
ethanol, 637
feeding restriction, 637
pharmacokinetics, 637
phase shifts, 637
Circadian rhythms
chronopharmacokinetics, 637
clearance rates, 637
eating, 637
ethanol, 637
feeding restriction, 637
pharmacokinetics, 637
phase shifts, 637
Clearance rates
chronopharmcokinetics, 637
circadian rhythms, 637
eating, 637
ethanol, 637
feeding restriction, 637
pharmacokinetics, 637
phase shifts, 637
Clonazepam
anxiolytic, 167
benzodiazepines, 167
chlordiazepoxide, 167
exploration, 167
light⇌dark chamber transitions, 167
locomotion, 167
sedation, 167
Clonidine
aggression, 153
fenfluramine, 643
fluoxetine, 643
imipramine, 153, 643
iprindole, 153
metergoline, 643
mianserin, 153, 643
olfactory bulbectomy, 643
passive avoidance learning, 643
quipazine, 643
Clozapine
dihydrotestosterone, 57
dopamine, 57
estradiol, 57
fluoxetine, 57
male rat, 57
5-methoxy-N,N-dimethyltryptamine, 57
serotonin, 57
sexual behavior, 57
spiperone, 57
CNS stimulants
cocaine cue, 513
dopamine, 513
drug discrimination, 513
monoamine oxidase, 513
β-phenylethylamine, 513
CSN stimulation
benzodiazepines, 415
drug abuse, 415
drug overdose, 415
flurazepam, 415
pentylenetetrazol, 415
Coca
activity, 403
cocaine, 403
eating, 403
Cocaine
activity, 403
afterdischarge thresholds, 695
amygdala, 695
coca, 403
eating, 403
focal brain stimulation, 695
hippocampus, 695
kindling, 695
limbic system, 695
locomotor activity, 69
norcocaine, 69
operant behavior, 69
self-administration, 69
sensitization, 695
septum, 695
temporal lobe epilepsy, 695
Cocaine cue
CNS stimulants, 513
dopamine, 513
drug discrimination, 513
monoamine oxidase, 513
β-phenylethylamine, 513
Cold water swims
amphetamine, 171
analgesia, 171, 829
apomorphine, 171

Cold water swims (continued)
collateral inhibition, 829
2-deoxy-D-glucose, 171
enkephalin, 829
morphine, 829
pain, 171, 829
D-phenylalanine, 829
stress, 171
Collateral inhibition
analgesia, 829
cold water swims, 829
enkephalin, 829
morphine, 829
pain, 829
D-phenylalanine, 829
Colony housed rats
drinking, 593
drug self-administration, 593
Color avoidance conditioning
S-adenosylhomocystein, 305
Competition
aggression, 221
amphetamine, 177, 221
anorexia, 221
behavioral toxicity, 221
diazepam, 177
dominance hierarchy, 177, 221
food-getting, 177
monkey, 177
sexual behavior, 221
social behavior, 177, 221
Conditioned avoidance
caudate nucleus, 5
dopamine, 5
movement initiation, 5
receptor, 5
Conditioned avoidance behavior
catecholamines, 137
disulfiram, 137
L-DOPA, 137
α-methyltyrosine, 137
TRH, 137
Conditioned discrimination
amphetamine, 887
lever pressing, 887
monkey, 887
multiple schedule, 887
pentobarbital, 887
phencyclidine, 887
repeated acquisition, 887
signal detection analysis, 887
Conditioned flavor aversion
amphetamine, 597
conditioned location preference, 501, 597
morphine, 501
naloxone, 501
reinforcement, 501
selective association, 501
Conditioned location preference
amphetamine, 597
conditioned flavor aversion, 501, 597
morphine, 501
naloxone, 501
reinforcement, 501
selective association, 501
Conditioned taste aversion
amphetamine, 31
animal models of alcoholism, 77
anxiolytic drugs, 761
conflict tests, 761
ethanol, 77
ethanol dose-response, 77
lead acetate, 133
LiCl, 77, 761
oral administration, 31
pentobarbital, 761
repeated aversion conditioning trials, 77
saccharin, 77
toxicity, 133
Conflict tests
anxiolytic drugs, 761
conditioned taste aversion, 761
LiCl, 761
pentobarbital, 761
Convulsants
audiogenic exictement, 9
kynurenines, 9
tryptophan metabolites, 9
Convulsions
aggregation, 475
alcohol withdrawal seizures, s225
anti-epileptic opiates, 343
lethality, 475
morphine, 343, 475
pentamethylenetetrazol, 343
stress, 475
Coronary arteries
effects of alcohol, s37
Corpuscular volume
alcoholism detection, s1
Corticosteroids
aggression, 27
diazepam, 27
extinction, 27
frustration, 27
pig, 27
response persistence, 27
Corticosterone
blood urea nitrogen, 719
caffeine, 719
chronic interstitial nephritis, 719
plasma renin, 719
population cage, 719
psychosocial stress, 719
Cortisol
dopamine, 663
grooming, 663
LH, 663
naltrexone, 663
prolactin, 663
sexual behavior, 663
talapoin monkey, 663
testosterone, 663
Cross-tolerance
chlordiazepoxide, 545
pentobarbital, 545
pigeon, 545
schedule-controlled behavior, 545
tolerance, 545
Cumulative dose-response
amphetamine, 647
fixed-ratio, 647
ketamine, 647
morphine, 647
pentobarbital, 647
phencyclidine, 647
Cyclic AMP
apomorphine, 307
caffeine, 307
dopamine, 307
haloperidol, 307
protein I and protein phosphorylation, s169
stimulus properties of drugs, 307

Cycloheximide
amphetamine, 193
dopamine, 193
memory, 193
mouse strains, 193
norepinephrine, 193
Cyclo(Leu-Gly)
apomorphine, 633
dopamine, 633
ethanol tolerance, s279
haloperidol, 633
hypothermia, 633
locomotor activity, 633
neuroleptics, 633
receptors, 633
supersensitivity, 633
tardive dyskinesia, 633

Data-recording procedures
blind observer, 243
interobserver agreement, 243
observational dependent variable, 243
pharmacological independent variable, 243
DeLange syndrome
grooming, 627
pemoline, 627
self-mutilation, 627
stereotypy, 627
2-Deoxy-D-glucose
amphetamine, 171
analgesia, 171
apomorphine, 171
cold-water swims, 171
pain, 171
stress, 171
2-Deoxyglucose
drinking, 507
lead, 507
LiCl, 507
NaCl, 507
saccharin, 507
taste aversion, 507
toxicants, 507
Depletion
p-chloroamphetamine, 569
p-chlorophenylalanine, 569
5,7-dihydroxytryptamine, 569
drug discrimination, 569
LSD, 569
serotonin, 569
supersensitivity, 569
Deprivation-induced
body weight, 877
environmental conditions, 877
schedule-induced, 877
self-injection, 877
Δ^9-tetrahydrocannabinol, 877
Desipramine
barbiturate sensitivity, 733
5,6-dihydroxytryptamine, 915
dopamine, 733
dopamine uptake, 915
EEG, 733
6-hydroxydopamine, 733, 915
methohexital, 733
α-methyltyrosine, 733
nomifensine, 915
norepinephrine, 733
rotation, 915
Development
activity, 371
aging, 155
amphetamine, 155
apomorphine, 371
catecholamines, 155
enkephalin, 883
enzyme activity, 883
escape performance, 371
maze running, 883
motor activity, 155
neonatal, 883
radioimmunoassay, 883
Developmental disturbances
amphetamine, 391
dopamine, 391
6-hydroxydopamine, 391
maternal behavior, 391
Developmental psychopharmacology
apomorphine, 685
arecoline, 685
behavioral teratology, 685
catalepsy, 45
chronic haloperidol, 685
dopaminergic-cholinergic interactions, 685
locomotor activity, 45
morphine, 45
stereotyped gnawing/mouthing, 45
Diaminodiphenoxybutane
electroretinogram, 429
operant behavior, 429
retinotoxicity, 429
visual evoked potential, 429
Diazepam
adjunctive behavior, 657
aggression, 27
amphetamine, 177, 657
chlorpromazine, 657
competition, 177
corticosteroids, 27
dominance hierarchy, 177
drinking, 657
extinction, 27
fixed interval, 657
food-getting, 177
frustration, 27
interpellet distributions, 657
monkey, 177
pig, 27
response persistence, 27
social behavior, 177
Diethyldithiocarbamate
amnesia, 805
antiadrenergic, 805
biogenic amines, 805
guanethidine, 805
memory, 805
Dihydrotestosterone
clozapine, 57
dopamine, 57
estradiol, 57
fluoxetine, 57
male rat, 57
5-methoxy-N,N-dimethyltryptamine, 57
serotonin, 57
sexual behavior, 57
spiperone, 57
5,6-Dihydroxytryptamine
desipramine, 915
dopamine uptake, 915
6-hydroxydopamine, 915
nomifensine, 915
rotation, 915

5,7-Dihydroxytryptamine
p-chloroamphetamine, 569
p-chlorophenylalanine, 569
depletion, 569
drug discrimination, 569
halothane, 247
5-hydroxytryptophan, 247
LSD, 569
5-methoxy-N,N-dimethyltryptamine, 247
methysergide, 247
respiratory control, 247
serotonin, 247, 569
supersensitivity, 569
Diisopropylfluorophosphate
animal model of parkinsonism, 187
atropine sulfate, 187
dopamine receptor binding, 187
6-hydroxydopamine, 187
locomotion, 187
muscarinic receptor binding, 187
stereotypy, 187
subsensitivity, 187
supersensitivity, 187
thermoregulation, 187
2,5-Dimethoxy-4-methylamphetamine
p-chlorophenylalanine, 605
operant behavior, 605,
serotonin, 605
Disulfiram
alcohol and glutathione levels, s53
implantation and biochemical effects, s73
catecholamines, 137
conditioned avoidance behavior, 137
L-DOPA, 137
implantation and biochemical effects, s73
α-methyltyrosine, 137
TRH, 137
DNLAAM
abstinence, 115
head shakes, 115
LAAM, 115
lever pressing, 115
methadone, 115
morphine, 115
NLAAM, 115
REM sleep, 115
self-administration, 115
DOM
amphetamine, 621
catecholamines, 621
hallucinogens, 621
6-hydroxydopamine, 621
LSD, 621
Dominance hierarchy
aggression, 221
amphetamine, 177, 221
anorexia, 221
behavioral toxicity, 221
competition, 177, 221
diazepam, 177
food-getting, 177
monkey, 177
sexual behavior, 221
social behavior, 177, 221
L-DOPA
apomorphine, 409
catecholamines, 137
conditioned avoidance behavior, 137
disulfiram, 137
dopamine depletion, 409
haloperidol, 409
locomotor activity, 409
methylamphetamine, 409
α-methyltyrosine, 137
TRH, 137
Dopamine
amfonelic acid, 497
amphetamine, 193, 235, 391, 497
apomorphine, 307, 497, 633
barbiturate sensitivity, 733
body weight, 461
brain perfusion, 235
caffeine, 307
caudate nucleus, 5
clozapine, 57
CNS stimulants, 513
cocaine cue, 513
conditioned avoidance, 5
cortisol, 663
cyclic AMP, 307
cycloheximide, 193
cyclo(Leu-Gly), 633
desipramine, 733
developmental disturbances, 391
dihydrotestosterone, 57
drug discrimination, 513
drug-induced stimuli, 497
EEG, 733
epinephrine, 107
estradiol, 57
fluoxetine, 57
L-fucose, 303
grooming, 663
haloperidol, 307, 633
hippocampal slices, 303
6-hydroxydopamine, 391, 733
hypothalamus, 461
hypothermia, 633
learning, 859
lesions, 461
LH, 663
locomotor activity, 633
male rat, 57
D-mannose, 303
maternal behavior, 391
memory, 193
methohexital, 733
5-methoxy-N,N-dimethyltryptamine, 57
α-methyltyrosine, 733
monoamine oxidase, 513
mouse strains, 193
movement initiation, 5
naltrexone, 663
neuroleptics, 633
norepinephrine, 107, 193, 235, 461, 733
obesity, 107
operant behavior, 235
β-phenylethylamine, 513
pimozide, 859
prolactin, 663
n-propylnoraporphine, 497
prostaglandin, 235
proteins, 303
receptors, 5, 633
rhesus monkey, 461
serotonin, 57
sexual behavior, 57, 663
simultaneous discrimination, 859
spiperone, 57
stimulus properties of drugs, 307
stress, 107, 461
supersensitivity, 633
sympatho-adrenal function, 107
talapoin monkey, 663

Dopamine (continued)
tardive dyskinesia, 633
testosterone, 663
thermogenesis, 107
Zucker rat, 107
Dopamine depletion
apomorphine, 409
L-DOPA, 409
haloperidol, 409
locomotor activity, 409
methylamphetamine, 409
Dopamine receptor antagonists
cannabidiol, 479
cannabinol, 479
grooming, 479
Δ^9-tetrahydrocannabinol, 479
Dopamine receptor binding
animal model of parkinsonism, 187
atropine sulfate, 187
diisopropylfluorophosphate, 187
6-hydroxydopamine, 187
locomotion, 187
muscarinic receptor binding, 187
stereotypy, 187
subsensitivity, 187
supersensitivity, 187
thermoregulation, 187
Dopamine uptake
desipramine, 915
5,6-dihydroxytryptamine, 915
6-hydroxydopamine, 915
nomifensine, 915
rotation, 915
Dopaminergic-cholinergic interactions
apomorphine, 685
arecoline, 685
behavioral teratology, 685
chronic haloperidol, 685
developmental psychopharmacology, 685
Dopaminergic mechanisms
cholinergic-dopaminergic balance, 385
motor activity, 385
pentylamine, 385
Dopaminergic system
modulation of ethanol by opioid system, s303
Dorsal tegmentum
amphetamine isomers, 365
hippocampus, 365
lateral hypothalamus, 365
locomotor activity, 365
methysergide, 365
prefrontal cortex, 365
self-stimulation, 365
serotonin, 365
Drinking
adjunctive behavior, 657
amphetamine, 657
angiotensin II, 229, 581
bombesin, 229
chlorpromazine, 657
colony housed rats, 593
2-deoxyglucose, 507
diazepam, 657
drug self-administration, 593
duck, 229
eledoisin, 229
fixed interval, 657
indomethacin, 787
interpellet distributions, 657
intracranial injection, 581
lateral preoptic area, 581
lead, 507
LiCl, 507
NaCl, 507
prostaglandin E_1, 787
saccharin, 507
substance P, 229
taste aversion, 507
toxicants, 507
DRL
drug-behavior interactions, 691
imipramine, 691
operant behavior, 691
schedule parameters, 691
Drug
amfonelic acid, 497
amitriptyline, 379, 575
amphetamine, 1, 31, 121, 155, 171, 177, 193, 221, 235, 349, 365, 391, 471, 497, 555, 597, 626, 647, 657, 745, 793, 817, 835, 869, 887, 895
apomorphine, 37, 171, 307, 331, 371, 397, 409, 497, 633, 685, 793, 817
arecoline, 685
atropine, s249
atropine sulfate, 89, 187, 673
bacitracin, 715
barbital, s249
bethanechol, 81
bicuculline methiodide, 561
2-bromo-D-lysergic acid diethylamide, 549
caffeine, 307, 421, 719
cannabidiol, 479
cannabinol, 479
carbachol, 81
chlordiazepoxide, 167, 545
p-chloroamphetamine, 283, 525, 569
p-chlorophenylalanine, 525, 569, 605
chlorpromazine, 479, 657
clonazepam, 167
clonidine, 153, 643
clorgyline, 513
clozapine, 57
coca, 403
cocaine, 69, 403, 513, 695
cycloheximide, 193
cyclo(Leu-Gly), 633
cyproheptadine, 525
2-deoxy-D-glucose, 171
2-deoxyglucose, 507
deprenyl, 513
desipramine, 733, 915
Diaminodiphenoxybutane, 429
diazepam, 27, 177, 657
diethyldithiocarbamate, 805
5,6-dihydroxytryptamine, 915
5,7-dihydroxytryptamine, 247, 525, 569
diisopropylfluorophosphate, 187
2,5-dimethoxy-4-methylamphetamine, 605, 621
N,N-dimethyltryptamine, 549
disulfiram, 137, s31, s53, s73
DLAAM, 115
L-DOPA, 137, 409
eledoisin, 229
D-Ala^2-Met^5-enkephalinamide, 103
ethanol, 77, 265, 291, 295, 325, 349, 449, 531, 637, 773, 777, 781, 811
fenfluramine, 643, 817
fluoxetine, 57, 575, 643
flurazepam, 415
glutamic acid, 705
guanethidine, 805
haloperidol, 103, 307, 409, 479, 555, 633, 685
halothane, 247
hemicholinium-3, 89

Drug (continued)
heroin, 457, 729, s245
hexamethonium, 851
6-hydroxydopa, 863
6-hydroxydopamine, 97, 187, 371, 391, 561, 621, 733, 915
5-hydroxytryptophan, 247, 575
imipramine, 153, 379, 643, 691
indomethacin, 787
inosine, 337
iprindole, 153
ketamine, 1, 443, 647
kynurenine, 9, 17
LAAM, 115
lead, 507
lead acetate, 133
LiCl, 77, 507, 761
lithium, 205
LSD, 549, 569, 621
mercury, 537
mescaline, 549, 601
metergoline, 525, 643
methadone, 115, 919
methergoline, 549
methohexital, 733
5-methoxy-N,N-dimethyltryptamine, 57, 247, 817
methylamphetamine, 409
α-methylparatyrosine, 525
methylphenidate, 467, 835
α-methyltyrosine, 137, 733
methysergide, 247, 365, 575, 673
mianserin, 153, 643
morphine, 45, 115, 343, 421, 435, 475, 501, 549, 585, 647, 673, 705, 799, 829, s257, s265
naloxone, 103, 421, 435, 457, 501, 585, 601, 673, 715, 739, 907, s269, s303
naltrexone, 663
nialamide, 513
nicotinamide, 337
nicotine, 209, 215
NLAAM, 115
nomifensine, 915
norcocaine, 69
pargyline, 513
pemoline, 621
pentamethylenetetrazol, 343
pentobarbital, 1, 349, 545, 549, 647, 761, 887
pentylamine, 385
pentylenetetrazol, 17, 337, 415
phencyclidine, 647, 835, 887
pheniprazine, 513
phenoxybenzamine, 51
phentolamine, 51
D-phenylalanine, 829
phenylethylamine, 513
picrotoxin, 561
pilocarpine, 673
pimozide, 859
di-n-propylacetate, 843
n-D-propylacetate, 287
n-propylnoraporphine, 497
psilocybin, 549
quinolinic acid, 17
quipazine, 643, 673, 817
reserpine, 835
salsolinol, 265
scopolamine, 183, 519
selenium, 537
spiperone, 57
spiroperidol, 479
strychnine, 17
Δ^9-tetrahydrocannabinol, 121, 199, 479, 549, 877
tetrahydroisoquinolines, 265
tetrahydropapaveroline, 265, s269
theophylline, 421
thioridazine, 397
thiosemicarbazide, 17
tranylcypromine, 513
zimelidine, 283
Drug abuse
baboon, 729
benzodiazepines, 415
choice, 729
CNS stimulation, 415
drug overdose, 415
eating, 729
economics, 729
flurazepam, 415
heroin, 729
pentylenetetrazol, 415
Drug-behavior interactions
DRL, 691
imipramine, 691
operant behavior, 691
schedule parameters, 691
Drug discrimination
p-chloroamphetamine, 569
p-chlorophenylalanine, 569
CNS stimulants, 513
cocaine cue, 513
depletion, 569
5,7-dihydroxytryptamine, 569
dopamine, 513
LSD, 549, 569
methergoline, 549
monoamine oxidase, 513
non-psychedelics, 549
β-phenylethylamine, 513
pigeon, 549
psychedelics, 549
serotonin, 569
supersensitivity, 569
Drug-induced depression
amphetamine, 555
animal models, 555
haloperidol, 555
lateral hypothalamus, 555
self-stimulation, 555
Drug-induced stimuli
amfonelic acid, 497
amphetamine, 497
apomorphine, 497
dopamine, 497
n-propylnoraporphine, 497
Drug interaction
amphetamine, 349
ethanol, 349
pentobarbital, 349
pigeon, 349
schedule-controlled behavior, 349
Drugs of abuse
action on brain reward systems, s213
intracranial self-stimulation and reward, s245
Drug overdose
benzodiazepines, 415
CNS stimulation, 415
drug abuse, 415
flurazepam, 415
pentylenetetrazol, 415
Drug self-administration
colony housed rats, 593
drinking, 593
DSIP
amphetamine, 895
locomotion, 895

DSIP (continued)
sleep, 895
temperature, 895
Duck
angiotensin II, 229
bombesin, 229
drinking, 229
eledoisin, 229
substance P, 229

Eating
activity, 403
baboon, 729
choice, 729
chronopharmacokinetics, 637
circadian rhythms, 637
clearance rates, 637
coca, 403
cocaine, 403
drug abuse, 729
economics, 729
ethanol, 637
feeding restriction, 637
heroin, 729
pharmacokinetics, 637
phase shifts, 637
Economics
baboon, 729
choice, 729
drug abuse, 729
eating, 729
heroin, 729
EEG
barbiturate sensitivity, 733
changes during chronic alcohol exposure, s233
desipramine, 733
dopamine, 733
6-hydroxydopamine, 733
methohexital, 733
α-methyltyrosine, 733
norepinephrine, 733
Electroconvulsive shock
antidepressants, 299
antihistamines, 299
hypnotics, 299
tonic seizures, 299
Electrode placement
catecholamines, 525
median raphe nucleus, 525
neurochemical basis, 525
self-stimulation, 525
serotonin, 525
Electrophysiology
ethanol and nervous tissue, s203
Electroretinogram
diaminodiphenoxybutane, 429
operant behavior, 429
retinotoxicity, 429
visual evoked potential, 429
Electroshock
amnesia, 257
avoidance training, 257
memory storage processes, 257
norepinephrine, 257
stress, 257
Eledoisin
angiotensin II, 229
bombesin, 229
drinking, 229
duck, 229
substance P, 229

Endorphin
analgesia, 715
bacitracin, 715
enkephalin, 715
enkephalinase, 715
modulation by ethanol and morphine, s265
modulation of ethanol effect on dopaminergic function, s303
naloxone, 715
β-Endorphin
catecholamines, 435
morphine, 435
naloxone, 435
sexual behavior, 435
Enkephalin
analgesia, 715, 829
bacitracin, 715
caudate nucleus, 103
cold water swims, 829
collateral inhibition, 829
development, 883
endorphin, 715
D-Ala^2-Met^5-enkephalinamide, 103
enkephalinase, 715
enzyme activity, 883
haloperidol, 103
maze running, 883
morphine, 829
myoclonus, 103
naloxone, 103, 715
neonatal, 883
nucleus accumbens, 103
pain, 829
D-phenylalanine, 829
radioimmunoassay, 883
substantia nigra compacta, 103
D-Ala^2-Met^5-Enkephalinamide
caudate nucleus, 103
enkephalin, 103
haloperidol, 103
myoclonus, 103
naloxone, 103
nucleus accumbens, 103
substantia nigra compacta, 103
Enkephalinase
analgesia, 715
bacitracin, 715
endorphin, 715
enkephalin, 715
naloxone, 715
Environmental conditions
body weight, 877
deprivation-induced, 877
schedule-induced, 877
self-injection, 877
Δ^9-tetrahydrocannabinol, 877
Enzyme activity
development, 883
enkephalin, 883
maze running, 883
neonatal, 883
radioimmunoassay, 883
Epinephrine
age, 129
chronic indwelling catheter, 129
dopamine, 107
estrous cycle, 129
immobilization stress, 129
norepinephrine, 107, 129
obesity, 107
role in ethanol metabolism, s67
stress, 107
sympatho-adrenal function, 107

Epinephrine (continued)
thermogenesis, 107
Zucker rat, 107
Equilibrium
activity, 863
female rat, 863
habituation, 863
6-hydroxydopa, 863
neonatal, 863
norepinephrine, 863
sexual behavior, 863
Erythrocytes
affective disorders, 205
lithium, 205
manic-depressives, 205
potassium, 205
sodium, 205
Escape performance
activity, 371
apomorphine, 371
development, 371
6-hydroxydopamine, 371
Escherichia coli
alcohol tolerance, s191
Estradiol
clozapine, 57
dihydrotestosterone, 57
dopamine, 57
fluoxetine, 57
male rat, 57
5-methoxy-N,N-dimethyltryptamine, 57
serotonin, 57
sexual behavior, 57
spiperone, 57
Estrous cycle
age, 129
chronic indwelling catheter, 129
epinephrine, 129
immobilization stress, 129
norepinephrine, 129
Ethanol
acoustic startle reflex, 531
activity, 531
acute response, 811
acute tolerance, 773
amphetamine, 349
analgesia, 773
animal model, 811
animal models of alcoholism, 77, 449
ataxia, 811
blood ethanol, 449
blood levels, 781
chronopharmacokinetics, 637
circadian rhythms, 637
clearance rates, 637
conditioned taste aversion, 77
drug interaction, 349
eating, 637
ethanol dose-response, 77
excitatory effect, 777
feeding restriction, 637
fetal alcohol syndrome, 531
free-choice ethanol intake, 449
iron-loading, 325
LiCl, 77
liquid diet, 781
locomotor activity, 777
modulation of endorphin activity, s265
neuromuscular junction, 811
pentobarbital, 349
pharmacogenetics, 773
pharmacokinetics, 637
phase shifts, 637
physical dependence, 781
pigeon, 349
porphyrin metabolism, 325
preference, 265
prenatal, 531
repeated aversion conditioning trials, 77
residual latency, 811
saccharin, 77
salsolinol, 265
schedule-controlled behavior, 349
selective breeding, 449
shock response, 773
silastic, 781
startle response, 773
Sustacal, 781
sustained release, 781
synaptic delay, 811
tetrahydroisoquinolines, 265
tetrahydropapaveroline, 265
tolerance, 777
vitamin E, 325
Ethanol concentration
blood ethanol concentration, 291
ethanol intake, 291
schedule induced polydipsia, 291
Ethanol dose-response
animal models of alcoholism, 77
conditioned taste aversion, 77
ethanol, 77
LiCl, 77
repeated aversion conditioning trials, 77
saccharin, 77
Ethanol elimination
blood acetaldehyde levels, s119
Ethanol intake
blood ethanol concentration, 291
ethanol concentration, 291
schedule induced polydipsia, 291
Ethanol metabolism
hormonal role, s67
Ethanol preference
association with actions of alcohol, s297
Ethanol sensitivity
aldehyde dehydrogenase, 295
blood acetaldehyde, 295
human erythrocytes, 295
Ethanol tolerance
neurohypophyseal peptide involvement, s257, s279, s285
Ethological analysis
apomorphine, 331
chicks, 331
pecking, 331
stimulus preference, 331
Excitatory effect
ethanol, 777
locomotor activity, 777
tolerance, 777
Exercise
blood pressure, 851
heart rate, 851
hexamethonium, 851
monkey, 851
Exploration
anxiolytic, 167
benzodiazepines, 167
chlordiazepoxide, 167
clonazepam, 167
light⇌dark chamber transitions, 167
locomotion, 167
sedation, 167
Extinction

Extinction (continued)
aggression, 27
corticosteroids, 27
diazepam, 27
frustration, 27
methylphenidate, 467
pig, 27
response persistence, 27
signalled reinforcement, 467
stimulus control, 467
Family history
hereditary aspects of alcoholism, s9
Feeding restriction
chronopharmacokinetics, 637
circadian rhythms, 637
clearance rates, 637
eating, 637
ethanol, 637
pharmacokinetics, 637
phase shifts, 637
Female rat
activity, 863
equilibrium, 863
habituation, 863
6-hydroxydopa, 863
neonatal, 863
norepinephrine, 863
sexual behavior, 863
Fenfluramine
amphetamine, 817
apomorphine, 817
clonidine, 643
fluoxetine, 643
imipramine, 643
lesions, 817
metergoline, 643
5-methoxy-N,N-dimethyltryptamine, 817
mianserin, 643
olfactory bulbectomy, 643
passive avoidance learning, 643
quipazine, 643, 817
raphe nuclei, 817
rotation, 817
Fetal alcohol syndrome
acoustic startle reflex, 531
activity, 531
ethanol, 531
prenatal, 531
Fixed interval
adjunctive behavior, 657
amphetamine, 657
chlorpromazine, 657
diazepam, 657
drinking, 657
interpellet distributions, 657
Fixed-ratio
amphetamine, 647
cumulative dose-response, 647
ketamine, 647
morphine, 647
pentobarbital, 647
phencyclidine, 647
Fluoxetine
amitriptyline, 575
animal model of depression, 575
clozapine, 57, 643
dihydrotestosterone, 57
dopamine, 57
estradiol, 57
fenfluramine, 643
5-hydroxytryptophan, 575
imipramine, 643
male rat, 57
metergoline, 643
5-methoxy-N,N-dimethyltryptamine, 57
methysergide, 575
mianserin, 643
olfactory bulbectomy, 643
passive avoidance learning, 643
quipazine, 643
receptors, 575
serotonin, 57, 575
sexual behavior, 57
spiperone, 57
Flurazepam
benzodiazepines, 415
CNS stimulation, 415
drug abuse, 415
drug overdose, 415
pentylenetetrazol, 415
Focal brain stimulation
afterdischarge thresholds, 695
amygdala, 695
cocaine, 695
hippocampus, 695
kindling, 695
limbic system, 695
sensitization, 695
septum, 695
temporal lobe epilepsy, 695
Food delivery schedule
change in dosage, 209
nicotine, 209
self-administration, 209
urinary pH, 209
Food-getting
amphetamine, 177
competition, 177
diazepam, 177
dominance hierarchy, 177
monkey, 177
social behavior, 177
Free-choice ethanol intake
animal models of alcoholism, 449
blood ethanol, 449
ethanol, 449
selective breeding, 449
Free recall
levels of processing, 199
linguistic information, 199
marijuana, 199
memory, 199
Frog righting
analgesia, 907
guinea pig ileum, 907
MIF-I, 907
naloxone, 907
pituitary, 907
Straub tail, 907
tail-flick, 907
withdrawal, 907
Frustration
aggression, 27
corticosteroids, 27
diazepam, 27
extinction, 27
pig, 27
response persistence, 27
L-Fucose
dopamine, 303
hippocampal proteins, 765
hippocampal slices, 303
D-mannose, 303
memory, 765

L-Fucose (continued)
proteins, 303
shuttle box, 765
Y-maze, 765

GABA
behavior, 843
bicuculline methiodide, 561
branched chain fatty acids, 843
6-hydroxydopamine, 561
metabolic compartmentation, 843
picrotoxin, 561
di-n-propylacetate, 843
quasi-morphine abstinence, 843
rotational behavior, 561
substantia nigra, 561
Gamma glutamyltranspeptidase
marker of alcoholism, s95
Gel filtration
kidney, 537
liver, 537
mercury, 537
plasma, 537
rabbit, 537
selenium, 537
stroma-free hemolysate, 537
tissue-soluble fraction, 537
Genetic markers
hereditary aspects of alcoholism, s9, s89
alcoholic liver disease, s89
Glucagon
role in ethanol metabolism, s67
β-Glucuronidase
histamine, 41
lysosomes, 41
stomach, 41
stress ulcers, 41
zinc, 41
Glutamate dehydrogenase
blood level as biological marker of alcoholic liver injury, s107
Glutamate receptors
ethanol and membrane function, s197
Glutamic acid
analgesia, 705
morphine, 705
norepinephrine, 705
raphe nuclei, 705
serotonin, 705
spinal cord, 705
Glutathione
levels in intoxication, s53
Gonadal atrophy
alcohol and sexual function, s125
Gonadal function
hormonal changes during intoxication and withdrawal, s131
Grooming
cannabidiol, 479
cannabinol, 479, 663
cortisol, 663
deLange syndrome, 627
dopamine receptor antagonists, 479
LH, 663
naltrexone, 663
pemoline, 627
prolactin, 663
self-stimulation, 627
sexual behavior, 663
stereotypy, 627
talapoin monkey, 663
testosterone, 663
Δ^9-tetrahydrocannabinol, 479

Guanethidine
amnesia, 805
antiadrenergic, 805
biogenic amines, 805
diethyldithiocarbamate, 805
memory, 805
Guinea pig atrium
amphetamine, 869
rhesus monkey, 869
self-administration, 869
structure-activity, 869
Guinea pig ileum
analgesia, 907
frog righting, 907
MIF-I, 907
naloxone, 907
pituitary, 907
Straub tail, 907
tail-flick, 907
withdrawal, 907

Habituation
activity, 863
equilibrium, 863
female rat, 863
6-hydroxydopa, 863
neonatal, 863
norepinephrine, 863
sexual behavior, 863
Hallucinogens
amphetamine, 621
catecholamines, 621
DOM, 621
6-hydroxydopamine, 621
LSD, 621
operant behavior, 621
Halogenated phenethylamines
p-chloroamphetamine, 283
serotonin behavioral syndrome, 283
zimelidine, 283
Haloperidol
amphetamine, 555
animal models, 555
apomorphine, 307, 409, 633
caffeine, 307
caudate nucleus, 103
cyclic AMP, 307
cyclo(Leu-Gly), 633
L-DOPA, 409
dopamine, 307, 633
dopamine depletion, 409
drug-induced depression, 555
enkephalin, 103
D-Ala^2-Met^5-enkephalinamide, 103
hypothermia, 633
lateral hypothalamus, 555
locomotor activity, 409, 633
methylamphetamine, 409
myoclonus, 103
naloxone, 103
neuroleptics, 633
nucleus accumbens, 103
receptors, 633
self-stimulation, 555
stimulus properties of drugs, 307
substantia nigra compacta, 103
supersensitivity, 633
tardive dyskinesia, 633
Halothane
5,7-dihydroxytryptamine, 247
5-hydroxytryptophan, 247

Halothane (continued)
5-methoxy-N,N-dimethyltryptamine, 247
methysergide, 247
respiratory control, 247
serotonin, 247
Head shakes
abstinence, 115
DNLAAM, 115
LAAM, 115
lever pressing, 115
methadone, 115
morphine, 115
NLAAM, 115
REM sleep, 115
self-administration, 115
Heart
cardiovascular effects of alcohol, s37
Heart rate
blood pressure, 851
exercise, 851
hexamethonium, 851
monkey, 851
Hemicholinium-3
acetylcholine, 89
atropine sulfate, 89
intracerebral infusion, 89
sexual behavior, 89
Heroin
adjunctive behavior, 457
baboon, 729
choice, 729
drug abuse, 729
eating, 729
economics, 729
intracranial selfstimulation and reward, s245
naloxone, 457
schedule, 457
self-administration, 457
Hexamethonium
blood pressure, 851
exercise, 851
heart rate, 851
monkey, 851
Hippocampal proteins
L-fucose, 765
memory, 765
shuttle box, 765
Y-maze, 765
Hippocampal slices
dopamine, 303
L-fucose, 303
D-mannose, 303
proteins, 303
Hippocampus
acetylcholine, 21
afterdischarge thresholds, 695
amphetamine isomers, 365
amygdala, 695
brightness discrimination, 21
choline, 21
cocaine, 695
dorsal tegmentum, 365
focal brain stimulation, 695
incorporation, 21
kindling, 695
lateral hypothalamus, 365
limbic system, 695
locomotor activity, 365
long-term memory, 21
methysergide, 365
prefrontal cortex, 365
self-stimulation, 365
sensitization, 695
septum, 695
serotonin, 365
temporal lobe epilepsy, 695
uptake, 21
Histamine
β-glucuronidase, 41
lysosomes, 41
stomach, 41
stress ulcers, 41
zinc, 41
Hormonal changes
alcohol intoxication and withdrawal, s131
ethanol infusion in normal subjects, s145
naloxone and ethanol effects, s145
Hormone
ACTH, 823
angiotensin II, 229, 359, 581
bombesin, 229
cholecystokinin, 125
corticosteroid, 27
corticosterone, 719
cortisol, 663
cyclo(Leu-Gly), s279
dihydrotestosterone, 57
epinephrine, s67
estradiol, 57
LH, 663
LHRH, 913
MIF, 37, 799, 901, 907
MSH, 37
oxytocin, s257, s285
prolactin, 663
renin, 719
substance P, 229
testosterone, 663
vasopressin, s257, s279, s285
Human
menstrual cycle, 737
olfactory influences, 737
Human erythrocytes
aldehyde dehydrogenase, 295
blood acetaldehyde, 295
ethanol sensitivity, 295
6-Hydroxydopa
activity, 863
equilibrium, 863
female rat, 863
habituation, 863
neonatal, 863
norepinephrine, 863
sexual behavior, 863
6-Hydroxydopamine
activity, 371
amphetamine, 391, 621
animal model of parkinsonism, 187
apomorphine, 371
atropine sulfate, 187
barbiturate sensitivity, 733
behavioral inhibitory actions, 97
bicuculline methiodide, 561
catecholamines, 97, 621
caudate nucleus, 97
desipramine, 733, 915
development, 371
developmental disturbances, 391
5,6-dihydroxytryptamine, 915
diisopropylfluorophosphate, 187
DOM, 621
dopamine, 391, 733
dopamine receptor binding, 187
dopamine uptake, 915

6-Hydroxydopamine (continued)
EEG, 733
escape performance, 371
GABA, 561
hallucinogens, 621
inhibitory motor conditioning, 97
learning, 97
locomotion, 187
LSD, 621
maternal behavior, 391
methohexital, 733
α-methyltyrosine, 733
muscarinic receptor binding, 187
nomifensine, 915
norepinephrine, 733
operant behavior, 621
picrotoxin, 561
rotation, 915
rotational behavior, 561
stereotypy, 187
subsensitivity, 187
substantia nigra, 561
supersensitivity, 187
thermoregulation, 187
5-Hydroxytryptophan
amitriptyline, 575
animal model of depression, 575
5,7-dihydroxytryptamine, 247
fluoxetine, 575
halothane, 247
5-methoxy-N,N-dimethyltryptamine, 247
methysergide, 247, 575
receptors, 575
respiratory control, 247
serotonin, 247, 575
Hypnotics
antidepressants, 299
antihistamines, 299
electroconvulsive shock, 299
tonic seizures, 299
Hypogonadisim
alcohol and sexual function, s125
Hypophysectomy
light cycle, 901
MIF-I, 901
pineal gland, 901
radioimmunoassay, 901
Hypothalamus
body weight, 461
dopamine, 461
lesions, 461
LHRH, 913
norepinephrine, 461
obesity, 461
pituitary, 913
rhesus monkey, 461
sexual behavior, 913
Hypothermia
apomorphine, 633
cyclo(Leu-Gly), 633
dopamine, 633
haloperidol, 633
locomotor activity, 633
neuroleptics, 633
receptors, 633
supersensitivity, 633
tardive dyskinesia, 633

Imipramine
aggression, 153
amitriptyline, 379
chronic amphetamine treatment, 379
clonidine, 153, 643
DRL, 691
drug-behavior interactions, 691
fenfluramine, 643
fluoxetine, 643
iprindole, 153
metergoline, 643
mianserin, 153, 643
olfactory bulbectomy, 643
operant behavior, 691
passive avoidance learning, 643
quipazine, 643
response depression, 379
schedule parameters, 691
self-stimulation, 379
substantia nigra, 379
Immobilization stress
age, 129
chronic indwelling catheter, 129
epinephrine, 129
estrous cycle, 129
norepinephrine, 129
Imprinting
atropine, 673
methysergide, 673
morphine, 673
naloxone, 673
opioids, 673
pilocarpine, 673
quipazine, 673
social comfort, 673
Inbred mice
activity, 443
antinociception, 443
ketamine, 443
Incorporation
acetylcholine, 21
brightness discrimination, 21
choline, 21
hippocampus, 21
long-term memory, 21
uptake, 21
Indomethacin
drinking, 787
prostaglandin E_{1}, 787
Influence of schedule
nicotine, 215
operant behavior, 215
self-administration, 215
Inhibitory motor conditioning
behavioral inhibitory actions, 97
catecholamines, 97
caudate nucleus, 97
6-hydroxydopamine, 97
learning, 97
Inosine
benzodiazepine receptor, 337
nicotinamide, 337
pentylenetetrazol, 337
Interobserver agreement
blind observer, 243
data-recording procedures, 243
observational dependent variable, 243
pharmacological independent variable, 243
Interpellet distributions
adjunctive behavior, 657
amphetamine, 657
chlorpromazine, 657
diazepam, 657
drinking, 657
fixed interval, 657

Intracellular recording
ethanol and electrophysiology, s203
Intracerebral infusion
acetylcholine, 89
atropine sulfate, 89
hemicholinium-3, 89
sexual behavior, 89
Intracerebroventricular injection
cholecystokinin, 125
labyrinthectomy, 125
rotation, 125
toxicity, 125
Intracranial injection
angiotensin II, 581
drinking, 581
lateral preoptic area, 581
Intralobular oxygen gradient
liver and ethanol, s41
Iontophoresis
angiotensin II, 359
medial preoptic area, 359
septum, 359
Iprindole
aggression, 153
clonidine, 153
imipramine, 153
mianserin, 153
Isoelectric focusing
serum transferrin assay, s47
Iron-loading
ethanol, 325
porphyrin metabolism, 325
vitamine E, 325

Ketamine
activity, 443
amphetamine, 1, 647
antinociception, 443
cumulative dose-response, 647
fixed-ratio, 647
inbred mice, 443
morphine, 647
operant behavior, 1
pentobarbital, 1, 647
phencyclidine, 647
pigeon, 1
punishment, 1
Kidney
gel filtration, 537
liver, 537
mercury, 537
plasma, 537
rabbit, 537
selenium, 537
stroma-free hemolysate, 537
tissue-soluble fraction, 537
Kindling
afterdischarge thresholds, 695
alcohol withdrawal seizures, s225
amygdala, 695
cocaine, 695
focal brain stimulation, 695
hippocampus, 695
limbic system, 695
sensitization, 695
septum, 695
temporal lobe epilepsy, 695
Kinesics
amphetamine, 121
proximics, 121
rhesus monkey, 121
ripple effect, 121
social behavior, 121
spacing, 121
Δ^9-tetrahydrocannabinol, 121
Kynurenines
audiogenic excitement, 9
convulsants, 9
pentylenetetrazol, 17
quinolinic acid, 17
seizures, 17
strychnine, 17
thiosemicarbazide, 17
tryptophan metabolites, 9

LAAM
abstinence, 115
DNLAAM, 115
head shakes, 115
lever pressing, 115
methadone, 115
morphine, 115
NLAAM, 115
REM sleep, 115
self-administration, 115
Labyrinthectomy
cholecystokinin, 125
intracerebroventricular injection, 125
rotation, 125
toxicity, 125
Lateral hypothalamus
amphetamine, 555
amphetamine isomers, 365
animal models, 555
dorsal tegmentum, 365
drug-induced depression, 555
haloperidol, 555
hippocampus, 365
locomotor activity, 365
methysergide, 365
naloxone, 739
periaqueductal gray, 739
prefrontal cortex, 365
self-stimulation, 365, 555, 739
serotonin, 365
Lateral preoptic area
angiotensin II, 581
drinking, 581
intracranial injection, 581
Lead
2-deoxyglucose, 507
drinking, 507
LiCl, 507
NaCl, 507
saccharin, 507
taste aversion, 507
toxicants, 507
Lead acetate
conditioned taste aversion, 133
toxicity, 133
Learning
behavioral inhibitory actions, 97
catecholamines, 97
caudate nucleus, 97
dopamine, 859
6-hydroxydopamine, 97
inhibitory motor conditioning, 97
pimozone, 859
simultaneous discrimination, 859
Lesions
amphetamine, 817
apomorphine, 817

Lesions (continued)
body weight, 461
dopamine, 461
fenfluramine, 817
hypothalamus, 461
5-methoxy-N,N-dimethyltryptamine, 817
norepinephrine, 461
obesity, 461
quipazine, 817
raphe nuclei, 817
rhesus monkey, 461
rotation, 817
Lethality
aggregation, 475
convulsions, 475
morphine, 475
stess, 475
Levels of processing
free recall, 199
linguistic information, 199
marijuana, 199
memory, 199
Lever pressing
abstinence, 115
amphetamine, 887
conditioned discrimination, 887
DNLAAM, 115
head shakes, 115
LAAM, 115
methadone, 115
monkey, 887
morphine, 115
multiple schedule, 887
NLAAM, 115
pentobarbital, 887
phencyclidine, 887
REM sleep, 115
repeated acquisition, 887
self-administration, 115
signal detection analysis, 887
LH
cortisol, 663
dopamine, 663
grooming, 663
naltrexone, 663
prolactin, 663
sexual behavior, 663
talapoin monkey, 663
testosterone, 663
LHRH
hypothalamus, 913
pituitary, 913
sexual behavior, 913
LiCl
animal models of alcoholism, 77
anxiolytic drugs, 761
conditioned taste aversion, 77, 761
conflict tests, 761
2-deoxyglucose, 507
drinking, 507
ethanol, 77
ethanol dose-response, 77
lead, 507
NaCl, 507
pentobarbital, 761
repeated aversion conditioning trials, 77
saccharin, 77, 507
taste aversion, 507
toxicants, 507
Light cycle
hypophysectomy, 901
MIF-I, 901
pineal gland, 901
radioimmunoassay, 901
Light ⇌ dark chamber transitions
anxiolytic, 167
benzodiazepines, 167
chlordiazepoxide, 167
clonazepam, 167
exploration, 167
locomotion, 167
sedation, 167
Limbic system
afterdischarge thresholds, 695
amygdala, 695
cocaine, 695
focal brain stimulation, 695
hippocampus, 695
kindling, 695
sensitization, 695
septum, 695
temporal lobe epilepsy, 695
Linguistic information
free recall, 199
levels of processing, 199
marijuana, 199
memory, 199
Lipid-protein interactions
membrane structure, s155
Liposomes
synaptic glutamate receptors and ethanol, s197
Liquid diet
blood levels, 781
ethanol, 781
physical dependence, 781
silastic, 781
Sustacal, 781
sustained release, 781
Lithium
affective disorders, 205
erythrocytes, 205
manic-depressives, 205
potassium, 205
sodium, 205
Liver
alcohol and intralobular oxygen gradient, s41
ethanol and tryptophan oxygenase and tyrosine aminotransferase, s139
gamma glutamyltranspeptidase and alcoholism, s95
gel filtration, 537
kidney, 537
mercury, 537
mitochondria ATP synthesis and ethanol, s63
peroxisomes and aldehyde dehydrogenase, s111
plasma, 537
rabbit, 537
regeneration and ethanol metabolism, s83
selenium, 537
stroma-free hemolysate, 537
tissue-soluble fraction, 537
Liver disease
hereditary aspects of alcoholism, s89
Liver injury
protein metabolism, s17
Locomotion
amphetamine, 895
animal model of parkinsonism, 187
anxiolytic, 167
atropine sulfate, 187
benzodiazepines, 167
chlordiazepoxide, 167
clonazepam, 167
diisopropylfluorophosphate, 187
dopamine receptor binding, 187

Locomotion (continued)
DSIP, 895
exploration, 167
6-hydroxydopamine, 187
light ⇌ dark chamber transitions, 167
muscarinic receptor binding, 187
sedation, 167
sleep, 895
stereotypy, 187
subsensitivity, 187
supersensitivity, 187
temperature, 895
thermoregulation, 187
Locomotor activity
amphetamine, 835
amphetamine isomers, 365
apomorphine, 409, 633
ataxia, 835
catalepsy, 45
cocaine, 69
cyclo(Leu-Gly), 633
developmental psychopharmacology, 45
L-DOPA, 409
dopamine, 633
dopamine depletion, 409
dorsal tegmentum, 365
ethanol, 777
excitatory effect, 777
haloperidol, 409, 633
hippocampus, 365
hypothermia, 633
lateral hypothalamus, 365
methylamphetamine, 409
methylphenidate, 835
methysergide, 365
morphine, 45
neuroleptics, 633
norcocaine, 69
operant behavior, 69
phencyclidine, 835
prefrontal cortex, 365
receptors, 633
reserpine, 835
self-administration, 69
self-stimulation, 365
serotonin, 365
stereotyped gnawing/mouthing, 45
stereotypy, 835
supersensitivity, 633
tardive dyskinesia, 633
tolerance, 777
Long-term memory
acetylcholine, 21
brightness discrimination, 21
choline, 21
hippocampus, 21
incorporation, 21
uptake, 21
LSD
amphetamine, 621
catecholamines, 621
p-chloroamphetamine, 569
p-chlorophenylalanine, 569
depletion, 569
5,7-dihydroxytryptamine, 569
DOM, 621
drug discrimination, 549, 569
hallucinogens, 621
6-hydroxydopamine, 621
methergoline, 549
non-psychedelics, 549
operant behavior, 621
pigeon, 549
psychedelics, 549
serotonin, 569
supersensitivity, 569
Lysosomes
β-glucuronidase, 41
histamine, 41
stomach, 41
stress ulcers, 41
zinc, 41

Male rat
clozapine, 57
dihydrotestosterone, 57
dopamine, 57
estradiol, 57
fluoxetine, 57
5-methoxy-N,N-dimethyltryptamine, 57
serotonin, 57
sexual behavior, 57
spiperone, 57
Manic-depressives
affective disorders, 205
erythrocytes, 205
lithium, 205
potassium, 205
sodium, 205
D-Mannose
dopamine, 303
L-fucose, 303
hippocampal slices, 303
proteins, 303
MAO
audiogenic seizures, 589
brain methyltransferases, 589
mouse strains, 589
Marijuana
free recall, 199
levels of processing, 199
linguistic information, 199
memory, 199
Maternal behavior
amphetamine, 391
developmental disturbances, 391
dopamine, 391
6-hydroxydopamine, 391
Maze running
development, 883
enkephalin, 883
enzyme activity, 883
neonatal, 883
radioimmunoassay, 883
Medial preoptic area
acetylcholine, 81
angiotensin II, 359
bethanechol, 81
carbachol, 81
iontophoresis, 359
mesencephalic reticular formation, 81
muscarinic receptors, 81
neocortex, 81
septum, 359
sexual behavior, 81
Median raphe nucleus
catecholamines, 525
electrode placement, 525
neurochemical basis, 525
self-stimulation, 525
serotonin, 525
Membrane properties
ethanol and synaptic glutamate receptors, s197

Membrane properties (continued)
lipid-protein interactions, s155
phospholipid methylation and signal transmission, s167
Memory
amnesia, 805
amphetamine, 193
antiadrenergic, 805
biogenic amines, 805
cycloheximide, 193
diethyldithiocarbamate, 805
dopamine, 193
free recall, 199
L-fucose, 765
guanethidine, 805
hippocampal proteins, 765
levels of processing, 199
linguistic information, 199
marijuana, 199
mouse strains, 193
norepinephrine, 193
shuttle box, 765
Y-maze, 765
Memory storage processes
amnesia, 257
avoidance training, 257
electroshock, 257
norepinephrine, 257
stress, 257
Menstrual cycle
human, 737
olfactory influences, 737
Mercury
gel filtration, 537
kidney, 537
liver, 537
plasma, 537
rabbit, 537
selenium, 537
stroma-free hemolysate, 537
tissue-soluble fraction, 537
Mescaline
naloxone, 601
operant behavior, 601
Mesencephalic reticular formation
acetylcholine, 81
bethanechol, 81
carbachol, 81
medial preoptic area, 81
muscarinic receptors, 81
neocortex, 81
sexual behavior, 81
Metabolic compartmentation
behavior, 843
branched chain fatty acids, 843
GABA, 843
di-n-propylacetate, 843
quasi-morphine abstinence, 843
Methadone
abstinence, 115
DNLAAM, 115
head shakes, 115
LAAM, 115
lever pressing, 115
morphine, 115
NLAAM, 115
opiates, 919
REM sleep, 115
self-administration, 115
self-stimulation, 919
Methergoline
clonidine, 643
drug discrimination, 549
fenfluramine, 643
fluoxetine, 643
imipramine, 643
LSD, 549
mianserin, 643
non-psychedelics, 549
olfactory bulbectomy, 643
passive avoidance learning, 643
pigeon, 549
psychedelics, 549
quipazine, 643
Method
gel filtration of plasma to detect mercury and selenium levels, 537
protection from shock-induced seizures as a measure of hypnotic potency of drugs, 299
radioimmunoassay, 883, 901
rapid method for the regional dissection of the rat brain ,453
subcutaneous silastic implants: maintenance of high blood ethanol levels in rats drinking a liquid diet, 781
titration procedure with rats using a nose poke response and tail shock, 653
using profiles of saccharin and water drinking to detect and discriminate actions of drugs and toxicants, 507
Methohexital
barbiturate sensitivity, 733
desipramine, 733
dopamine, 733
EEG, 733
6-hydroxydopamine, 733
α-methyltyrosine, 733
norepinephrine, 733
5-Methoxy-N,N-dimethyltryptamine
amphetamine, 817
apomorphine, 817
clozapine, 57
dihydrotestosterone, 57
5,7-dihydroxytryptamine, 247
dopamine, 57
estradiol, 57
fenfluramine, 817
fluoxetine, 57
halothane, 247
5-hydroxytryptophan, 247
lesions, 817
male rat, 57
methysergide, 247
quipazine, 817
raphe nuclei, 817
respiratory control, 247
rotation, 817
serotonin, 57, 247
sexual behavior, 57
spiperone, 57
Methylamphetamine
apomorphine, 409
L-DOPA, 409
dopamine depletion, 409
haloperidol, 409
locomotor activity, 409
Methylphenidate
amphetamine, 835
ataxia, 835
extinction, 467
locomotor activity, 835
phencyclidine, 835
reserpine, 835
signalled reinforcement, 467
stereotypy, 835
stimulus control, 467
α-Methyltyrosine
barbiturate sensitivity, 733

α-Methyltyrosine (continued)
catecholamines, 137
conditioned avoidance behavior, 137
desipramine, 733
disulfiram, 137
L-DOPA, 137
dopamine, 733
EEG, 733
6-hydroxydopamine, 733
methohexital, 733
norepinephrine, 733
TRH, 137
Methysergide
amitriptyline, 575
amphetamine isomers, 365
animal model of depression, 575
atropine, 673
5,7-dihydroxytryptamine, 247
dorsal tegmentum, 365
fluoxetine, 575
halothane, 247
hippocampus, 365
5-hydroxytryptophan, 247, 575
imprinting, 673
lateral hypothalamus, 365
locomotor activity, 365
5-methoxy-N,N-dimethyltryptamine, 247
morphine, 673
naloxone, 673
opioids, 673
pilocarpine, 673
prefrontal cortex, 365
receptors, 575
respiratory control, 247
quipazine, 673
self-stimulation, 365
serotonin, 247, 365, 575
social comfort, 673
Mianserin
aggression, 153
clonidine, 153, 643
fenfluramine, 643
fluoxetine, 643
imipramine, 153, 643
iprindole, 153
metergoline, 643
olfactory bulbectomy, 643
passive avoidance learning, 643
quipazine, 643
Mice
aggression, 287
motor activity, 287
n-D-propylacetate, 287
psychotropic drugs, 287
MIF
apomorphine, 37
autoreceptor, 37
MSH, 37
tardive dyskinesia, 37
MIF-I
analgesia, 907
frog righting, 907
guinea pig ileum, 907
hypophysectomy, 901
light cycle, 901
morphine, 799
naloxone, 907
Pavlovian conditioning, 799
pineal gland, 901
pituitary, 907
radioimmunoassay, 901
Straub tail, 907
tail-flick, 907
tolerance, 799
withdrawal, 907
Mongolian gerbil
acetylcholinesterase, 519
choline acetyltransferase, 519
scent marking behavior, 519
scopolamine, 519
Monkey
amphetamine, 177, 887
blood pressure, 851
competition, 177
conditioned discrimination, 887
diazepam, 177
dominance hierarchy, 177
exercise, 851
food-getting, 177
heart rate, 851
hexamethonium, 851
lever pressing, 887
multiple schedule, 887
pentobarbital, 887
phencyclidine, 887
repeated acquisition, 887
signal detection analysis, 887
social behavior, 177
Monoamine oxidase
CNS stimulants, 513
cocaine cue, 513
dopamine, 513
drug discrimination, 513
β-phenylethylamine, 513
Morphine
abstinence, 115
acetylcholine, 421
adenosine, 421
aggregation, 475
amphetamine, 647
analgesia, 705, 829
anti-epileptic opiates, 343
atropine, 673
behavioral activation, 585
caffeine, 421
catalepsy, 45
catecholamines, 435
cerebral cortex, 421
cold water swims, 829
collateral inhibition, 829
conditioned flavor aversion, 501
conditioned location preference, 501
convulsions, 343, 475
cumulative dose-response, 647
developmental psychopharmacology, 45
DNLAAM, 115
β-endorphin, 435
enkephalin, 829
fixed-ratio, 647
glutamic acid, 705
head shakes, 115
norepinephrine, 705
imprinting, 673
ketamine, 647
LAAM, 115
lethality, 475
lever pressing, 115
locomotor activity, 45
methadone, 115
methysergide, 673
MIF-I, 799
modulation of endorphin activity, s265
naloxone, 421, 435, 501, 673
naloxone antagonism, 585

Morphine (continued)
NLAAM, 115
opioids, 673
pain, 829
Pavlovian conditioning, 799
pentamethylenetetrazol, 343
pentobarbital, 647
phencyclidine, 647
D-phenylalanine, 829
pilocarpine, 673
quipazine, 673
raphe nuclei, 705
reinforcement, 501
REM sleep, 115
selective association, 501
self-administration, 115
serotonin, 705
sexual behavior, 435
social comfort, 673
spinal cord, 705
stereotyped gnawing/mouthing, 45
stress, 475
theophylline, 421
tolerance, 799
Morphine tolerance
neurohypophyseal peptide involvement, s257
Motor activity
aggression, 287
aging, 155
amphetamine, 155
catecholamines, 155
cholinergic-dopaminergic balance, 385
development, 155
dopaminergic mechanisms, 385
mice, 287
pentylamine, 385
n-D-propylacetate, 287
psychotropic drugs, 287
Motor behavior
apomorphine, 397
stereotypy, 397
striatum, 397
thioridazine, 397
Mouse strains
amphetamine, 193
audiogenic seizures, 589
brain methyltransferases, 589
cycloheximide, 193
dopamine, 193
MAO, 589
memory, 193
norepinephrine, 193
Movement initiation
caudate nucleus, 5
conditioned avoidance, 5
dopamine, 5
receptor, 5
MSH
apomorphine, 37
autoreceptor, 37
MIF, 37
tardive dyskinesia, 37
Multiple schedule
amphetamine, 887
conditioned discrimination, 887
lever pressing, 887
monkey, 887
pentobarbital, 887
phencyclidine, 887
repeated acquisition, 887
signal detection analysis, 887

Muscarinic receptor binding
animal model of parkinsonism, 187
atropine sulfate, 187
diisopropylfluorophosphate, 187
dopamine receptor binding, 187
6-hydroxydopamine, 187
locomotion, 187
stereotypy, 187
subsensitivity, 187
supersensitivity, 187
thermoregulation, 187
Muscarinic receptors
acetylcholine, 81
bethanechol, 81
carbachol, 81
medial preoptic area, 81
mesencephalic reticular formation, 81
neocortex, 81
sexual behavior, 81
Myoclonus
caudate nucleus, 103
enkephalin, 103
D-Ala^2-Met^5-enkephalinamide, 103
haloperidol, 103
naloxone, 103
nucleus accumbens, 103
substantia nigra compacta, 103

NaCl
2-deoxyglucose, 507
drinking, 507
lead, 507
LiCl, 507
saccharin, 507
taste aversion, 507
toxicants, 507
$Na^+ + K^+$-ATPase
catecholamine-ethanol interactions, s183
Naloxone
acetylcholine, 421
adenosine, 421
adjunctive behavior, 457
analgesia, 715, 907
atropine, 673
aversion to alcohol, s269
bacitracin, 715
caffeine, 421
catecholamines, 435
caudate nucleus, 103
cerebral cortex, 421
conditioned flavor aversion, 501
conditioned location preference, 501
endorphin, 715
β-endorphin, 435
enkephalin, 103, 715
D-Ala^2-Met^5-enkephalinamide, 103
enkephalinase, 715
ethanol and dopaminergic system, s303
ethanol and hormonal effects in normal subjects, s145
frog righting, 907
guinea pig ileum, 907
haloperidol, 103
heroin, 457
imprinting, 673
lateral hypothalamus, 739
mescaline, 601
methysergide, 673
MIF-I, 907
morphine, 421, 435, 501, 673
myoclonus, 103

Naloxone (continued)
nucleus accumbens, 103
operant behavior, 601
opioids, 673
periaqueductal gray, 739
pilocarpine, 673
pituitary, 907
quipazine, 673
reinforcement, 501
schedule, 457
selective association, 501
self-administration, 457
self-stimulation, 739
sexual behavior, 435
social comfort, 673
Straub tail, 907
substantia nigra compacta, 103
tail-flick, 907
theophylline, 421
withdrawal, 907
Naloxone antagonism
behavioral activation, 585
morphine, 585
Naltrexone
cortisol, 663
dopamine, 663
grooming, 663
LH, 663
prolactin, 663
sexual behavior, 663
talapoin monkey, 663
testosterone, 663
Neocortex
acetylcholine, 81
bethanechol, 81
carbachol, 81
medial preoptic area, 81
mesencephalic reticular formation, 81
muscarinic receptors, 81
sexual behavior, 81
Neonatal
activity, 863
development, 883
enkephalin, 883
enzyme activity, 883
equilibrium, 863
female rat, 863
habituation, 863
6-hydroxydopa, 863
maze running, 883
norepinephrine, 863
radioimmunoassay, 883
sexual behavior, 863
Neurochemical basis
catecholamines, 525
electrode placement, 525
median raphe nucleus, 525
self-stimulation, 525
serotonin, 525
Neurohypophyseal peptides
ethanol tolerance, s257, s279, s285
Neuroleptics
apomorphine, 633
cyclo(Leu-Gly), 633
dopamine, 633
haloperidol, 633
hypothermia, 633
locomotor activity, 633
receptors, 633
supersensitivity, 633
tardive dyskinesia, 633
Neuromuscular junction
acute response, 811
animal model, 811
ataxia, 811
ethanol, 811
residual latency, 811
synaptic delay, 811
Neuronal metabolism
ethanol effects, s175
Nicotinamide
benzodiazepine receptor, 337
inosine, 337
pentylenetetrazol, 337
Nicotine
change in dosage, 209
food delivery schedule, 209
influence of schedule, 215
operant behavior, 215
self-administration, 209, 215
urinary pH, 209
Nigrostriatal system
amphetamine, 743
postural asymmetry, 743
rotation, 743
NLAAM
abstinence, 115
DNLAAM, 115
head shakes, 115
LAAM, 115
lever pressing, 115
methadone, 115
morphine, 115
REM sleep, 115
self-administration, 115
Nomifensine
desipramine, 915
5,6-dihydroxytryptamine, 915
dopamine uptake, 915
6-hydroxydopamine, 915
rotation, 915
Non-psychedelics
drug discrimination, 549
LSD, 549
methergoline, 549
pigeon, 549
psychedelics, 549
Norcocaine
cocaine, 69
locomotor activity, 69
operant behavior, 69
self-administration, 69
Norepinephrine
activity, 863
age, 129
amnesia, 257
amphetamine, 193, 235
analgesia, 705
avoidance training, 257
barbiturate sensitivity, 733
body weight, 461
brain perfusion, 235
chronic indwelling catheter, 129
cycloheximide, 193
desipramine, 733
dopamine, 107, 193, 235, 461, 733
EEG, 733
electroshock, 257
epinephrine, 107, 129
equilibrium, 863
estrous cycle, 129
female rat, 863
glutamic acid, 705

Norepinephrine (continued)
habituation, 863
6-hydroxydopa, 863
6-hydroxydopamine, 733
hypothalamus, 461
immobilization stress, 129
lesions, 461
memory, 193
memory storage processes, 257
methohexital, 733
α-methyltyrosine, 733
morphine, 705
mouse strains, 193
neonatal, 863
obesity, 107
operant behavior, 235
phenoxybenzamine, 51
phentolamine, 51
prostaglandin, 235
raphe nuclei, 705
REM sleep rebound, 51
rhesus monkey, 461
serotonin, 705
sexual behavior, 863
spinal cord, 705
stress, 107, 257, 461
sympathoadrenal function, 107
thermogenesis, 107
Zucker rat, 107
Nose poke response
operant titration technique, 653
tail shock, 653
NSP
ACTH, 823
brain protein synthesis, 823
brain specific protein, 823
S-100, 823
Nucleus accumbens
caudate nucleus, 103
enkephalin, 103
D-Ala^2-Met^5-enkephalinamide, 103
haloperidol, 103
myoclonus, 103
naloxone, 103
substantia nigra compacta, 103

Obesity
body weight, 461
dopamine, 107, 461
epinephrine, 107
hypothalamus, 461
lesions, 461
norepinephrine, 107, 461
rhesus monkey, 461
stress, 107
sympatho-adrenal function, 107
thermogenesis, 107
Zucker rat, 107
Observational dependent variable
blind observer, 243
data-recording procedures, 243
interobserver agreement, 243
pharmacological independent variable, 243
Olfactory bulbectomy
clonidine, 643
fenfluramine, 643
fluoxetine, 643
imipramine, 643
metergoline, 643
mianserin, 643
passive avoidance learning, 643
quipazine, 643
Olfactory influences
human, 737
menstrual cycle, 737
Operant behavior
amphetamine, 1, 235, 621
brain perfusion, 235
catecholamines, 621
p-chlorophenylalanine, 605
cocaine, 69
diaminodiphenoxybutane, 429
2,5-dimethoxy-4-methylamphetamine, 605
DOM, 621
dopamine, 235
DRL, 691
drug-behavior interactions, 691
electroretinogram, 429
hallucinogens, 621
6-hydroxydopamine, 621
imipramine, 691
influence of schedule, 215
ketamine, 1
locomotor activity, 69
LSD, 621
mescaline, 601
naloxone, 601
nicotine, 215
norcocaine, 69
norepinephrine, 235
pentobarbital, 1
pigeon, 1
prostaglandin, 235
punishment, 1
retinotoxicity, 429
schedule parameters, 691
self-administration, 69, 215
serotonin, 605
visual evoked potential, 429
Operant titration technique
nose poke response, 653
tail shock, 653
Opiates
action on brain reward systems, s213
methadone, 919
self-stimulation, 919
Opioids
atropine, 673
imprinting, 673
methysergide, 673
morphine, 673
naloxone, 673
pilocarpine, 673
quipazine, 673
social comfort, 673
Oral administration
amphetamine, 31
conditioned taste aversion, 31
Ornithine decarboxylase
regenerating liver and ethanol, s83
Oxytocin
involvement in tolerance to drugs, s257, s285

Pain
amphetamine, 171
analgesia, 171, 829
apomorphine, 171
cold-water swims, 171, 829
collateral inhibition, 829
2-deoxy-D-glucose, 171
enkephalin, 829

Pain (continued)
morphine, 829
D-phenylalanine, 829
stress, 171
Passive avoidance learning
clonidine, 643
fenfluramine, 643
fluoxetine, 643
imipramine, 643
metergoline, 643
mianserin, 643
olfactory bulbectomy, 643
quipazine, 643
Pavlovian conditioning
MIF-I, 799
morphine, 799
tolerance, 799
Pecking
apomorphine, 331
chicks, 331
ethological analysis, 331
stimulus preference, 331
Pemoline
deLange syndrome, 627
grooming, 627
self-multilation, 627
stereotypy, 627
Pentamethylenetetrazol
anti-epileptic opiates, 343
convulsions, 343
morphine, 343
Pentobarbital
amphetamine, 1, 349, 647, 887
anxiolytic drugs, 761
chlordiazepoxide, 545
conditioned discrimination, 887
conditioned taste aversion, 761
conflict tests, 761
cross-tolerance, 545
cumulative dose-response, 647
drug interaction, 349
ethanol, 349
fixed-ratio, 647
ketamine, 1, 647
lever pressing, 887
LiCl, 761
monkey, 887
morphine, 647
multiple schedule, 887
operant behavior, 1
phencyclidine, 647, 887
pigeon, 1, 349, 545
punishment, 1
repeated acquisition, 887
schedule-controlled behavior, 349, 545
signal detection analysis, 887
tolerance, 545
Pentylamine
cholinergic-dopaminergic balance, 385
dopaminergic mechanisms, 385
motor activity, 385
Pentylenetetrazol
benzodiazepine receptor, 337
benzodiazepines, 415
CNS stimulation, 415
drug abuse, 415
drug overdose, 415
flurazepam, 415
kynurenine, 17
inosine, 337
nicotinamide, 337
quinolinic acid, 17
seizures, 17
strychnine, 17
thiosemicarbazide, 17
Periaqueductal gray
lateral hypothalamus, 739
naloxone, 739
self-stimulation, 739
Pharmacogenetics
acute tolerance, 773
analgesia, 773
ethanol, 773
shock response, 773
startle response, 773
Pharmacokinetics
chronopharmacokinetics, 637
circadian rhythms, 637
clearance rates, 637
eating, 637
ethanol, 637
feeding restriction, 637
phase shifts, 637
Pharmacological independent variable
blind observer, 243
data-recording procedures, 243
interobserver agreement, 243
observational dependent variable, 243
Phase shifts
chronopharmacokinetics, 637
circadian rhythms, 637
clearance rates, 637
eating, 637
ethanol, 637
feeding restriction, 637
pharmacokinetics, 637
Phencyclidine
amphetamine, 647, 835, 887
ataxia, 835
conditioned discrimination, 887
cumulative dose-response, 647
fixed-ratio, 647
ketamine, 647
lever pressing, 887
locomotor activity, 835
methylphenidate, 835
monkey, 887
morphine, 647
multiple schedule, 887
pentobarbital, 647, 887
repeated acquisition, 887
reserpine, 835
signal detection analysis, 887
stereotypy, 835
Phenoxybenzamine
norepinephrine, 51
phentolamine, 51
REM sleep rebound, 51
Phentolamine
norepinephrine, 51
phenoxybenzamine, 51
REM sleep rebound, 51
D-Phenylalanine
analgesia, 829
cold water swims, 829
collateral inhibition, 829
enkephalin, 829
morphine, 829
pain, 829
β-Phenylethylamine
CNS stimulants, 513
cocaine cue, 513
dopamine, 513
drug discrimination, 513

β-Phenylethylamine (continued)
monoamine oxidase, 513
Phospholipid methylation
signal transmission through membranes, s167
Physical dependence
blood levels, 781
ethanol, 781
liquid diet, 781
silastic, 781
Sustacal, 781
sustained release, 781
Picrotoxin
bicuculline methiodide, 561
GABA, 561
6-hydroxydopamine, 561
rotational behavior, 561
substantia nigra, 561
Pig
aggression, 27
corticosteroids, 27
diazepam, 27
extinction, 27
frustration, 27
response persistence, 27
Pigeon
amphetamine, 1, 349
chlordiazepoxide, 545
cross-tolerance, 545
drug discrimination, 549
drug interaction, 349
ethanol, 349
ketamine, 1
LSD, 549
methergoline, 549
non-psychedelics, 549
operant behavior, 1
pentobarbital, 1, 349, 545
psychedelics, 549
punishment, 1
schedule-controlled behavior, 349, 545
tolerance, 545
Pilocarpine
atropine, 673
imprinting, 673
methysergide, 673
morphine, 673
naloxone, 673
opioids, 673
quipazine, 673
social comfort, 673
Pimozide
dopamine, 859
learning, 859
simultaneous discrimination, 859
Pineal gland
hypophysectomy, 901
light cycle, 901
MIF-I, 901
radioimmunoassay, 901
Pituitary
analgesia, 907
frog righting, 907
guinea pig ileum, 907
hypothalamus, 913
LHRH, 913
MIF-I, 907
naloxone, 907
sexual behavior, 913
Straub tail, 907
tail-flick, 907
withdrawal, 907
Plasma
gel filtration, 537
kidney, 537
liver, 537
mercury, 537
rabbit, 537
selenium, 537
stroma-free hemolysate, 537
tissue-soluble fraction, 537
Plasma levels
amphetamine, 471
catecholamines, 471
chronic indwelling catheter, 471
social interactions, 471
sociopharmacology, 471
Plasma renin
blood urea nitrogen, 719
caffeine, 719
chronic interstitial nephritis, 719
corticosterone, 719
population cage, 719
psychosocial stress, 719
Population cage
blood urea nitrogen, 719
caffeine, 719
chronic interstitial nephritis, 719
corticosterone, 719
plasma renin, 719
psychosocial stress, 719
Porphyrin metabolism
ethanol, 325
iron-loading, 325
vitamin E, 325
Postural asymmetry
amphetamine, 743
nigrostriatal system, 743
rotation, 743
Potassium
affective disorders, 205
erythrocytes, 205
lithium, 205
manic-depressives, 205
sodium, 205
Preference
ethanol, 265
salsolinol, 265
tetrahydroisoquinolines, 265
tetrahydropapaveroline, 265
Prefrontal cortex
amphetamine isomers, 365
dorsal tegmentum, 365
hippocampus, 365
lateral hypothalamus, 365
locomotor activity, 365
methysergide, 365
self-stimulation, 365
serotonin, 365
Pregnancy
decrease in ethanol consumption, s149
Prenatal
acoustic startle reflex, 531
activity, 531
ethanol, 531
fetal alcohol syndrome, 531
Prolactin
cortisol, 663
dopamine, 663
grooming, 663
LH, 663
naltrexone, 663
sexual behavior, 663
talapoin monkey, 663

Prolactin (continued)
testosterone, 663
di-n-Propylacetate
behavior, 843
branched chain fatty acids, 843
GABA, 843
metabolic compartmentation, 843
quasi-morphine abstinence, 843
n-D-Propylacetate
aggression, 287
mice, 287
motor activity, 287
psychotropic drugs, 287
n-Propylnoraporphine
amfonelic acid, 497
amphetamine, 497
apomorphine, 497
dopamine, 497
drug-induced stimuli, 497
Prostaglandin
amphetamine, 235
brain perfusion, 235
dopamine, 235
drinking, 787
indomethacin, 787
norepinephrine, 235
operant behavior, 235
Protein degradation
ethanol and regenerating liver, s83
Protein I
protein phosphorylation, s169
Protein metabolism
liver injury, s17
Protein phosphorylation
protein I, s169
Protein secretion
acetaldehyde and ethanol, s31
Protein synthesis
acetaldehyde and ethanol, s31
Proteins
dopamine, 303
L-fucose, 303
hippocampal slices, 303
D-mannose, 303
Proximics
amphetamine, 121
kinesics, 121
rhesus monkey, 121
ripple effect, 121
social behavior, 121
spacing, 121
Δ^9-tetrahydrocannabinol, 121
Psychedelics
drug discrimination, 549
LSD, 549
methergoline, 549
non-psychedelics, 549
pigeon, 549
Psychosocial stress
blood urea nitrogen, 719
caffeine, 719
chronic interstitial nephritis, 719
corticosterone, 719
plasma renin, 719
population cage, 719
Psychotropic drugs
aggression, 287
mice, 287
motor activity, 287
n-D-propylacetate, 287
Punishment
amphetamine, 1
ketamine, 1
operant behavior, 1
pentobarbital, 1
pigeon, 1

Quasi-morphine abstinence
behavior, 843
branched chain fatty acids, 843
GABA, 843
metabolic compartmentation, 843
di-n-propylacetate, 843
Quinolinic acid
kynurenine, 17
pentylenetetrazol, 17
seizures, 17
strychnine, 17
thiosemicarbazide, 17
Quipazine
amphetamine, 817
apomorphine, 817
atropine, 673
clonidine, 643
fenfluramine, 643, 817
fluoxetine, 643
imipramine, 643
imprinting, 673
lesions, 817
metergoline, 643
5-methoxy-N,N-dimethyltryptamine, 817
methysergide, 673
mianserin, 643
morphine, 673
naloxone, 673
olfactory bulbectomy, 643
opioids, 673
passive avoidance learning, 643
pilocarpine, 673
raphe nuclei, 817
rotation, 817
social comfort, 673

Rabbit
gel filtration, 537
kidney, 537
liver, 537
mercury, 537
plasma, 537
selenium, 537
stroma-free hemolysate, 537
tissue-soluble fraction, 537
Radioimmunoassay
development, 883
enkephalin, 883
enzyme activity, 883
hypophysectomy, 901
light cycle, 901
maze running, 883
MIF-I, 901
neonatal, 883
pineal gland, 901
Raphe nuclei
amphetamine, 817
analgesia, 705
apomorphine, 817
fenfluramine, 817
glutamic acid, 705
lesions, 817
5-methoxy-N,N-dimethyltryptamine, 817
morphine, 705
norepinephrine, 705

Raphe nuclei (continued)
quipazine, 817
rotation, 817
serotonin, 705
spinal cord, 705
Receptors
amitriptyline, 575
animal model of depression, 575
apomorphine, 633
caudate nucleus, 5
conditioned avoidance, 5
cyclo(Leu-Gly), 633
dopamine, 5, 633
fluoxetine, 575
haloperidol, 633
5-hydroxytryptophan, 575
hypothermia, 633
locomotor activity, 633
methysergide, 575
movement initiation, 5
neuroleptics, 633
serotonin, 575
supersensitivity, 633
tardive dyskinesia, 633
Reinforcement
conditioned flavor aversion, 501
conditioned location preference, 501
morphine, 501
naloxone, 501
selective association, 501
REM sleep
abstinence, 115
DNLAAM, 115
head shakes, 115
LAAM, 115
lever pressing, 115
methadone, 115
morphine, 115
NLAAM, 115
self-administration, 115
REM sleep rebound
norepinephrine, 51
phenoxybenzamine, 51
phentolamine, 51
Repeated acquisition
amphetamine, 887
conditioned discrimination, 887
lever pressing, 887
monkey, 887
multiple schedule, 887
pentobarbital, 887
phencyclidine, 887
signal detection analysis, 887
Repeated aversion conditioning trials
animal models of alcoholism, 77
conditioned taste aversion, 77
ethanol, 77
ethanol dose-response, 77
LiCl, 77
saccharin, 77
Reserpine
amphetamine, 835
ataxia, 835
locomotor activity, 835
methylphenidate, 835
phencyclidine, 835
stereotypy, 835
Residual latency
acute response, 811
animal model, 811
ataxia, 811
ethanol, 811
neuromuscular junction, 811
synaptic delay, 811
Respiratory control
5,7-dihydroxytryptamine, 247
halothane, 247
5-hydroxytryptophan, 247
5-methoxy-N,N-dimethyltryptamine, 247
methysergide, 247
serotonin, 247
Response depression
amitriptyline, 379
chronic amphetamine treatment, 379
imipramine, 379
self-stimulation, 379
substantia nigra, 379
Response persistence
aggression, 27
corticosteroids, 27
diazepam, 27
extinction, 27
frustration, 27
pig, 27
Retinotoxicity
diaminodiphenoxybutane, 429
electroretinogram, 429
operant behavior, 429
visual evoked potential, 429
Reward systems
action of drugs of abuse, s213
Rhesus monkey
amphetamine, 121, 869
body weight, 461
dopamine, 461
guinea pig atrium, 869
hypothalamus, 461
kinesics, 121
lesions, 461
norepinephrine, 461
obesity, 461
proximics, 121
ripple effect, 121
self-administration, 869
social behavior, 121
spacing, 121
structure-activity, 869
Δ^9-tetrahydrocannabinol, 121
Ripple effect
amphetamine, 121
kinesics, 121
proximics, 121
rhesus monkey, 121
social behavior, 121
spacing, 121
Δ^9-tetrahydrocannabinol, 121
Rotation
amphetamine, 743, 817
apomorphine, 817
cholecystokinin, 125
desipramine, 915
5,6-dihydroxytryptamine, 915
dopamine uptake, 915
fenfluramine, 817
6-hydroxydopamine, 915
intracerebroventricular injection, 125
labyrinthectomy, 125
lesions, 817
5-methoxy-N,N-dimethyltryptamine, 817
nigrostriatal system, 743
nomifensine, 915
postural asymmetry, 743
quipazine, 817
raphe nuclei, 817

Rotation (continued)
toxicity, 125
Rotational behavior
bicuculline methiodide, 561
GABA, 561
6-hydroxydopamine, 561
picrotoxin, 561
substantia nigra, 561

S-100
ACTH, 823
brain protein synthesis, 823
brain specific protein, 823
NSP, 823
Saccharin
animal models of alcoholism, 77
conditioned taste aversion, 77
2-deoxyglucose, 507
drinking, 507
ethanol, 77
ethanol dose-response, 77
lead, 507
LiCl, 77, 507
NaCl, 507
repeated aversion conditioning trials, 77
taste aversion, 507
toxicants, 507
Salsolinol
ethanol, 265
preference, 265
tetrahydroisoquinolines, 265
tetrahydropapaveroline, 265
Scent marking behavior
acetylcholinesterase, 519
choline acetyltransferase, 519
Mongolian gerbil, 519
scopolamine, 519
Schedule
adjunctive behavior, 457
heroin, 457
naloxone, 457
self-administration, 457
Schedule-controlled behavior
amphetamine, 349
chlordiazepoxide, 545
cross-tolerance, 545
drug interaction, 349
ethanol, 349
pentobarbital, 349, 545
pigeon, 349, 545
tolerance, 545
Schedule-induced
body weight, 877
deprivation-induced, 877
environmental conditions, 877
self-injection, 877
Δ^9-tetrahydrocannabinol, 877
Schedule induced polydipsia
blood ethanol concentration, 291
ethanol concentration, 291
ethanol intake, 291
Schedule parameters
DRL, 691
drug-behavior interactions, 691
imipramine, 691
operant behavior, 691
Scopolamine
acetylcholinesterase, 519
acquisition, 183
active avoidance, 183
choline acetyltransferase, 519
Mongolian gerbil, 519
scent marking behavior, 519
spontaneous locomotor activity, 183
task dependent, 183
tolerance development, 183
Sedation
anxiolytic, 167
benzodiazepines, 167
chlordiazepoxide, 167
clonazepam, 167
exploration, 167
light $\rightleftharpoons$ dark chamber transitions, 167
locomotion, 167
Seizures
kynurenine, 17
pentylenetetrazol, 17
quinolinic acid, 17
strychnine, 17
thiosemicarbazide, 17
Selective association
conditioned flavor aversion, 501
conditioned location preference, 501
morphine, 501
naloxone, 501
reinforcement, 501
Selective breeding
animal models of alcoholism, 449
blood ethanol, 449
ethanol, 449
free-choice ethanol intake, 449
Selenium
gel filtration, 537
kidney, 537
liver, 537
mercury, 537
plasma, 537
rabbit, 537
stroma-free hemolysate, 537
tissue-soluble fraction, 537
Self-administration
abstinence, 115
adjunctive behavior, 457
amphetamine, 869
change in dosage, 209
cocaine, 69
DNLAAM, 115
food delivery schedule, 209
guinea pig atrium, 869
head shakes, 115
heroin, 457
influence of schedule, 215
LAAM, 115
lever pressing, 115
locomotor activity, 69
methadone, 115
morphine, 115
naloxone, 457
nicotine, 209, 215
NLAAM, 115
norcocaine, 69
operant behavior, 69, 215
REM sleep, 115
rhesus monkey, 869
schedule, 457
structure-activity, 869
urinary pH, 209
Self-injection
body weight, 877
deprivation-induced, 877
environmental conditions, 877
schedule-induced, 877
Δ^9-tetrahydrocannabinol, 877

Self-mutilation
deLange syndrome, 627
grooming, 627
pemoline, 627
stereotypy, 627
Self-stimulation
amitriptyline, 379
amphetamine, 555
amphetamine isomers, 365
animal models, 555
catecholamines, 525
chronic amphetamine treatment, 379
dorsal tegmentum, 365
drug-induced depression, 555
electrode placement, 525
haloperidol, 555
hippocampus, 365
imipramine, 379
lateral hypothalamus, 365, 555, 739
locomotor activity, 365
median raphe nucleus, 525
methadone, 919
methysergide, 365
naloxone, 739
neurochemical basis, 525
opiates, 919
periaqueductal gray, 739
prefrontal cortex, 365
response depression, 379
reward and drugs of abuse, s245
serotonin, 365, 525
substantia nigra, 379
Sensitization
afterdischarge thresholds, 695
amygdala, 695
cocaine, 695
focal brain stimulation, 695
hippocampus, 695
kindling, 695
limbic system, 695
septum, 695
temporal lobe epilepsy, 695
Septum
afterdischarge thresholds, 695
amygdala, 695
angiotensin II, 359
cocaine, 695
focal brain stimulation, 695
hippocampus, 695
iontophoresis, 359
kindling, 695
limbic system, 695
medial preoptic area, 359
sensitization, 695
temporal lobe epilepsy, 695
Serotonin
amitriptyline, 575
amphetamine isomers, 365
analgesia, 705
animal model of depression, 575
catecholamines, 525
p-chloroamphetamine, 569
p-chlorophenylalanine, 569, 605
clozapine, 57
depletion, 569
dihydrotestosterone, 57
5,7-dihydroxytryptamine, 247, 569
2,5-dimethoxy-4-methylamphetamine, 605
dopamine, 57
dorsal tegmentum, 365
drug discrimination, 569
electrode placement, 525
estradiol, 57
fluoxetine, 57, 575
glutamic acid, 705
halothane, 247
hippocampus, 365
5-hydroxytryptophan, 247, 575
lateral hypothalamus, 365
locomotor activity, 365
LSD, 569
male rat, 57
median raphe nucleus, 525
5-methoxy-N,N-dimethyltryptamine, 57, 247
methysergide, 247, 365, 575
morphine, 705
neurochemical basis, 525
norepinephrine, 705
operant behavior, 605
prefrontal cortex, 365
raphe nuclei, 705
receptors, 575
respiratory control, 247
self-stimulation, 365, 525
sexual behavior, 57
spinal cord, 705
spiperone, 57
supersensitivity, 569
Serotonin behavioral syndrome
p-chloroamphetamine, 283
halogenated phenethylamines, 283
zimelidine, 283
Serum aspartate transaminase
alcoholism detection, s1
Serum gamma-glutamyl-transpetidase
alcoholism detection, s1
Sexual behavior
acetylcholine, 81, 89
activity, 863
aggression, 221
amphetamine, 221
anorexia, 221
atropine sulfate, 89
behavioral toxicity, 221
bethanechol, 81
carbachol, 81
catecholamines, 435
clozapine, 57
competition, 221
cortisol, 663
dihydrotestosterone, 57
dominance hierarchy, 221
dopamine, 57, 663
β-endorphin, 435
equilibrium, 863
estradiol, 57
female rat, 863
fluoxetine, 57
grooming, 663
habituation, 863
hemicholinium-3, 89
6-hydroxydopa, 863
hypothalamus, 913
intracerebral infusion, 89
LH, 663
LHRH, 913
male rat, 57
medial preoptic area, 81
mesencephalic reticular formation, 81
5-methoxy-N,N-dimethyltryptamine, 57
morphine, 435
muscarinic receptors, 81
naloxone, 435
naltrexone, 663

Sexual behavior (continued)
neocortex, 81
neonatal, 863
norepinephrine, 863
pituitary, 913
prolactin, 663
serotonin, 57
social behavior, 221
spiperone, 57
talapoin monkey, 663
testosterone, 663
Sexual function
ethanol and gonadal atrophy, s125
Shock response
acute tolerance, 773
analgesia, 773
ethanol, 773
pharmacogenetics, 773
startle response, 773
Shuttle box
L-fucose, 765
hippocampal proteins, 765
memory, 765
Y-maze, 765
Sialic acid
serum transferrin in alcoholism, 247
Signal detection analysis
amphetamine, 887
conditioned discrimination, 887
lever pressing, 887
monkey, 887
multiple schedule, 887
pentobarbital, 887
phencyclidine, 887
repeated acquisition, 887
Signalled reinforcement
extinction, 467
methylphenidate, 467
stimulus control, 467
Silastic
blood levels, 781
ethanol, 781
liquid diet, 781
physical dependence, 781
Sustacal, 781
sustained release, 781
Simultaneous discrimination
dopamine, 859
learning, 859
pimozide, 859
Sleep
amphetamine, 895
DSIP, 895
locomotion, 895
temperature, 895
Social behavior
aggression, 221
amphetamine, 121, 177, 221
anorexia, 221
behavioral toxicity, 221
competition, 177, 221
diazepam, 177
dominance hierarchy, 177, 221
food-getting, 177
kinesics, 121
monkey, 177
proximics, 121
rhesus monkey, 121
ripple effect, 121
sexual behavior, 221
spacing, 121
Δ^9-tetrahydrocannabinol, 121
Social comfort
atropine, 673
imprinting, 673
methysergide, 673
morphine, 673
naloxone, 673
opioids, 673
pilocarpine, 673
quipazine, 673
Social interactions
amphetamine, 471
catecholamines, 471
chronic indwelling catheter, 471
plasma levels, 471
sociopharmacology, 471
Sociopharmacology
amphetamine, 471
catecholamines, 471
chronic indwelling catheter, 471
plasma levels, 471
social interactions, 471
Sodium
affective disorders, 205
erythrocytes, 205
lithium, 205
manic-depressives, 205
potassium, 205
Spacing
amphetamine, 121
kinesics, 121
proximics, 121
rhesus monkey, 121
ripple effect, 121
social behavior, 121
Δ^9-tetrahydrocannabinol, 121
Spinal cord
analgesia, 705
glutamic acid, 705
morphine, 705
norepinephrine, 705
raphe nuclei, 705
serotonin, 705
Spiperone
clozapine, 57
dihydrotestosterone, 57
dopamine, 57
estradiol, 57
fluoxetine, 57
male rat, 57
5-methoxy-N,N-dimethyltryptamine, 57
serotonin, 57
sexual behavior, 57
Spontaneous locomotor activity
acquisition, 183
active avoidance, 183
scopolamine, 183
task dependent, 183
tolerance development, 183
Startle response
acute tolerance, 773
analgesia, 773
ethanol, 773
pharmacogenetics, 773
shock response, 773
Stereotyped gnawing/mouthing
catalepsy, 45
developmental psychopharmacology, 45
locomotor activity, 45
morphine, 45
Stereotypy
amphetamine, 793, 835
animal model of parkinsonism, 187

Stereotypy (continued)
apomorphine, 397, 793
ataxia, 835
atropine sulfate, 187
deLange syndrome, 627
diisopropylfluorophosphate, 187
dopamine receptor binding, 187
grooming, 627
6-hydroxydopamine, 187
locomotion, 187
locomotor activity, 835
methylphenidate, 835
motor behavior, 397
muscarinic receptor binding, 187
pemoline, 627
phencyclidine, 835
reserpine, 835
self-multilation, 627
striatum, 397
subsensitivity, 187
supersensitivity, 187
thermoreguiation, 187
thioridazine, 397
tolerance, 793
Stimulants
action on brain reward systems, s213
Stimulus control
extinction, 467
methylphenidate, 467
signalled reinforcement, 467
Stimulus preference
apomorphine, 331
chicks, 331
ethological analysis, 331
pecking, 331
Stimulus properties of drugs
apomorphine, 307
caffeine, 307
cyclic AMP, 307
dopamine, 307
haloperidol, 307
Stomach
β-glucuronidase, 41
histamine, 41
lysosomes, 41
stress ulcers, 41
zinc, 41
Straub tail
analgesia, 907
frog righting, 907
guinea pig ileum, 907
MIF-I, 907
naloxone, 907
pituitary, 907
tail-flick, 907
withdrawal, 907
Stress
aggregation, 475
amnesia, 257
amphetamine, 171
analgesia, 171
apomorphine, 171
avoidance training, 257
cold-water swims, 171
convulsions, 475
2-deoxy-D-glucose, 171
dopamine, 107
electroshock, 257
epinephrine, 107
lethality, 475
memory storage processes, 257
morphine, 475
norepinephrine, 107, 257
obesity, 107
pain, 171
sympatho-adrenal function, 107
thermogenesis, 107
Zucker rat, 107
Stress ulcers
β-glucuronidase, 41
histamine, 41
lysosomes, 41
stomach, 41
zinc, 41
Striatum
apomorphine, 397
motor behavior, 397
stereotypy, 397
thioridazine, 397
Stroma-free hemolysate
gel filtration, 537
kidney, 537
liver, 537
mercury, 537
plasma, 537
rabbit, 537
selenium, 537
tissue-soluble fraction, 537
Structure-activity
amphetamine, 869
guinea pig atrium, 869
rhesus monkey, 869
self-administration, 869
Strychnine
kynurenine, 17
pentylenetetrazol, 17
quinolinic acid, 17
seizures, 17
thiosemicarbazide, 17
Subsensitivity
animal model of parkinsonism, 187
atropine sulfate, 187
diisopropylfluorophosphate, 187
dopamine receptor binding, 187
6-hydroxydopamine, 187
locomotion, 187
muscarinic receptor binding, 187
stereotypy, 187
supersensitivity, 187
thermoregulation, 187
Substance P
angiotensin II, 229
bombesin, 229
drinking, 229
duck, 229
eledoisin, 229
Substantia nigra
amitriptyline, 379
bicuculline methiodide, 561
chronic amphetamine treatment, 379
GABA, 561
6-hydroxydopamine, 561
imipramine, 379
picrotoxin, 561
response depression, 379
rotational behavior, 561
self-stimulation, 379
Substantia nigra compacta
caudate nucleus, 103
enkephalin, 103
D-Ala^2-Met^5-enkephalinamide, 103
haloperidol, 103
myoclonus, 103
naloxone, 103

Substantia nigra compacta (continued)
nucleus accumbens, 103
Supersensitivity
animal model of parkinsonism, 187
apomorphine, 633
atropine sulfate, 187
p-chloroamphetamine, 569
p-chlorophenylalanine, 569
cyclo(Leu-Gly), 633
depletion, 569
5,7-dihydroxytryptamine, 569
diisopropylfluorophosphate, 187
dopamine, 633
dopamine receptor binding, 187
drug discrimination, 569
haloperidol, 633
6-hydroxydopamine, 187
hypothermia, 633
locomotion, 187
locomotor activity, 633
LSD, 569
muscarinic receptor binding, 187
neuroleptics, 633
receptors, 633
serotonin, 569
stereotypy, 187
subsensitivity, 187
tardive dyskinesia, 633
thermoregulation, 187
Sustacal
blood levels, 781
ethanol, 781
liquid diet, 781
physical dependence, 781
silastic, 781
sustained release, 781
Sustained release
blood levels, 781
ethanol, 781
liquid diet, 781
physical dependence, 781
silastic, 781
Sustacal, 781
Sympatho-adrenal function
dopamine, 107
epinephrine, 107
norepinephrine, 107
obesity, 107
stress, 107
thermogenesis, 107
Zucker rat, 107
Synaptic delay
acute response, 811
animal model, 811
ataxia, 811
ethanol, 811
neuromuscular junction, 811
residual latency, 811

Tail-flick
analgesia, 907
frog righting, 907
guinea pig ileum, 907
MIF-I, 907
naloxone, 907
pituitary, 907
Straub tail, 907
withdrawal, 907
Tail shock
nose poke response, 653
operant titration technique, 653

Talapoin monkey
cortisol, 663
dopamine, 663
grooming, 663
LH, 663
naltrexone, 663
prolactin, 663
sexual behavior, 663
testosterone, 663
Tardive dyskinesia
apomorphine, 37, 633
autoreceptor, 37
cyclo(Leu-Gly), 633
dopamine, 633
haloperidol, 633
hypothermia, 633
locomotor activity, 633
MIF, 37
MSH, 37
neuroleptics, 633
receptors, 633
supersensitivity, 633
Task dependent
acquisition, 183
active avoidance, 183
scopolamine, 183
spontaneous locomotor activity, 183
tolerance development, 183
Taste aversion
2-deoxyglucose, 507
drinking, 507
lead, 507
LiCl, 507
NaCl, 507
saccharin, 507
toxicants, 507
Taste factors
aversion to alcohol, s269
Temperature
amphetamine, 895
DSIP, 895
locomotion, 895
sleep, 895
Temporal lobe epilepsy
afterdischarge thresholds, 695
amygdala, 695
cocaine, 695
focal brain stimulation, 695
hippocampus, 695
kindling, 695
limbic system, 695
sensitization, 695
septum, 695
Testosterone
cortisol, 663
dopamine, 663
grooming, 663
LH, 663
naltrexone, 663
prolactin, 663
sexual behavior, 663
talapoin monkey, 663
Δ^9-Tetrahydrocannabinol
amphetamine, 121
body weight, 877
cannabidiol, 479
cannabinol, 479
deprivation-induced, 877
dopamine receptor antagonists, 479
environmental conditions, 877
grooming, 479
kinesics, 121

Δ⁹-Tetrahydrocannabinol (continued)
proximics, 121
rhesus monkey, 121
ripple effect, 121
schedule-induced, 877
self-injection, 877
social behavior, 121
spacing, 121
Tetrahydroisoquinolines
aversion to alcohol, s269
ethanol, 265
preference, 265
salsolinol, 265
tetrahydropapaveroline, 265
Tetrahydropapaveroline
ethanol, 265
preference, 265
salsolinol, 265
tetrahydroisoquinolines, 265
Theophylline
acetylcholine, 421
adenosine, 421
caffeine, 421
cerebral cortex, 421
morphine, 421
naloxone, 421
Thermogenesis
dopamine, 107
epinephrine, 107
norepinephrine, 107
obesity, 107
stress, 107
sympatho-adrenal function, 107
Zucker rat, 107
Thermoregulation
animal model of parkinsonism, 187
atropine sulfate, 187
diisopropylfluorophosphate, 187
dopamine receptor binding, 187
6-hydroxydopamine, 187
locomotion, 187
muscarinic receptor binding, 187
stereotypy, 187
subsensitivity, 187
supersensitivity, 187
Thioridazine
apomorphine, 397
motor behavior, 397
stereotypy, 397
striatum, 397
Thiosemicarbazide
kynurenine, 17
pentylenetetrazol, 17
quinolinic acid, 17
seizures, 17
strychnine, 17
Tissue-soluble fraction
gel filtration, 537
kidney, 537
liver, 537
mercury, 537
plasma, 537
rabbit, 537
selenium, 537
stroma-free hemolystate, 537
Tolerance
amphetamine, 793
apomorphine, 793
chlordiazepoxide, 545
cross-tolerance, 545
ethanol, 777
excitatory effect, 777
locomotor activity, 777
MIF-I, 799
morphine, 799
Pavlovian conditioning, 799
pentobarbital, 545
pigeon, 545
relation to ethanol preference, s297
schedule-controlled behavior, 545
stereotypy, 793
Tolerance development
acquisition, 183
active avoidance, 183
scopolamine, 183
spontaneous locomotor activity, 183
task dependent, 183
Tonic seizures
antidepressants, 299
antihistamines, 299
electroconvulsive shock, 299
hypnotics, 299
Toxicants
2-deoxyglucose, 507
drinking, 507
lead, 507
LiCl, 507
NaCl, 507
saccharin, 507
taste aversion, 507
Toxicity
cholecystokinin, 125
conditioned taste aversion, 133
intracerebroventricular injection, 125
labyrinthectomy, 125
lead acetate, 133
rotation, 125
Transferrin
serum level in alcoholism, s47
TRH
catecholamines, 137
conditioned avoidance behavior, 137
disulfiram, 137
L-DOPA, 137
α-methyltyrosine, 137
Tryptophan metabolites
audiogenic excitement, 9
convulsants, 9
kynurenines, 9
Tryptophan oxygenase
ethanol and liver function, s139
Twin studies
hereditary aspects of alcoholism, s9
Tyrosine aminotransferase
ethanol and liver function, s139
regenerating liver and ethanol, s83

Uptake
acetylcholine, 21
brightness discrimination, 21
choline, 21
hippocampus, 21
incorporation, 21
long-term memory, 21
Urinary pH
change in dosage, 209
food delivery schedule, 209
nicotine, 209
self-administration, 209

Vasopressin
involvement in tolerance to drugs, s257, s285

Visual evoked potential
diaminodiphenoxybutane, 429
electroretinogram, 429
operant behavior, 429
retinotoxicity, 429
Vitamin E
ethanol, 325
iron-loading, 325
porphyrin metabolism, 325

Withdrawal
alcohol and seizures, s225
analgesia, 907
frog righting, 907
guinea pig ileum, 907
hormonal change in alcoholism, s131
MIF-I, 907
naloxone, 907
pituitary, 907
Straub tail, 907
tail-flick, 907

Y-Maze
L-fucose, 765
hippocampal proteins, 765
memory, 765
shuttle box, 765

Zimelidine
p-chloroamphetamine, 283
halogenated phenethylamines, 283
serotonin behavioral syndrome, 283
Zinc
β-glucuronidase, 41
histamine, 41
lysosomes, 41
stomach, 41
stress ulcers, 41
Zucker rat
dopamine, 107
epinephrine, 107
norepinephrine, 107
obesity, 107
stress, 107
sympatho-adrenal function, 107
thermogenesis, 107

AUTHOR INDEX

ABRAHAM, L. D., 5
ALEXANDER, B. K., 593
ALPERT, J. E., 391
ALTSHULER, H. L., s233
ANANDAM, N., 531
ANDO, T., 429
APPEL, J. B., 569
APRISON, M. H., 575
ARNONE, M., 27
AXELROD, J., s167

BARBACCIA, M. L., s303
BARFIELD, R. J., 435
BARRETT, R. J., 555
BASS, M. B., 773
BAUER, R. H., 155
BAUM, M. J., 57
BEAN, N. J., 673
BEDFORD, J. A., 69, 177, 221, 403
BEILSTEIN, B. A., 37
BELLAROSA, A., 221
BELMORE, S. M., 199
BHARGAVA, H. N., 633
BIOULAC, B., 359
BISHOP, P., 673
BLOOM, F. E., s203
BODNAR, R. M., 171, 829
BOERNGEN, R., 777
BOGGAN, W. O., s149
BOKONJIC, D., 183
BORG, S., s47
BORNE, R. F., 69
BOTTENUS, R. E., s63
BOUCHER, R., 125
BOURN, W. M., 733
BOZARTH, M. A., s245
BRADFORD, B. U., s67
BRADLEY, E. L., 739
BRANDÃO, M. L., 1
BRAUN, H., 743
BREESE, G. R., 247, 461
BROEKKAMP, C. L., 643
BRUINVELS, J., 843
BRUST-CARMONA, H., 97
BRUTUS, M., 171
BURCH, N. R., s233
BURGESS, J. W., 121
BURKS, A., s31
BURNE, T. A., 653
BURTON, W., s233
CARINO, M. A., 397
CARR, L. A., 193
CASTELLANO, C., 443
CAZA, P. A., 45
CESARE, D. A., 545
CHEEMA, A., 41
CHELACK, B. J., 421
CHESHER, G. B., 479
CHIAO, Y.-B., s125
CHIARAVIGLIO, E., 787
CHIBA, S., 429
CHO, C. H., 41
CHU, N.-S., s241
CLEARY, J., 243
CLEMENS, L. G., 81, 89
COAMBS, R. B., 593
COBB, C. F., s125
COHEN, D. J., 391
COLLINS, J. P., 695
COLPAERT, F. C., 513
COMMISSARIS, R. L., 601, 605, 621
CONCANNON, J. T., 761
CONNOR, J. D., 283
CONRAD, D. G., 729
CORDON, J. J., 621
COY, D. H., 883, 895, 901, 913
CRABBE, J. C., JR., s285
CRAIGMILL, A. L., 475
CRAWLEY, J., 167
CUNNINGHAM, C. C., s63

DAFTER, R. E., 467
DAMIANO, B. P., 283
DANTZER, R., 27, 133
DAVIS, C. M., 593
DAVIS, K. L., 37
DEAKIN, J. F. W., 525
DE CARO, G., 229
DEITRICH, R. A., 265, s291
DETURCK, K. H., 129, 471
DE WIED, D., s257
DOHANICH, G. P., 81, 89
DOLPHIN, A. C., s169
DORTMANS, C., s285
DOSSETT, R., s233
DOYLE, R. L., 589
DRUST, E. G., 283
DUNCAN, C., 265
DUNN, A. J., 823
DYKSTRA, L. A., 349
DZOLJIC, M. R., 103

EAGON, P. K., s125
EATON, L. C., s191
EBIHARA, Y., s95
EHRENSING, R. H., 907
ELSMORE, T. F., 729
ELSOHLY, M. A., 403
EMMETT-OGLESBY, M. W., 467
ERIKSSON, C. J. P., s101, s291, 781
ERWIN, V. G., s297
EWING, J. A., s269

FALETTI, M. V., 851
FELEGI, W., 531
FESSLER, R. G., 835
FIESCHI, L., 137
FILIBECK, U., 443
FILUS, S., s63
FLETCHER, G. V., 729
FONTES, J. C. S., 1
FORNAL, C., 51
FOSSOM, L. H., 235
FRANKLIN, K. B. J., 365
FREDA, J., 761
FRENK, H., 343
FRIED, R., s73
FRIEDMAN, H. J., 773
FUKUNAGA, M., 295

GAIDE, M. S., 851
GARBER, S. L., 637
GARRIGOU, D., 643
GAVALER, J. S., s125

GAVIN, W. J., 851
GERBER, C. J., s245
GILDERSLEEVE, N. B., 823
GLASSER, R. S., 863
GLUSMAN, M., 171
GOELZ, S. E., s169
GOLD, P. E., 257
GOODWIN, F. K., 167
GRAEFF, F. G., 1
GREENGARD, P., s169
GREENMAN, C. B., 171
GREENSHAW, A. J., 31
GRIFFITH, O. H., s155
GRISOLÍA, S., s53
GROSS, K., 739
GROVE, L., 177
GUERRI, C., s53

HADAWAY, P. F., 593
HALPERIN, J. M., 299
HÄRKONEN, M., s131
HARLAN, B., s233
HARTMAN, J. A., 453
HARVAN, P. A., 919
HASTINGS, A. G., s145
HEALEY, M. L., 349
HEFFNER, T. G., 453
HELLSTRÖM, E., s73
HENRY, J. P., 719
HERBERT, J., 663
HERZ, A., s265
HINGTGEN, J. N., 575
HIRANO, T., s89
HIRATA, F., s167
HOFFMAN, P. L., s279
HOLMAN, E. W., 501, 597
HOLOHEAN, A. M., 569
HONZA, R., 765
HORITA, A., 397
HORN, C. A., 739
HSIAO, S., 627
HUGHES, S. S., s149
HUMPHRYS, R. R., 81
HUTTUNEN, M. O., s131

IMURA, N., 537
INGRAM, L. O., s191
INOUE, K., 295
IORIO, L. C., 299
IRVIN, M. D., 739
ISHII, H., s89, s95

JACKSON, D. M., 479
JACOBS, A. W. C. M., 843
JACQUET, Y. F., 585
JANSSEN, P. A. J., 513
JÄRBE, T. U. C., 549
JEFFCOATE, W. J., s145
JI, S., s41
JIANG, Z. G., 421
JOHANSON, C. E., 869
JORK, R., 303
JOST, P. C., s155

KALANT, H., s183
KAMMERER, E., 21
KASTIN, A. J., 37, 799, 883, 895, 901, 907, 913
KELLY, D. D., 171
KEMNITZ, J. W., 461
KENDALL, J., s233
KEVERNE, E. B., 663
KHAZAN, N., 115
KLOSE, K. J., 851
KOCH, K. I., 781
KOHNO, H., s89
KOKKINIDIS, L., 379
KORDECKA-MAGIERA, A., 153
KOSTRZEWA, R. M., 863, 883
KÓSZÓ, F., 325
KOZLOWSKI, M. R., 561
KRAEMER, G. W., 461
KULKOSKY, P. J., 77, 449
KURIBARA, H., 657
KUSE, A. R., s297
KUTSCHER, C. L., 507

LAHOSTE, G. J., 799
LAI, H., 397
LAMPE, R. A., s197
LANG, W. J., 209, 215
LAPIN, I. P., 9, 17, 337
LATIFF, A. A., 209
LATTNER, M., 829
LAWRENCE, S. P., 901
LEDIG, M., s175
LEMASTERS, J. J., s41
LESSE, H., 695
LESTER, D., 773
LESTER, R., s125
LEVIN, B. E., 107
LEVITT, R. A., 739
LIEBER, C. S., s17, s107
LIEBERMAN, K. W., 205
LIEBESKIND, J. C., 501
LINDAHL, R., s111
LINDROS, K. O., s119
LIPTON, S. V., 371
LLOYD, K. G., 643
LOCHRY, E. A., s149
LÖSSNER, B., 303, 765
LOVELL, D. K., 177, 403
LUCOT, J. B., 409
LUNDBERG, D., 247
LYNESS, W. H., 605, 621

McCLEARN, G. E., s297
McFAUL, J. A., s197
McGINITY, J. W., 781
McGOUGH, J. P., 371
McGUIRE, P. S., 691
McINTOSH, T. K., 435
McKEARNEY, J. W., 545
McLEAN, J. H., 863

MACDONALD, I., s145
MACHLIS, L. E., 331
MAJ, J., 153
MANDEL, P., s175
MANN, J. F. E., 125
MARIOTTI, M., 229
MAROLI, A. N., 919
MARSHALL, J. F., 561
MARTIN, B., s31
MASSI, M., 229
MASUR, J., 777
MATTHIES, H., 21, 303, 765
MAY, J. G., 863
MELLER, R. E., 663
MELTZER, H. Y., 835
MERCER, J. D., 31
MICHAELIS, E. K., s197
MICHAELIS, M. L., s197
MICOSSI, L. G., 229
MILETICH, R., 51
MILLER, L. L., 199
MOERSCHBAECHER, J. M., 887
MOGILNICKA, E., 153
MOHRLAND, J. S., 475
MONAGHAN, M., 243
MOORE, K. E., 601, 605, 621
MORA, S., 137
MORGAN, M. Y., s1
MORLAND, J., s31
M'PARIA, J.-R., s175
MUELLER, K., 627
MUELLER, R. A., 247
MURPHY, J. M., 257
MYERS, R. D., s269
MYSLOBODSKY, M. S., 743

NAGANUMA, A., 537
NAGAYAMA, H., 575
NASELLO, A. G., 137
NIELSEN, J. A., 235
NIEMEGEERS, C. J. E., 513
NISSEN, C., 907
NOGUCHI, Y., 429
NORDMANN, J., s139
NORDMANN, R., s139

OEI, T. P. S., 457
OKUNO, F., s95
OLSON, G. A., 799
OLSON, R. D., 799
ORATZ, M., s31
OVERSTREET, D. H., 183, 187

PALFAI, T., 805
PANKSEPP, J., 673
PARSONS, D. S., 739
PASHKO, S., 471
PEACHEY, J. E., s101
PÉREZ GUAITA, M. F., 787
PFEIFFER, C. J., 41
PHILLIS, J. W., 421
PHOEBUS, E., 121
PICCIRILLO, M., 391
PICKMAN, C., 501
PIKKARAINEN, P., s119
PINEL, J. P. J., s225
PLATTS, P., s145
POEL-HEISTERKAMP, A. L. V.D., 103
POLING, A., 243
POPOV, N., 765
PÖSÖ, H., s83
PREDY, P. A., 379
PROUDFIT, H. K., 705
PUGLISI-ALLEGRA, S., 287

RADULOVACKI, M., 51
RANDALL, C. L., s149
RANGARAJ, N., s183
RAUCA, CH., 21
REBEC, G. V., 793
RECH, R. H., 601, 605, 621
REED, T. E., 811
REGGIANI, A., s303
REIGEL, C. E., 733
RENZI, P., 287
REYES-VÁZQUEZ, C., 97
RIBIERE, C., s139
RICE, A., 501
RIDOUT, M., s145
RIFFEE, W. H., 5

RIGTER, H., s285
RILEY, A. L., 77
RITCH, M. A., 859
RITZMANN, R. F., s279, 633, 715
ROBERTS, T., 597
ROBERTSON, A., 365
ROBERTSON, T. W., 851
RODRIGUEZ, F., 359
ROEHRS, T. A., 291
ROSECRANS, J. A., 311
ROSENBERG, H. C., 415
ROSIC, N., 183
ROSKAM, S. E., 597
ROTHSCHILD, M. A., s31
ROUACH, H., s139
RUBIN, E., s37
RUSSELL, M. J., 737

SAHLEY, T. L., 673
SALASPURO, M., s119
SAMSON, H. H., 291
SANGER, D. J., 31
SATAKE, N., 305
SATO, S., 429
SCHALLERT, T., 187
SCHALLY, A. V., 883, 907, 913
SCHECHTER, M. D., 307, 497
SCHILLER, P. W., 125
SCHNEIDERMAN, N., 851
SCHREIBER, S. S., s31
SCHUCKIT, M. A., s9
SCHULZECK, S., 765
SCHUSTER, C. R., 409
SCOTT, R. H., 739
SEGAL, D. S., 793
SEIDEN, L. S., 409, 453, 691
SELBY, C., s145
SELLECK, S. B., 581
SELLINGER, O. Z., 589
SHALABY, I. A., 685
SHAYWITZ, B. A., 371, 391
SHERMAN, J. E., 501, 597
SHEPHERD, D. T., 859
SHIGETA, Y., s89, s95
SHYBUT, G., 869
SIMMONS, M. A., 569
SIMMONS, W. H., 715
SIMON, N., 325
SIMONNET, G., 359
SIMPSON, J. B., 581
SICKEL, J. L., 77
SIGGINS, G. R., s203
SIKLÓSI, CS., 325
SILBRET, M., 851
SINGER, G., 877
SLATER, P., 817
SLOVITER, R. S., 283
SMITH, H. E., s111
SMITH, L. A., 209, 215
SODETZ, F. J., 729
SOURKES, T. L., 385
SPACH, P. I., s63
SPANO, P. F., s303
SPARBER, S. B., 235
SPEAR, L. P., 45, 685
SPERRY, R., 397
SQUIRES, K. C., s241
STARR, M. S., 57
STEINFELS, G. F., 115
STEPHENS, P. M., 719
STERN, J. M., 531
STIBLER, H., s47
STILWELL, D. J., 739
STOKES, P., 205
STOWELL, A., s119
STURGEON, R. D., 835
STURTEVANT, R. P., 637
STUTZ, R. M., 919
SULLIVAN, A. C., 107
SWITZ, G. M., 737
SYDOW, O., s47

TABAKOFF, B., svii, s279
TADOKORO, S., 657
TAKAGI, S., s89, s95
TAKAHASHI, R. N., 877
TAKATA, H., s89
TAYLOR, K. E., 467
THOMPSON, D. M., 887
THOMPSON, I. P., 31
THOMPSON, K., 737
THURMAN, R. G., s41, s67
TILSON, H. A., 653
TOMBAUGH, T. N., 859
TOTTMAR, O., s73
TRABUCCHI, M., s303
TRESSEL, W. R., 593
TRISCARI, J., 107
TSANG, W. K., 919
TSUCHIYA, M., s89, s95
TURNER, C. E., 403

URCA, G., 343

VALLANO, M. L., 435
VAN DER LAAN, J. W., 843
VAN REE, J. M., s257
VAN THIEL, D. H., s125
VENTO, A. L., 37
VILBERG, T., 673
VINCENT, J. D., 359
VOGEL, W. H., 129, 471
VREELAND, N. S., s191

WADDINGTON, J. L., 915
WAGNER, G. C., 409
WAHLSTRÖM, G., s249
WALLACE, M. M., 829
WALSH, T. J., 805
WEHRY, S. M., 193
WEISBARD, C., 121
WENGER, G. R., 647
WEST, K. B., 569
WETZEL, W., 765
WHITE, D. K., 555
WHITE, F. J., 569
WIDY-TYSZKIEWICZ, E., 385
WILCOX, R. E., 5
WILSON, M. C., 69, 177, 221, 403
WISE, R. A., s213, s245
WITT, P. N., 121
WOJCIK, W. J., 51
WOLF, M. D., 5
WOOLVERTON, W. L., 869
WORNER, T. M., s107
WU, P. H., 421

YAMAMOTO, B. K., 507
YAMAMURA, H. I., 187
YAMASAWA, K., 295
YASURAOKA, S., s95
YEHUDA, S., 895
YLIKAHRI, R. H., s131
YOSHIMURA, H., 519
YOSHITAKE, Y., s89
YOUNG, G. A., 115
YUKI, T., s67

ZACHARKO, R. M., 379
ZADINA, J. E., 907, 913
ZIMBRICK, J. D., s197